

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07F 9/06, 9/28, A61K 31/675, 31/41, 31/415, A01N 57/00, 43/50, 43/52, 43/56, 3/64, 43/82, 43/80, 43/80, 43/50, C12Q 1/100, G01N 33/63 *		A1	(11) International Publication Number: WO 93/16674
			(43) International Publication Date: 2 September 1993 (02.09.93)
(21) International Application Number: PCT/US93/01247		(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/ US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US). SMITHKLINE BEECHAM PLC [GB/ GB]; New Horizon Court, Brentford, TW8 9BD (GB). THE JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US).	
(22) International Filing Date: 11 February 1993 (11.02.93)		(72) Inventors; and	
(30) Priority data:		(75) Inventors/Applicants (for US only) : WINKLER, James, David [US/US]; 701 Hartranft Avenue, Fort Washing- ton, PA 19034 (US). CHILTON, Floyd, Harold, III [US/US]; 106 Needham Street, Pilot Mountain, NC 27041 (US). HICKEY, Deirdre, Mary, Bernadette [GB/ GB]; SmithKline Beecham, The Frythe, Welwyn, Hert- fordshire AL6 9AR (GB).	
07/833,879 11 February 1992 (11.02.92) US			
07/833,877 11 February 1992 (11.02.92) US			
07/834,048 11 February 1992 (11.02.92) US			
07/833,880 11 February 1992 (11.02.92) US			
07/833,878 11 February 1992 (11.02.92) US			
9202827.3 11 February 1992 (11.02.92) GB			
07/833,850 11 February 1992 (11.02.92) US			
(60) Parent Applications or Grants			
GB 9202827.3 ()			
Filed on 11 February 1992 (11.02.92)			
(63) Related by Continuation			
US 07/833,850 (CIP)			
Filed on 11 February 1992 (11.02.92)			
US 07/833,877 (CIP)			
Filed on 11 February 1992 (11.02.92)			
US 07/833,878 (CIP)			
Filed on 11 February 1992 (11.02.92)			
US 07/833,879 (CIP)			
Filed on 11 February 1992 (11.02.92)			
US 07/833,880 (CIP)			
Filed on 11 February 1992 (11.02.92)			
US 07/834,048 (CIP)			
Filed on 11 February 1992 (11.02.92)			
		(74) Agents: DINNER, Dara, L. et al.; SmithKline Beecham Corporation, Corporate Patents - U.S., UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).	
		(81) Designated States: AU, CA, GB, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: CoA-IT AND PAF INHIBITORS

Effect of Compound 3 on CoA-IT Activity



(57) Abstract

Compound 3 (μM)

Coenzyme A-independent transacylase is required for the release of free arachidonic acid, and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby. The figure shows the effect of compound three on CoA-IT activity.

* Due to a late transmittal of the International Search Report, the classification of the subject matter of the invention was not available to the International Bureau before the technical preparations for international publication had been completed. The provisional classification symbol used for preparing the publication was replaced thereafter by the classification indicated in the Search Report received later.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

CoA-IT AND PAF INHIBITORS

FIELD OF THE INVENTION

5 The invention relates to the area of inflammatory mediators. The invention is based on the discovery that blocking a key enzyme responsible for arachidonate movement (or remodelling), Coenzyme A-independent transacylase (CoA-IT), inhibits the production of lipid mediators (free arachidonic acid, arachidonic acid metabolites, and platelet-activating factor (PAF)). It has been discovered that CoA-IT is required for the
10 release of free arachidonic acid and the synthesis of arachidonic acid metabolites and PAF. As CoA-IT is involved in arachidonate phospholipid metabolism, and required for the release of free arachidonic acid and the production of eicosanoids and PAF, inhibition
15 of such would be useful for the treatment of disease states caused thereby.

BACKGROUND OF THE INVENTION

 An early event in the response of most inflammatory cells to immunologic activation and other stimuli is the release of newly formed
20 products (mediators) which alter the function and biochemistry of surrounding cells and tissues. The ensuing biological responses, as well as much of the pathogenesis which is attributed to inflammation and allergy, are thought to be dependent on the effects that these newly-formed mediators have on adjacent cells within the inflammatory region.

25 In the last 20 years, it has become apparent that lipid mediators are among the most potent and important products which are generated during inflammatory reactions. The synthesis of most lipid mediators is initiated by the cleavage of complex phospholipid molecules which contain arachidonate at their sn-2 position. Free arachidonic acid is released
30 from these phospholipids and this represents the rate-limiting step in the formation of eicosanoids (leukotrienes, prostaglandins and thromboxanes). As arachidonic acid is released, it is then converted to oxygenated derivatives by at least two enzymatic systems (lipoxygenase and/or cyclooxygenase). Concomitant with arachidonate release,
35 lysophospholipids are formed. One of these lyso phospholipids, 1-alkyl-2-lyso-sn-glycero-3-phosphocholine, is then acetylated to form platelet-activating factor (PAF). Each of the cell types involved in the

inflammatory response produce and secrete a unique subset of lipid mediators. The quantities and nature of the metabolites depend on which enzymes and precursor phospholipid pools are available to inflammatory cells.

5 Once lipid mediators such as PAF and eicosanoids are formed by the aforementioned pathways, they induce signs and symptoms observed in the pathogenesis of various inflammatory disorders. Indeed, the pathophysiological activity of arachidonic acid (and its metabolites) is well known to those skilled in the art. For example, these mediators have been
10 implicated as having an important role in allergy, asthma, anaphylaxis, adult respiratory distress syndrome, reperfusion injury, inflammatory bowel disease, rheumatoid arthritis, endotoxic shock, and cardiovascular disease. Aalmon and Higgs [Br. Med. Bull (1978) 43:285-296]; Piper et al. [Ann. NY Acad. Sci. (1991) 629:112-119]; Holtzman [Am. Rev. Respir. Dis. (1991) 143:188-203]. Snyder (Am. J. Physiol. Cell Physiol.) (1990) 259:C697-C708]; Prescott et al. [J. Biol. Chem. (1990) 265:17381-17384].
15

Similar to arachidonate products, PAF is a potent proinflammatory mediator produced by a variety of cells. In vitro, PAF stimulates the movement and aggregation of neutrophils and the release therefrom of
20 tissue-damaging enzymes and oxygen radicals. PAF has also been implicated in activation of leukocytes, monocytes, and macrophages. These activities contribute to the actions of PAF as having (pathological) physiological activity in inflammatory and allergic responses. PAF has also been implicated in smooth muscle contraction, pain, edema,
25 hypotensive action, increases in vascular permeability, cardiovascular disorders, asthma, lung edema, endotoxin shock, and adult respiratory distress syndrome. PAF elicits these responses either directly through its own cellular receptor(s) or indirectly by inducing the synthesis of other mediators.

30 Accordingly, a method which antagonises the production of free arachidonic acid, its metabolites or PAF will have clinical utility in the treatment of a variety of allergic, inflammatory and hypersecretory conditions such as asthma, arthritis, rhinitis, bronchitis and urticaria, as well as reperfusion injury and other disease involving lipid mediators
35 of inflammation.

Many published patent applications or issued US patents exist which describe various compounds having utility as PAF or Eicosanoid

antagonists. Such patents include U.S. Pat. No. 4,788,205, 4,801,598, 4,981,860, 4,992,455, 4,983,592, 5,011,847, 5,019,581 and 5,002,941.

Described in this application is a method to inhibit the generation of lipid mediators. As mentioned above, arachidonate-containing phospholipids are the key precursors for a broad range of lipid mediators including arachidonic acid, eicosanoids and PAF. Because of the special role arachidonate-containing phospholipids have in mediator generation, inflammatory cells treat these phospholipids differently than other fatty acid-containing phospholipids. In particular, there are enzymes which control the amount of arachidonate in different phospholipid pools and these enzymes are tightly regulated to maintain arachidonate homeostasis. The movement of arachidonate into and from all phospholipids was originally thought to be exclusively by CoA-dependent acyl transferase activities. Holub *et al.*, *Adv. Lipid Res.*, 16:1-125 (1978); Lands *et al.*, In *The Enzymes of Biological Membranes*, ed. Martonosi, A., pp. 3-85, Plenum Press, NY, 1976. However, it has now been demonstrated that an enzyme, CoA-IT, is involved in the movement of arachidonate into particular (1-alkyl- and 1-alkenyl) phospholipid pools. These are the phospholipid pools of arachidonate that are preferentially mobilized during cell activation. Moreover, arachidonic acid and lyso-PAF released from these pools are utilized for eicosanoid and PAF, respectively.

CoA-IT has a specificity for certain phospholipids as donor and acceptor molecules. The fatty acid transferred is long chained and unsaturated, and almost exclusively arachidonate. Other fatty acids such as the 16:0, 18:1 or 18:2 are not apparently moved into alkyl and 1-alkenyl phospholipid pools by CoA-IT. The specificity of CoA-IT is in direct contrast to many other CoA-dependent acylation activities which acylate a wide variety of lysophospholipids with no selectivity for arachidonate.

Accordingly, a method by which CoA-IT is inhibited will consequently and preferentially decrease the arachidonate content of 1-alkyl- and 1-alkenyl-linked phospholipids and will therefore decrease the production of pro-inflammatory mediators such as free arachidonic

acid, leukotriene and PAF during an inflammatory response. Accordingly, a method by which CoA-IT is inhibited, will have clinical utility in the treatment of allergic, inflammatory and hypersecretory conditions.

5

SUMMARY OF THE INVENTION

It is an object of this invention to provide a method of treating or reducing allergy and inflammation. It is also an object of this invention to
10 inhibit undesirable lipid mediator production.

This invention is based on the discovery that blocking CoA-independent transacylase, using selective pharmacologic tools, prevents the movement of arachidonate into phospholipid pools needed for the concomitant formation of PAF, free arachidonic acid and its metabolites
15 such as eicosanoids.

The invention relates to a method of treating disease or disorders mediated by free arachidonic acid, its metabolites and/or PAF by administering to a patient in need thereof, an effective amount of a compound which inhibits the production, activation or action of CoA-IT.
20 Inhibition of CoA-IT inhibits lipid mediator production as well as signs and symptoms of disease and disorders induced by lipid mediators.

The premise of this invention is that blocking the movement of arachidonate into specific arachidonate-containing phospholipid pools inhibits lipid mediator (PAF and eicosanoid) production by inflammatory
25 cells. More precisely, when arachidonate is prevented from entering key common precursor phospholipids, precursor molecules will not be formed. If key precursor pools are not formed, arachidonate cannot be removed from these precursors. This means that free arachidonic acid and lyso PAF will be not be mobilized and therefore PAF as well as
30 eicosanoids will not be produced. The end result of CoA-IT inhibition will be reduced signs and symptoms of allergy and inflammation mediated by eicosanoids and PAF.

Still another aspect of the invention relates to a method of screening chemical compounds for potential anti-inflammatory action. In this way,
35 chemical compounds can be rapidly and easily screened for the ability to inhibit CoA-IT and be useful as an anti-inflammatory agent.

Another aspect of the invention relates to the therapeutic use, in

medicine, of the compounds, and pharmaceutical compositions, as disclosed herein, in particular for compounds of Formulas (I) to (VI), as inhibitors of CoA-IT activity. As CoA-IT activity is required for the release of lipid inflammatory mediators, such as arachidonic acid and the production of platelet-activating factor, by inflammatory cells and that inhibition of the production, activation or activity of CoA-IT will have beneficial and therapeutic effect the compounds of the present invention, as described herein, which are inhibitors of CoA-IT are useful in the treatment of disease states caused thereby.

Treatment of disease states caused by these lipid inflammatory mediators i.e., arachidonate, eicosanoids and PAF, include certain cardiovascular disorders such as but not limited to, myocardial infarction, stroke, circulatory shock, or hypotension, ischemia, reperfusion injury, inflammatory diseases such as, but not limited to, arthritis, inflammatory bowel disease, Crohn's disease, or ulcerative colitis, respiratory disease such as but not limited to, asthma, or adult respiratory distress syndrome, anaphylaxis, shock such as but not limited to endotoxic shock, topical diseases, such as but not limited to actinic keratosis, psoriasis, or contact dermatitis, or pyresis.

DETAILED DESCRIPTION OF THE INVENTION

It has now been discovered that CoA-IT activity is required for lipid mediator production. Specifically, it has been discovered that CoA-IT activity is required for the movement of arachidonate into phospholipid pools from which it can be released to form free arachidonic acid and for the production of lyso PAF needed for PAF synthesis. Further, CoA-IT has been shown to be crucial in the mobilization of lyso-PAF and free arachidonic acid during inflammatory cell activation. Inhibition of CoA-IT activity will result in a decreased production of PAF and a decreased release of free arachidonic acid from cellular phospholipids.

More specifically, Figure 1 shows a simplified scheme of how arachidonic acid is directed through phospholipids of inflammatory cells. As arachidonic acid enters inflammatory cells or is produced within these cells, it is converted to arachidonoyl-CoA by the enzyme arachidonoyl CoA synthetase. At that point, arachidonic acid is incorporated into the sn-2 position of a lyso phospholipid by arachidonoyl-CoA acyl transferase. The arachidonate-containing phospholipids

formed in this reaction appear to belong to a special group or pool (pool A) of phospholipids which contains predominantly 1-acyl-linkages at the sn-1 position of the molecule. When cells are not stimulated, arachidonic acid is slowly transferred from this first pool to other pools (pool B) of phospholipids which contain predominantly 1-alkyl and 1-alk-1-enyl linkages at the sn-1 position and phosphatidylcholine and phosphatidylethanolamine linkages at the sn-3 position of phospholipids. This transfer into other pools of AA-containing phospholipids is accomplished by the enzyme CoA-IT.

During inflammatory cell stimulation, there is a calcium-dependent activation of an enzyme phospholipase A₂ which removes arachidonic acid from arachidonate-containing phospholipids which are predominantly in the second (1-alkyl and 1-alk-1-enyl) pool (pool B). Arachidonic acid and lyso phospholipids formed in this reaction become key intermediates for eicosanoid generation and platelet activating factor generation, respectively. In particular, one of these arachidonate-containing phospholipids in pool B, 1-alkyl-2-arachidonyl-sn-glycero-3-phosphocholine, is a common precursor for arachidonate and platelet-activating factor. During inflammatory cell activation, arachidonic acid is rapidly depleted from phospholipids in pool B. As these pools are depleted by the action of phospholipase A₂, they are rapidly replenished by CoA-IT. It is our discovery that the movement of arachidonate into special pools mediated by CoA-IT is required for lipid mediator production and that the blockage of CoA-IT will inhibit lipid mediator production. This will have beneficial therapeutic effects for diseases mediated, in some part, by eicosanoids and platelet-activating factor.

1. Characteristics of CoA-IT Activity

CoA-IT activity had been defined to have the following characteristics.

A. Co-factors

CoA-IT activity is independent of the presence of Coenzyme A. In addition, no other co-factors required for activity or that modulate activity have been discovered. CoA-IT activity is not altered by the absence or presence of calcium (0-10 mM), magnesium (0-10 mM), EGTA (0-2 mM), EDTA (0-10 mM), ATP, CoA or CoA-fatty acids.

B. pH

CoA-IT activity over a wide range of pH levels was determined. The results demonstrate that the enzyme is active over a broad pH range of 6.5 - 9. The activity of the enzyme rapidly decreases below pH 6.5 and above pH 10.

5

C. Kinetics

The kinetics of the CoA-IT reaction were studied with various concentrations of 1-alkyl-2-lyso-GPC. CoA-IT activity increases as a function of the concentration of substrate, 1-alkyl-2-lyso-GPC. The enzyme exhibits an apparent substrate affinity (K_m) for 1-alkyl-2-lyso-GPC of 0.1 - 2 μ M.

10

D. Other Characteristics

CoA-IT is stable when treated with dithiothreitol (DTT) or 2-mercaptoethanol (1-10 mM). CoA-IT is inactivated by exposure to heat or acid and is inhibited by addition of detergents such as 3-octyl glucoside, deoxycholate, cholate, Triton X-100, Cl2E8, CHAPS and hexadecyltrimethyl ammonium bromide.

15

E. Specificity

A key characteristic of CoA-IT is the exquisite specificity of this enzyme for polyunsaturated fatty acids and especially arachidonic acid. Sugiura et al. (J. Biol. Chem. (1987) 262:1199-1205); Chilton et al. (J Biol. Chem. (1983) 258:7268-7271); Kramer and Deykin (J. Biol. Chem. (1983) 258:13806-13811).

20

25

F. Location

Within the cell, CoA-IT activity is completely and tightly associated with microsomal membranes. Treatment of these membranes with 2 M KCl fails to extract more than 75% of the CoA-IT activity, suggesting that CoA-IT is an integral membrane component. The subcellular location of CoA-IT activity remains to be determined.

30

Evidence of CoA-IT activity exists in a variety of inflammatory cells, including human neutrophils, monocytes, lung mast cells, guinea pig eosinophils and human U937 monocytic and HL-60 granulocyte cell lines. There is also preliminary evidence that somewhat less CoA-IT activity is found in tissues such as lung, liver and kidney. Less activity yet

35

is found in heart, skeletal muscle and brain.

G. Comparison with other enzymes

- 5 CoA-IT has characteristics which distinguish its activity from the activities of other enzymes involved in lipid metabolism, such as phospholipase A₂, lipoxygenases, cyclooxygenases, CoA-dependent acyltransferases and PAF acetyl transferase.

- 10 These differences include different co-factor requirements, location within cells, effects of detergents on activity, effects of heat or acid treatment, stability to reducing agents such as dithiothreitol (DTT) and selectivity for arachidonate-containing substrates. The following Table, Table I, summarizes these differences in characteristics between CoA-IT and other enzymes.

Table I Comparison of CoA-IT to other enzymes

<u>Property</u>	<u>CoA-IT</u>	<u>Pan.PLA₂</u>	<u>LMW PLA₂</u>	<u>HMW PLA₂</u>
Co-factors	None	Ca ²⁺	Ca ²⁺	Ca ²⁺
Location	membrane	extracellular	extracellular	cytosol
Detergent	inhibition	stimulation	inhibition	stimulation
Heat/Acid	unstable	stable	stable	unstable
DTT	no effect	inhibition	inhibition	no effect
AA Sel	yes	no	no	yes

<u>Property</u>	<u>CoA-IT</u>	<u>CoA-D</u>	<u>AcetylTase</u>	<u>AcetylHy</u>
Co-factors	None	CoA	Ca ²⁺ /A-CoA	none
Location	membrane	membrane	membrane	cyto/LDL
Detergent	inhibition	mixed	no effect	mixed
Heat/Acid	unstable	---	---	stable
DTT	no effect	no effect	no effect	inhibition
AA Sel	yes	no	no	no

5

<u>Property</u>	<u>CoA-IT</u>	<u>CO</u>	<u>5LO</u>
Co-factors	None	peroxide	peroxide
Location	membrane	membrane	cyto-memb
Detergent	inhibition	no effect	---
Heat/Acid	unstable	unstable	unstable
DTT	no effect	---	no effect
AA Sel	yes	yes	yes

Key to Table I:

	Pan.	Pancreatic	cyto	cytosol
10	LDL	low density lipoprotein	Ca ²⁺	calcium
	CoA-D	CoA-dependant acyltransferase	CO	cyclooxygenase
	AcetylTase	Acetyl-CoA transferase	5LO	5-lipoxygenase
	---	no data available	DTT	dithiotheritol
	LMW	low molecular weight	A-CoA	Acetic-CoA
15	HMW	high molecular weight	AA Sel	Arachidonic acid selectivity

This distinction of CoA-IT from the other enzymes based on characteristics is important for several reasons. First, the data indicate that CoA-IT activity is a novel enzyme activity. Second, even though a microsomal preparation is used to assess CoA-IT activity, the distinct
5 characteristics of CoA-IT assure that the assays measure only CoA-IT activity. Finally, the characteristics of CoA-IT demonstrate that the pharmacological utility of inhibition of CoA-IT is unique.

2. CoA-IT inhibition

10 Inhibitors of CoA-IT activity have now been discovered and characterized. Suitable inhibitors can readily be identified employing assay (a) described below. For example, Figure 2 shows the effect of compound 3 on CoA-IT activity. Often, inhibitors will include an imidazole structure.

15

3. Role of CoA-IT in PAF Production and AA Release

The molecule 1-alkyl-2-arachidonoyl-GPC has been shown to be a necessary precursor for PAF production (Chilton *et al.*, *J. Biol. Chem.* (1984) 259, 12014-12020). CoA-IT activity plays two pivotal roles in PAF
20 production, centering on this molecule. First, CoA-IT activity is required for the specific movement of arachidonate into 1-alkyl-2-arachidonoyl-GPC to produce the necessary precursor molecule for PAF. Second, CoA-IT activity has been shown to promote the breakdown of the precursor of PAF, 1-alkyl-2-arachidonoyl-GPC into lyso PAF, to allow PAF production.
25 This CoA-IT mediated production to lyso PAF can be differentiated from PLA₂ activity. CoA-IT activity plays a central and necessary role in the production of PAF.

There is strong evidence that, in activated inflammatory cells, arachidonate is released from specific phospholipid pools. For example,
30 in neutrophils and mast cells the primary source of free arachidonic acid is 1-alkenyl-2-arachidonoyl-GPE. As shown in Figure 1, CoA-IT activity, due to its unique properties, can replenish this pool with arachidonate to allow and maintain the release of free arachidonic acid. It has now been discovered that CoA-IT activity is necessary and essential for the release
35 of free arachidonic acid and the subsequent formation of bioactive lipid mediators.

To further demonstrate the utility of inhibiting CoA-IT, the

-11-

compound of Example 3 was shown to inhibit the production of PAF (assay c) and the release of free arachidonic acid (assay b) from human neutrophils. The method of synthesis of this compound and its structural formula is set forth below. This compound inhibited PAF production (Figure 3) and free arachidonic acid release (Figure 4) completely and in a concentration dependent fashion. The specificity for inhibition of CoA-IT activity for these compounds and not the activity of other enzymes, such as PLA2 and PAF acetyl transferase, has been demonstrated. These data demonstrate that inhibition of CoA-IT can and will inhibit the production of PAF and the release of free arachidonic acid.

4. Role of CoA-IT in Inflammatory Responses *in vivo*

The ability of compounds that inhibit CoA-IT to affect *in vivo* inflammatory responses was assessed. Inflammatory responses were induced in the mouse ear by the topical application of a pro-inflammatory agent, such as 12-O-tetradecanoylphorbol 13-acetate. This produced an edematous response, as measured by increases in ear thickness, as well as increased inflammatory cellular infiltrate, as measured by increases in myeloperoxidase activity as described in the methods. Application of compounds that inhibit CoA-IT had an anti-inflammatory effect, as demonstrated for compound 3 in Figure 5. This proven anti-inflammatory effect is predictive of therapeutic usefulness in a wide variety of inflammatory diseases and conditions.

5. Assays

(a) Assay for CoA-IT Activity

The following is a method to measure CoA-IT activity and the effects of compounds on CoA-IT activity. The assay is based upon mixing cellular material containing CoA-IT activity with a stable lyso phospholipid such as 1-alkyl-2-acyl-GPC and measuring the production of phospholipid product such as 1-alkyl-2-acyl-GPC occurring in the absence of added CoA or CoA-fatty acids.

Cell Preparation

Any inflammatory cell that contains high levels of CoA-IT activity can be used, such as neutrophils, macrophages or cell lines such as U937 cells. U937 cells were obtained from American Type Culture Collection

-12-

and grown in RPMI-1640 media (Gibco, Grand Island, New York) supplemented with 10% fetal bovine serum (Hyclone, Logan, UT) at 37°C, 5%CO₂. Cells were grown without differentiation (basal state) by any agent, such as dimethyl sulfoxide. As used herein, "inflammatory cells" include, but are not limited to neutrophils, macrophages, monocytes, lymphocytes, eosinophils, basophils, and mast cells.

Microsomal preparation

Microsomes were prepared using standard techniques. In this case, cells were washed with a buffer of 250 mM sucrose, 10 mM Tris, 1 mM EGTA, 1 mM MgCl₂, pH 7.4 and ruptured by N₂ cavitation (750 psi, 10 minutes). The ruptured cells were centrifuged 1000 X g, 5 minutes. The resulting supernatant was centrifuged at 20,000 X g, ~20 minutes. Microsomes were prepared from this supernatant by centrifugation at 100,000 x g, 60 minutes. The resulting pellet was washed once with assay buffer (150 mM NaCl, 10 mM Na₂KPO₄, 1 mM EGTA, pH 7.4), recentrifuged and the pellet resuspended in assay buffer (4-20 mg protein/ml) and was stored at -80°C until assayed.

CoA-IT activity

CoA-IT activity was measured in 1.5 ml centrifuge tubes in a total volume of 100 ul. Microsomes were diluted in assay buffer to the desired protein concentration (6-20 ug/tube). The reaction was initiated by addition of [3H] 1-alkyl-2-lyso-sn-glycero-3-phosphocholine (GPC) (~ 0.1 uCi/tube) and 1 µM final cold 1-alkyl-2-lyso-GPC in assay buffer with 0.25 mg/ml fatty acid-poor bovine serumalbumin (BSA) (Calbiochem, La Jolla, CA). [3H]1-alkyl-2-lyso-GPC, approximately 50 Ci/mmol, was from NEN-Dupont (Boston, Massachusetts) and cold 1-alkyl-2-lyso-GPC was from Biomol (Plymouth Meeting, Pennsylvania). Microsomes were pretreated with desired agents for the desired time (10 minutes) before the addition of [3H]1-alkyl-2-lyso-GPC. The reaction was run for the desired time (10 minutes) at 37°C. The reaction was stopped and the lipids extracted by addition of 100 ul of chloroform:methanol (1:2, v/v) followed by 100 ul of chloroform and 100 ul of 1 M KCl. The samples were vortexed and centrifuged at high speed in a microfuge for 2-3 minutes. An aliquot of the chloroform-extracted materials were separated, usually by TLC in chloroform/methanol/acetic acid/water (50:25:8:4, v/v), visualized by

radioscanning (Bioscan) and the product, [^3H] 1-alkyl-2-acyl-GPC, was scraped and quantified by liquid scintillation spectroscopy. With this TLC system, the synthetic standards of 1-alkyl-2-lyso-GPC and 1-alkyl-2-acyl-GPC were well separated, with R_f values of approximately 0.25 and 0.65, respectively.

Protein concentration were assessed using the protein assay reagents from Bio-Rad (Richmond, California).

Results

A variety of compounds have been tested in this assay to determine its selectivity and inability to detect trivial, non-selective inhibitors. Inhibitors of 5-lipoxygenase (5-LO) and cyclooxygenase (CO), such as indomethacin, naproxen, 6-(4'-Fluorophenyl)-5-(4-pyridyl)-2,3-dihydroimidzo-[2,1-b]thiazole and 6-(4'-Fluorophenyl)-5-(4-pyridyl)2,3-dihydroimidzo-[2,1-b]thiazole-dioxide had no effect on CoA-IT activity at concentrations up to 100 μM . The anti-oxidant BHT also has no effect at concentrations up to 100 μM . Compounds which complex with phospholipids and inhibit PLA₂ activity, such as quinacrine and aristolochic acid have no effect on CoA-IT activity at concentrations up to 500 μM . Doxepine, a compound reported to inhibit PAF release did not inhibit CoA-IT at concentrations up to 100 μM . Sodiumdiclofenac, reported to decrease leukotriene production by altering arachidonic acid metabolism, had no effect on CoA-IT activity at concentrations up to 500 μM . These results show that the assay for CoA-IT activity is sensitive and selective.

Representative compounds which inhibit CoA-IT activity in a microsomal CoA-IT assay (assay a) at 50 μM are:

1. Ethyl 6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate
2. Sodium 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-heptanesulphone
3. Diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane phosphonate
4. 8-(1,4,5-Triphenylimidazol-2-yl-oxy)octanoic acid
5. 8-(2,3-Diphenylmaleimido)octanoic acid
6. 11-(2,3-Diphenylmaleimido)undecanoic acid
7. Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate

8. Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate
9. Ethyl 5-(1,4,5-triphenylimidazol-1-yl-oxy)valerate
10. 2-(7-Carboxyheptyl)-4,5-diphenyloxazole
11. Ethyl-6-(3-methyl-4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-
5 hexanoate
12. Ethyl-8-(4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octanoate
13. 8-[1-(1,4,5-Triphenylimidazol-2-yl-oxy)]octanoic acid, ammonium salt
14. 1-(7-Methoxycarbonylheptyl)-4,5-diphenyl-1,2,3-triazole
15. 8-(1,4,5-Triphenylimidazol-2-yl-oxy)-octanamide
16. 1-(7-Carboxyheptyl)-2,3,4-triphenylimidazole
17. 8-(4,5-Diphenylimidazol-2-yl-thio)octanoic acid
18. 9-[1-(3,4,5-Triphenyl-2-oxo-2,3-dihydroimidazolyl)]nonanoic acid
19. 2-(9-Hydroxynonyl)-4,5-diphenyl-1,2,3-triazole
20. Diethyl 7-(1,4,5-triphenylimidazol-2-yl-oxy)heptane phosphanate
21. 1-(6-Ethoxycarbonylhexyl)-2,4,5-triphenylimidazole
22. Ethyl 8-(4,5-Diphenylimidazol-1-yl)octanoate
23. 11-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)undecanoic acid
24. 7-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)heptanitrile
25. 7-(3,4,5-Triphenylimidazol-1-yl-oxy)heptanitrile
26. 1-(6-Carboxyhexyl)-2,4,5-triphenylimidazole
27. 2-(6-Carboxyheptyl)-4,5-diphenyl-1,2,3-triazole
28. 1-(8-Bromooctyl)-4,5-diphenyl-1,2,3-triazole
29. 1-(8-Carboxyoctyl)-2,4,5-triphenylimidazole
30. Ethyl [7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)methyl
25 phosphonate
31. 2-(2-Methoxyethoxy)ethyl-8-(4,5-diphenylimidazol-1-yl)octanoate
32. 1-(8-Cyanooctyl)-4,5-diphenyl-1,2,3-triazole
33. 1-(7-Carboxyheptyl)-2-(4-methoxyphenyl)-4,5-diphenylimidazole
34. 1-(7-Ethoxycarbonylheptyl)-2-methyl-4,5-diphenylimidazole
35. Methyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-5-heptynoate
36. 2-Benzyl-1-(7-carboxyheptyl)-4,5-diphenylimidazole
37. Ethyl 8-(phenanthro[9,10-d]imidazol-1-yl)octanoate
38. 1-(7-Carboxyheptyl)-2-(4-hydroxyphenyl)-4,5-diphenylimidazole
39. Ethyl 7-(1,4,5-triphenylimidazol-2-yloxy)heptane methylphosphinate
40. 2-[4-(3-Carboxypropoxy)phenyl]-4,5-diphenylimidazole
41. 1-(7-Carboxyheptyl)-4,5-bis(2-chlorophenyl)-2-phenylimidazole
42. 1-(7-Carboxyheptyl)-2-(4-hydroxy-3,5-diiodophenyl)-4,5-

diphenylimidazole

43. 1-(7-Carboxyheptyl)-2-phenyl-4,5-bis(4-methoxyphenyl)imidazole
44. 1-(10-Carboxydecyl)-2,4,5-triphenylimidazole
45. 1-(7-Carboxyheptyl)-2-phenylimidazole
- 5 46. 1-(7-Ethoxycarbonyl)-4-phenylimidazole
47. 8-(3,4-Diphenylpyrazol-1-yl)octanoic acid
48. 1-(8-carboxy-8,8-dimethyloctyl)-2,4,5-triphenylimidazole
49. 1-(7 Carboxyheptyl)-2-octylthio-4,5-diphenylimidazole
50. 4-[4-(2,4,5-Triphenylimidazol-1-yl)butyloxy]benzoic acid
- 10 51. 1-(Carboxyheptyl)-2-heptyl-4,5-diphenylimidazole
52. 1-(7-(5-Tetrazolyl)heptyl)-2,4,5-triphenylimidazole
53. Sodium 7-(2,4,5-triphenylimidazole-1-yl)heptane sulphonate
54. 2-[5-(1,3-dioxalan-2-yl)pentylthio]-1-(7-ethoxycarbonylheptyl)-4,5-diphenylimidazole
- 15 56. 7-(2,4,5-Triphenylimidazol-1-yl)heptane phosphonic acid

(b) Arachidonic Acid Release AssayPreparation of human neutrophils

Human neutrophils were obtained in the laboratory using three different methods. One method used leukaphoresis packs from normal humans and neutrophils were isolated using the histopaque-1077 technique. The blood was centrifuged at 300 x g for 10 minutes. The cell pellets were resuspended in PBS composed of 137 mM NaCl, 8.8 mM Na₂HPO₄, 1.5 mM KH₂PO₄, 2.7 mM KCl (Dulbecco's Gibco Laboratories, Long Island, New York) and layered over histopaque-1077 (Sigma, St. Louis, Missouri). The pellets were collected after centrifugation (300 x g for 30 minutes) and washed once in PBS. The cell pellets were exposed briefly to dionized water to lyse any erythrocytes. The remaining cells were collected by centrifugation, suspended in PBS, counted and identified after cytospinning and staining. The final leukocyte preparation was of greater than 95% purity and viability.

The second method isolated human neutrophils from fresh heparinized normal blood using the Histopaque-1077 technique. The blood was layered over Histopaque-1077 (Sigma, St. Louis Missouri) and centrifuged at 400 x g for 30 minutes. The cell pellets were resuspended in 35 ml of PBS and 12 ml of 6% Dextran, followed by Dextran sedimentation at room temperature for 45 minutes. The upper layer was collected and

further centrifugated for 10 minutes at 1000 rpm. The cell pellets were exposed briefly to deionized water to lyse erythrocytes. The remaining cells were collected by centrifugation, suspended in PBS, counted and identified after cytopinning and staining. The final leukocyte preparation was of greater than 95% purity and viability.

The third method isolated human neutrophils from freshly drawn heparinized normal blood using the Percoll technique. The blood was first treated with 6% Dextran at room temperature for a 1 hour sedimentation. The upper layers of plasma were collected and centrifuged at 400 x g for 10 minutes. The cell pellets were resuspended in Percoll 1.070 g/ml supplemented with 5% fetal bovine serum and layered on discontinuous gradients (1.080, 1.085, 1.090, 1.095 g/ml) followed by centrifugation at 400 x g for 45 minutes. The neutrophils were collected from interfaces of 1.080 and 1.085 and the 1.085 and 1.090 Percoll densities, followed by a centrifugation at 400 x g for 45 minutes. The neutrophils were suspended in PBS, counted and identified after cytopinning and staining. The final leukocyte preparation was of greater than 95% purity and viability.

There was no difference noted in the response of the neutrophils nor in the effects of test compounds in neutrophils isolated by the three different techniques.

Treatment of human neutrophils

Neutrophils were suspended in PBS with 1 mM Ca^{2+} and 1.1 mM Mg^{2+} at concentrations of 5 to 20 x 10⁶ cells per ml. Cells were added to test tubes and treated with the desired compounds for 5 to 10 minutes, then challenged with calcium ionophore A23187, 2 μM , or vehicle control, PBS containing 0.25-1 mg/ml BSA. After 5 to 20 minutes, the reactions were terminated by addition of an equal volume of chloroform:methanol (1:2, v/v) to the samples. [²H₈]Arachidonic acid (50, 100 or 200 ng) was added as an internal standard and the lipids were extracted by addition of equal volumes of chloroform and distilled water. The samples were vortexed and centrifuged at high speed and the chloroform layer removed to a clean tube.

Assay for free arachidonic acid

The chloroform extract for each sample was evaporated to dryness and the material resuspended in hexane. The hexane was passed

-17-

through a Silica solid phase column (500 mg), washed 2x with hexane and a fatty acid enriched fraction eluted with hexane:ethyl ether (1:1, v/v). Solvents were removed from the samples under a stream of nitrogen then the samples were converted to pentafluorobenzyl esters using
5 pentafluorobenzyl bromide and diisopropylethylamine in acetonitrile. Solvents were removed and samples were suspended in hexane. GC/MS analysis was performed on a suitable instrument, such as a Finnigan MAT TSQ 700 GC/MS/MS/DS (San Jose, California) operated as a single stage quadrupole system or a Hewlett-Packard 5890 with a 5989A M5
10 system.

The peaks corresponding to arachidonic acid and [$^2\text{H}_8$]Arachidonic acid were identified and the areas of those peaks compared and the released arachidonic acid calculated as ng of arachidonic acid for each sample.

15 Protein concentrations were assessed using the protein assay reagents from Bio-Rad (Richmond, CA).

(c) Assay for Production of Platelet-Activating Factor (PAF)
Preparation of human neutrophils:

20 Blood was obtained from normal humans and neutrophils were isolated as described for the arachidonic acid release assay, above. The final leukocyte preparation was of greater than 95% purity and viability.

Treatment of human neutrophils

Neutrophils were suspended in PBS at concentrations of 5 to 20 x 10⁶
25 cells per ml. Cells were added to test tubes and treated with the desired compounds for 5 to 10 minutes, then challenged with calcium ionophore A23187, 2 μM and 20-30 μCi of [^3H]acetic acid (NEN-Dupont, Boston, Massachusetts), or the vehicle of PBS with 0.25-1 mg/ml of the. After 5 to 20 minutes, the reactions were terminated by addition of an equal volume
30 of chloroform:methanol (1:2, v/v) to the samples and the lipids were extracted by addition of equal volumes of chloroform and distilled water. The samples were vortexed and centrifuged at high speed and the chloroform layer removed to a clean tube.

35 Assay for PAF

The chloroform from each tube was evaporated to dryness and the material suspended in a small volume of chloroform or chloroform:methanol (25-100 μl) and the total material spotted on a Silica

TLC plate. The plates were developed in chloroform/methanol/ acetic acid/water (50:25:8:4, v/v) visualized by radioscanning (Bioscan) and the product, [³H]PAF, was scraped and quantified by liquid scintillation spectroscopy. With this TLC system, the R_f value for a synthetic standard of PAF was approximately 0.33.

(d) Assay (Method) for TPA-induced Inflammation

Animals:

Male Balb/c inbred mice were obtained from Charle River Breeding Laboratories (Kingston, NY). Within a single experiment mice (22-25g) were age-matched. These *in vivo* experiments typically involved use of 5-6 animals/group.

TPA-induced Inflammation:

TPA (12-O-tetradecanoylphorbol 13-acetate) (Sigma Chemical Company) in acetone (4 µg/20µl) was applied to the inner and outer surfaces of the left ear of BALB/c male mice. The thickness of both ears was then measured with a dial micrometer (Mitutoyo, Japan) at both 2 and 4 hours after treatment, and the data expressed as the change in thickness (10⁻³cm) between treated and untreated ears. The application of acetone did not cause an edematous response; therefore, the difference in ear thickness represented the response to the TPA. After measuring the edema, the inflamed left ears were removed and stored at -70°C until they were assayed for MPO (myeloperoxidase) activity where appropriate.

Assay of Myeloperoxidase (MPO) in Inflamed Ear Tissue:

On the day of the assay, partially thawed ear tissues were minced and then homogenized (10% w/v) with a Tissumizer homogenizer (Tekmar Co.) in 50 mM phosphate buffer (pH 6) containing 0.5% HTAB. The tissue homogenates were taken through three cycles of freeze-thaw, followed by brief sonication (10 sec). The method of Bradley et al. was used with modifications as described. The appearance of a colored product from the MPO-dependent reaction of o-dianisidine (0.167 mg/ml; Sigma) and hydrogen peroxide (0.0005%; Sigma) was measured spectrophotometrically at 460 nm. Supernatant MPO activity was quantified kinetically (change in absorbance measured over 3 min, sampled at 15-sec intervals) using a Beckman DU-7 spectrophotometer

and a Kinetics Analysis package (Beckman Instruments, Inc.). One unit of MPO activity is defined as that degrading one micromole of peroxide per minute at 25°C.

5 **Statistics:**

Statistical analysis was done using Student's "t" test. The ED₃₅ and ED₅₀ are values which caused a 35% and 50% (respectively) inhibition of the inflammatory response and were calculated by regression analysis of the dose response data.

10 The compound of Example 3 demonstrated a positive inhibition in this animal model demonstrating a clear utility in the treatment of topically administered diseases associated with inflammation as noted herein such as, but not limited to, inflammatory bowel disease, contact dermatoses, actinic keratosis, psoriasis, or conjunctivitis.

15 Alternatively, a dosage of 50 µM/kg per os dose may be administered to the animals and the assay conducted accordingly. A positive *in vivo* response would similarly be indicative for use in disease states which require systemic treatments, as described herein, such as,
20 but not limited to, asthma, adult respiratory distress syndrome or allergic responses.

6. **Assay for screening chemical compounds for potential anti-inflammatory action**


25 An assay method for determining the inhibitory activity of compounds for CoA-IT and the inhibition of PAF and free arachidonic acid production is also encompassed by the invention. The method comprises (1) measuring the inhibition of the CoA-independent acylation of lysophospholipids in broken cell preparations of said compounds; (2)
30 measuring the inhibition of PAF production in activated inflammatory cells of said compounds; and/or (3) measuring the inhibition of free arachidonic acid release in activated inflammatory cells of said compounds. The activity of the compound is determined by inhibition of at least 20% of the activities of CoA-IT, PAF or free arachidonic acid release.
35 This assay method provides a means wherein chemical compounds can be easily screened for CoA-IT inhibiting activity.

As used herein, various abbreviations and explanations are as follows: [³H], a molecule that contains tritium atoms, a radioactive isotope; A23187, a compound that allows free entry of calcium into a cell; 5 AA, arachidonic acid; arachidonate, arachidonic acid contained within a phospholipid; free arachidonic acid, arachidonic acid that is not contained within a phospholipid; [²H₈]arachidonic acid, the form of arachidonic acid labeled with 8 deuterium atoms, a stable isotope; 1-alkyl, 1-Q-alkyl; 1-alkenyl, 1-Q-alk-1'-enyl; BSA, bovine serum albumin; 10 CoA, coenzyme A; CoA-IT, CoA-independent transacylase; DTT, dithiothreitol; EGTA, [ethylenedis(oxyethylenenitrilo)]tetra acetic acid, a calcium chelator; GPC, sn-glycero-3-phosphocholine; EDTA, a metal ion chelator; GPE, sn-glycero-3-phosphoethanolamine; GC/MS, gas chromatography and mass spectrometry; 5HETE, 5(S)-hydroxyeicosa- 15 6,8,11,14-tetraenoic acid; 15HETE, 15(S)-hydroxyeicosa-5,8,11,13-tetraenoic acid; HL-60, American Type Tissue Culture designated cell line similar to a monocyte; LTB₄, leukotriene B₄; LTC₄, leukotriene C₄; LTD₄, leukotriene D₄; lyso PAF, 1-alkyl-2-lyso-GPC, lyso platelet-activating factor; PLA₂, phospholipase A₂; PBS, phosphate buffered saline; PAF, platelet 20 activating factor, 1-alkyl-2-acetyl-GPC; PL, phospholipid; PC, phosphatidylcholine; PE, phosphatidylethanolamine, PI, phosphatidylinositol; PMN, polymorphonuclear neutrophilic cell, neutrophil; PS phosphatidylserine; Rf, the distance a compound travels as a fraction of the solvent front; TLC, thin layer chromatography; U937, 25 American Type Tissue Culture designated cell line similar to a monocyte.

Compounds

Illustrative of compounds useful in this inventions are the compounds of Formulas (I) to (VI), as noted below. Compounds which 30 are also useful in the instant invention and which do not specifically fall within any of the structures herein are further described below. Another invention is the pharmaceutical compositions for use herein comprising the compounds as noted herein, and in particular the pharmaceutical compositions comprising a compounds of Formulas (I) to (VI), or a 35 pharmacuetically acceptable salt thereof and a pharmacuetically acceptable carrier or diluent.

Compounds of Formula (I) are represented by the structure:



- wherein
- 5 R_1 is hydrogen, C_{1-4} alkyl, optionally substituted phenyl or optionally substituted heteroaryl;
 - n is an integer having a value of 4 to 12;
 - X is 5-tetrazolyl, SO_3H , $P(O)(OR_2)_2$, $P(O)(OH)_2$, or $P(O)(R_2)(OR_2)$;
 - R_2 is hydrogen or C_{1-4} alkyl;
 - 10 R_3 is independently C_{1-4} alkyl, halo substituted C_{1-4} alkyl, halogen, hydroxy or C_{1-4} alkoxy;
 - m is an integer having a value of 1 to 3;
 - q is an integer having a value of 1 to 3;
 - or a pharmaceutically acceptable salt thereof.
 - 15 Suitably, R_1 is hydrogen, C_{1-4} alkyl, optionally substituted phenyl or optionally substituted heteroaryl. Preferably R_1 is optionally substituted phenyl; most preferably an unsubstituted phenyl.
 - 20 Suitably, n is 4 to 12; preferably n is 4 to 8, most preferably n is 6 or 7.
 - Suitably m and p are 1 to 3, preferably 1.
 - 25 Suitably, X is 5-tetrazolyl, SO_3H , $P(O)(OR_2)_2$, $P(O)(OH)_2$, or $P(O)(R_2)(OR_2)$ in which R_2 is independently a C_{1-4} alkyl group. Preferably X is $P(O)(OEt)_2$ or $P(O)(Me)(OEt)$.
 - 30 Suitable R_3 substituents include, for example, 1 to 3 groups which may be the same or different and are selected from C_{1-4} alkyl, such as methyl or ethyl, halo C_{1-4} alkyl such as CF_3 , halogen, such as F or Cl, hydroxy and C_{1-4} alkoxy, such as methoxy. Preferably R_3 is

hydrogen.

Suitable heteroaryl groups include, for example, saturated or unsaturated 5- or 6-membered rings comprising 1 to 3 heteroatoms
5 selected from nitrogen, oxygen and sulphur.

Preferably such rings include, for example, thienyl and furyl rings.

- 10 Compounds of structure (I) include:
1. Diethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane phosphonate;
 2. Ethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)methyl-phosphinate;
 - 15 3. 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane phosphonic acid;
 4. Sodium 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane sulphonate;
 5. Diisopropyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane phosphonate;
 - 20 6. Dimethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane phosphonate;
 7. Diethyl-6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexane phosphonate; or
 - 25 8. Diethyl-8-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octane phosphonate.

A preferred compound of Formula (I) is 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-heptanephosphonate.

30

Another aspect of the present invention is the novel compounds and their pharmaceutical compositions of Formula (I) which are:


- Diisopropyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane phosphonate;
- 35 Dimethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane phosphonate;

Diethyl-6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexane
phosphonate;

Diethyl-8-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octane
phosphonate; and the pharmaceutically acceptable salts thereof.

5

The compounds of structure (I) can be prepared using procedures
analogous to those known in the art. The present invention therefore
provides in a further aspect a process for the preparation of compounds
of structure (I) in which X is other than 5-tetrazolyl which comprises
10 reaction of a compound of structure (Ia):



in which

15 R_1 , R_3 , m , n , and p are as described for structure (I) and L is a
leaving group, with a suitable source of the group X ; and optionally
thereafter forming a pharmaceutically acceptable salt thereof.

Compounds of structure (I) in which X is 5-tetrazolyl, can be
prepared from compounds of structure (Ia) by standard techniques, for
example, when L is bromine, by reaction with sodium cyanide in a
20 suitable solvent such as dimethylsulphoxide, to form the intermediate
compound in which L is cyano; followed by reaction with tri- n -butyl tin
azide in, for example, tetrahydrofuran to form the desired compound of
structure (I).

25 Suitable leaving groups L will be apparent to those skilled in the
art and include, for example, halogen, such as bromine.


Suitable sources of the group X will again be apparent to those
skilled in the art and include, for example, where X is SO_3Na , sodium
sulphite.

30 The reaction between the compounds of structure (Ia) and the
source of X is carried out in a solvent at elevated temperature.
Preferably, for example where X is SO_3Na the reaction is carried out in

aqueous ethanol at reflux temperature for a suitable period to allow the reaction to go to completion; and where X is a phosphorus containing group the reaction is carried out in an organic solvent such as toluene or xylene.

5

The compounds of structure (Ia) can be prepared from compounds of structure (Ib):



10

in which

R_1 , R_3 , m , n , and p are as described for structure (I) by reaction with, for example, a compound of formula $L^1(CH_2)_nL$, in which L and L^1 are suitable leaving groups, in the presence of a base such as potassium carbonate and a suitable solvent such as butanone. Suitable groups L are as described for structure (Ia). Suitable groups L^1 will be apparent to those skilled in the art, and include halogen, in particular bromine.

15


Compounds of structure (Ib) are known or can be prepared by standard techniques.

20

The compounds of Examples 1 to 8 found in the Synthetic Chemistry section serve to illustrate the preparation of compounds representative of structure (I).

25

Compounds of Formula (II) are represented by the structure



(II)

wherein

R is hydrogen, C₁₋₈alkyl, C₁₋₈alkoxy, SC₁₋₈alkyl, optionally substituted phenyl, phenyl C₁₋₄alkyl in which the phenyl group is
 5 optionally substituted, C₁₋₆alkylCHO or C₁₋₆alkylCH(OR¹)(OR²) in which each group R¹ and R² is C₁₋₄alkyl, or together form an ethane 1,2-diyl or propane 1,3-diyl group;

n is 2 to 6 and m is 0 to 6;

R³, R⁴, R⁵ and R⁶ are independently hydrogen or C₁₋₄alkyl;

10 AB is a single bond, -CH=CH-, -S-, S-phenyl or O-phenyl;
 X is CO₂H or a group hydrolysable to CO₂H, 5-tetrazolyl, SO₃H, P(O)(OR)₂, P(O)(OH)₂, or P(O)(R)(OR) in which R is hydrogen or C₁₋₄alkyl;

15 R⁷ is independently selected from hydrogen, C₁₋₄alkyl, haloC₁₋₄alkyl, halogen, hydroxy, or C₁₋₄alkoxy;

p is an integer having a value of 1 to 3;

or a pharmaceutically acceptable salt thereof;

provided that:

20 a) when X is 5-tetrazolyl, R⁷ is hydrogen, R is phenyl, and AB is a bond, then n + m are equal to a number greater than 6;

b) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is hydrogen, then R is not hydrogen;

c) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is hydrogen, then R is not alkyl or hydrogen;

25 d) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 4-hydroxy, then R is not phenyl ;

e) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 4-Methoxy or is 4-hydroxy, then R is not hydrogen;

30 f) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 2-chloro, then R is not hydrogen;

g) when (R⁷)_p is the same and is hydrogen, R is phenyl, n is 4, m is 0, and AB is O-phenyl then X is not CO₂-C₁₋₆alkyl;

h) when R is hydrogen, (R⁷)_p is the same and is hydrogen, AB is a bond, n + m is equal to 7, than X is not CH₃O-(CH₂)₂-O-(CH₂)₂-O-C(O)-;

35 i) when X is CO₂-C₁₋₆ alkyl, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is hydrogen, then R is not phenyl or 4-

methoxyphenyl;

- j) when X is CO₂-C₁₋₆ alkyl, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 4-bromo or 4-methoxy, then R is not hydrogen;
- k) when X is CO₂-C₁₋₆ alkyl, AB is a bond, n + m is equal to 7, and
5 (R⁷)_p is the same and is hydrogen, then R is not 2-(4-methoxybenzyl);
- l) when (R⁷)_p is the same and is hydrogen, R is phenyl, AB is a bond n + m is equal to 10, then X is not CO₂-C₁₋₆ alkyl;
- m) when (R⁷)_p is the same and is hydrogen, R is phenyl, n is 4, m is 0 and AB is O-phenyl, then X is not CO₂-C₁₋₆ alkyl;
- 10 n) when AB is -S-, n is 5 or 6, and m is 1 then X is CO₂H;
or a pharmaceutically acceptable salt thereof.

Suitably, p is 1 to 3, and R⁷ is independently selected from hydrogen, C₁₋₄alkyl, haloC₁₋₄alkyl, such as CF₃, halogen, hydroxy or
15 C₁₋₄alkoxy. Preferably R⁷ is hydrogen.

Suitably, R is hydrogen, C₁₋₈alkyl, C₁₋₈alkoxy, SC₁₋₈alkyl, optionally substituted phenyl, phenyl C₁₋₄alkyl in which the phenyl group is optionally substituted, C₁₋₆alkylCHO or C₁₋₆alkylCH(OR¹)(OR²)
20 in which each group R¹ and R² is C₁₋₄alkyl, or together form an ethane 1,2-diyl or propane 1,3-diyl group.

Preferably R is C₁₋₄alkyl or optionally substituted phenyl. When R is an optionally substituted phenyl the substituents include, for example, 1
25 to 3 groups which may be the same or different and are selected from C₁₋₄alkyl, haloC₁₋₄alkyl, such as CF₃, halogen, hydroxy and C₁₋₄alkoxy.

Suitably, n and m together are 4 to 12, preferably 4 to 8, and most preferably 6 or 7.

30

Suitably, R³, R⁴, R⁵ and R⁶ are the same or different and are each hydrogen or C₁₋₄alkyl. Preferably, R³, R⁴, R⁵ and R⁶ are the same and are each hydrogen.

35

Suitably, AB is a single bond, -CH=CH-, S-phenyl or O-phenyl. Preferably, AB is a single bond.

Suitably, X is CO₂H or a group hydrolysable to CO₂H, 5-tetrazolyl, SO₃H, P(O)(OR)₂, P(O)(OH)₂, or P(O)(R)(OR) in which R is hydrogen or C₁₋₄alkyl. Preferably X is CO₂H, a group hydrolysable to CO₂H or 5-tetrazolyl.

Suitable heteroaryl groups include, for example, saturated or unsaturated 5- or 6-membered rings comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur. Preferably such rings include, for example, thienyl and furyl rings.

Suitable groups X, hydrolysable to CO₂H include for example, nitriles, amides and ester groups. Examples of ester groups are C₁₋₆alkyl esters and optionally substituted benzyl esters. Particular ester groups include mono-C₁₋₄alkoxycarbonyl groups such as ethoxycarbonyl and methoxycarbonyl, and tri-C₁₋₄alkoxy carbonyl groups such as methoxyethoxyethoxy carbonyl groups (CH₃O(CH₂)₂O(CH₂)₂O-C(O)-).

Compounds of Formula (II) include:

- 20 1-(7-Ethoxycarbonylheptyl)-2,4,5-triphenylimidazole;
- 1-(7-Carboxyheptyl)-2,4,5-triphenylimidazole;
- 1-(7-Methoxycarbonylheptyl)-2,4,5-triphenylimidazole;
- 1-(6-Ethoxycarbonylhexyl)-2,4,5-triphenylimidazole;
- 1-(6-Carboxyhexyl)-2,4,5-triphenylimidazole;
- 25 1-(8-Carboxyoctyl)-2,4,5-triphenylimidazole;
- 1-(10-Carboxydecyl)-2,4,5-triphenylimidazole;
- 1-(7-Ethoxycarbonylheptyl)-2-methyl-4,5-diphenylimidazole;
- 1-(7-Carboxyheptyl)-2-methyl-4,5-diphenylimidazole;
- 1-[7-(5-Tetrazolylheptyl)]-2,4,5-triphenylimidazole;
- 30 2-(2-Methoxyethoxy)ethyl-8-(2,4,5-triphenylimidazol-1-yl)octanoate;
- Ethyl 8-(4,5-diphenylimidazol-1-yl)octanoate;
- 8-(4,5-Diphenyl-imidazol-1-yl)octanoic acid;
- 2-(2-Methoxyethoxy)ethyl-8-(4,5-diphenylimidazole-1-yl)octanoate;
- 1-(7-Ethoxycarbonylheptyl)2-(4-methoxyphenyl)-4,5-
- 35 diphenylimidazole;
- 1-(7-Carboxyheptyl)-2-(4-methoxyphenyl)-4,5-diphenylimidazole;
- 1-(7-Carboxyheptyl)-2-(4-hydroxyphenyl)-4,5-diphenylimidazole;

- 1-(7-Carboxyheptyl)-2-(4-hydroxy-3,5-diiodophenyl)-4,5-diphenylimidazole;
- 2-Benzyl-1-(7-ethoxycarbonylheptyl)-4,5-diphenylimidazole;
- 2-Benzyl-1-(7-carboxyheptyl)-4,5-diphenylimidazole;
- 5 1-(7-Ethoxycarbonylheptyl)-2-[4-octyloxyphenyl]-4, 5-diphenylimidazole;
- 1-(7-Carboxyheptyl)-2-[4-octyloxyphenyl]-4,5-diphenylimidazole;
- 1-(7-Ethoxycarbonylheptyl)-2-octylthio-4,5-diphenylimidazole;
- 1-(7-Carboxyheptyl)-2 octylthio-4,5-diphenylimidazole;
- 10 1-(7-Ethoxycarbonylheptyl)-4,5-bis-4-hydroxyphenyl)-imidazole;
- 4,5-Bis(2-chlorophenyl)-1-(7-ethoxycarbonyl-heptyl)imidazole;
- 4,5-Bis(2-chloro-phenyl)-1-(7-ethoxycarbonylheptyl)-2-phenylimidazole;
- 1-(7-Carboxyheptyl)-4,5-bis-(2-chlorophenyl)-2-phenylimidazole;
- 15 1-(7-Ethoxy-carbonylheptyl)-4,5-bis-(4-methoxyphenyl)-2-phenylimidazole;
- 1-(7-Carboxyheptyl)-4,5-bis(4-methoxy-phenyl)-2-phenylimidazole;
- 1-(7-Ethoxycarbonylheptyl)-2-heptyl-4,5-diphenylimidazole;
- 1-(7-Carboxyheptyl)-2-heptyl-4,5-diphenylimidazole;
- 20 7-(1,2,4-Triphenylimidazolyl)-hept-5-ynoic acid;
- 9-(1,2,4-Triphenylimidazolyl)-2,2-dimethylnonanoic acid;
- 4-[4-(2,4,5-Triphenylimidazolyl)butyloxy]benzoic acid;
- 7-(2,4,5-Triphenylimidazol-1-yl)heptanesulphonate;
- Sodium 7-(2,4,5-Triphenylimidazol-1-yl)heptanesulphonate;
- 25 7-(2,4,5-Triphenylimidazol-1-yl)heptanephosphonate;
- 7-(2,4,5-Triphenylimidazol-1-yl)heptanephosphonic acid;
- Ethyl 8-(phenanthro[9.10-d]imidazol-1-yl)octanoate; or
- 1-(7-Carboxyheptyl)-2-(5-[1,3-dioxalan-2-yl]pentylthio)-4,5-diphenyl
- imidazole.

30

Preferred compounds of Formula (II) include:

- 1-(7-Carboxyheptyl)-2-heptyl-4,5-diphenylimidazole;
- 1-(7-(5-Tetrazolylheptyl)-2,4,5-triphenylimidazole;
- 1-(10-Carboxydecyl)-2,4,5-triphenylimidazole;
- 35 4-[4-(2,4,5-triphenylimidazolyl)butyloxy]benzoic acid;
- 9-(1,2,4-tri-phenylimidazolyl)-2,2-dimethylnonanoic acid;
- 1-(8-Carboxyoctyl)-2,4,5-triphenylimidazole;

-29-

- 1-(7-Carboxy-heptyl)-2-(4-hydroxy-3,5-diiodophenyl)-4,5-diphenylimidazole;
Ethyl 8-(4,5-diphenylimidazol-1-yl)octanoate;
1-(7-Ethoxycarbonyl-heptyl)-2-methyl-4,5-diphenylimidazole;
5 1-(7-Carboxyheptyl)-2-(4-hydroxyphenyl)-4,5-diphenylimidazole;
1-(7-carboxyheptyl)-2,4,5-triphenylimidazole;
1-(6-ethoxy-carbonylhexyl)-2,4,5-triphenylimidazole;
1-(6-carboxyhexyl)-2,4,5-triphenylimidazole;
2-(2-methoxyethoxy)ethyl 8-(4,5-diphenylimidazole-1-yl)octanoate;
10 1-(7-carboxyheptyl)-2-(4-methoxyphenyl)-4,5-diphenylimidazole;
2-benzyl-1-(7-carboxyheptyl)-4,5-diphenylimidazole;
1-(7-carboxyheptyl)-4,5-bis(2-chloro-phenyl)-2-phenylimidazole;
1-(7-carboxyheptyl)-4,5-bis(4-methoxy-phenyl)-2-phenylimidazole;
7-(2,4,5-tri-phenylimidazol-1-yl)heptane-sulphonate;
15 7-(2,4,5-triphenylimidazol-1-yl)heptanephosphonic acid; or
Ethyl 8-(phenanthrimidazol-1-yl)octanoate.

More preferred compounds of Formula (II) are:

- 1-(7-Carboxyheptyl)-2-heptyl-4,5-diphenylimidazole;
20 1-(7-(5-Tetrazolylheptyl)-2,4,5-triphenylimidazole;
1-(10-Carboxydecyl)-2,4,5-triphenylimidazole;
4-[4-(2,4,5-triphenylimidazolyl)butyloxy]benzoic acid;
9-(1,2,4-tri-phenylimidazolyl)-2,2-dimethylnonanoic acid;
1-(8-Carboxyoctyl)-2,4,5-triphenylimidazole;
25 1-(7-Carboxy-heptyl)-2-(4-hydroxy-3,5-diiodophenyl)-4,5-diphenylimidazole;
Ethyl 8-(4,5-diphenylimidazol-1-yl)octanoate;
1-(7-Ethoxycarbonyl-heptyl)-2-methyl-4,5-diphenylimidazole; or
1-(7-Carboxy-heptyl)-2-(4-hydroxyphenyl)-4,5-diphenylimidazole.
30

Most preferred compounds of Formula (II) are:


- 1-(7-Carboxyheptyl)-2-heptyl-4,5-diphenylimidazole;
1-(7-(5-Tetrazolylheptyl)-2,4,5-triphenylimidazole; or
1-(10-Carboxydecyl)-2,4,5-triphenylimidazole.
35

The compounds of structure (II) can be prepared using procedures analogous to those known in the art. The present invention therefore

-30-


provides in a further aspect a process for the preparation of compounds of structure (II) which comprises:

- (a) for compounds other than those in which X is 5-tetrazolyl,
5 reaction of a compound of structure (IIa):




- in which Ar, R, R³, R⁴, R⁵, R⁶, R⁷, AB, n, p, and m are as described for structure (II) and L is a leaving group, with a suitable
10 source of the group X;

- (b) reaction of a compound of structure (IIb):




- 15 in which R and R⁷ are as described for structure (II) with a compound of structure (IIc):




- 20 in which R³, R⁴, R⁵, R⁶, AB, n, m and X are as described for structure (II) and L is a leaving group; or

- (c) for compounds in which A is other than a bond or
25 -CH=CH-, reaction of a compound of structure (IIId):

-31-



in which Ar, R, R³, R⁴, R⁷, and n are as described for structure (II) and L is a leaving group, with a compound of structure (IIe):



in which A¹B¹ is -C≡C-, S, O, SPh or OPh, R⁵, R⁶, m and X are as described for structure (II) and L' is hydrogen or a metal;

(d) for compounds in which X is 5-tetrazolyl reaction of a compound of structure (IIa) in which L is CN, with tri-n-butyl tin azide, and optionally thereafter converting one group X into another group X, and optionally forming a salt.

Suitable leaving groups L will be apparent to those skilled in the art and include, for example, halogen, such as bromine, and sulphonic acid derivatives such as tosylate and mesylate.

Suitable metals include, for example, alkali metals such as sodium or lithium.

Suitable sources of the group X will again be apparent to those skilled in the art and include, for example, where X is SO₃Na, sodium sulphite.

The reaction between the compounds of structure (IIa) and the source of X is carried out in a solvent at elevated temperature. Preferably, for example where X is SO₃Na the reaction is carried out in aqueous ethanol at reflux temperature for a suitable period to allow the reaction to go to completion; and where X is a phosphorus containing group the reaction is carried out in an organic solvent such as toluene or xylene.

5 The reaction between compounds of structure (IIb) and structure (IIc) can be carried out in an organic solvent in the presence of a base, at a temperature of between ambient and the reflux temperature of the solvent used. Suitable solvents include, for example, C₁₋₄ alkanols such as methanol or ethanol, dimethyl formamide and butanone, and suitable bases include, for example, potassium carbonate, sodium hydroxide and sodium hydride.

10 The reaction between compounds of structure (IIId) and structure (IIe) is carried out in a suitable solvent in the presence of a base at a temperature of between ambient and the reflux temperature of the solvent used.

15 Suitable solvents and reagents include, for example, potassium carbonate as the base in butanone as solvent, and sodium in methanol as a solvent.


20 Compounds of structure (II) in which X is 5-tetrazolyl, can be prepared from compounds of structure (IIa) by standard techniques, for example, when L is bromine, by reaction with sodium cyanide in a suitable solvent such as dimethylsulphoxide, to form the intermediate compound in which L is cyano; followed by reaction with tri-n-butyl tin azide in, for example, tetrahydrofuran to form the desired compound of
25 structure (II).

The intermediate compounds of structures (IIa), (IIb), (IIc), (IIId) and (IIe) are known or can be prepared by standard techniques.

30 Examples 9 to 49 found in the synthetic chemistry section serve to illustrate the preparation of compounds representative of structure (II).

The compounds of Formula (III) are represented by the structure

-33-



wherein

R₁ is hydrogen, C₁₋₄ alkyl, optionally substituted phenyl or optionally substituted heteroaryl;

5 n is 4 to 12;

Y is oxygen or sulfur;

X is 5-tetrazolyl, cyano, SO₃H, P(O)(OR₂)₂, P(O)(OH)₂, or P(O)(R₂)(OR₂);

R₂ is hydrogen or C₁₋₄ alkyl;

10 R₃ is independently hydrogen, C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl, halogen, hydroxy or C₁₋₄ alkoxy;

m is an integer having a value of 1 to 3;

q is an integer having a value of 1 to 3;

provided that when X is cyano, R₁ is an optionally substituted phenyl; or a pharmaceutically acceptable salt thereof.

15

Suitably, R₁ is hydrogen, C₁₋₄ alkyl, optionally substituted phenyl or optionally substituted heteroaryl. Preferably R₁ is optionally substituted phenyl; most preferably an unsubstituted phenyl.

20

Suitably, n is 4 to 12; preferably n is 4 to 8, most preferably n is 6 or 7.

Suitably Y is oxygen or sulphur; preferably Y is oxygen.

Suitably m and p are 1 to 3, preferably 1.

25

Suitably, X is 5-tetrazolyl, SO₃H, P(O)(OR₂)₂, P(O)(OH)₂, or P(O)(R₂)(OR₂) in which R₂ is independently a C₁₋₄ alkyl group. Preferably X is P(O)(OEt)₂ or P(O)(Me)(OEt).

30

Suitable R₃ substituents include, for example, 1 to 3 groups which may be the same or different and are selected from C₁₋₄ alkyl, such as

methyl or ethyl, haloC₁₋₄ alkyl such as CF₃, halogen, such as F or Cl, hydroxy and C₁₋₄ alkoxy, such as methoxy.

Suitable heteroaryl groups include, for example, saturated or
5 unsaturated 5- or 6-membered rings comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur.

Preferably such rings include, for example, thienyl and furyl
rings.

10

Compounds of structure (III) include:

Sodium 6-(1,4,5-triphenylimidazol-2-yl-oxy)hexanesulphonate;
Sodium 7-(1,4,5-triphenylimidazol-2-yl-oxy)heptanesulphonate;
7-(1,4,5-Triphenylimidazol-2-yl-oxy)heptanemethylphosphinate;
15 7-(1,4,5-Triphenylimidazol-2-yl-oxy)heptanephosphonate;
Ethyl-7-(1,4,5-triphenyl-imidazol-2-yl-oxy)heptane methylphosphinate;
Diethyl-7-(1,4,5-triphenyl-imidazol-2-yl-oxy)heptane phosphonate; and
7-(3,4,5-Triphenylimidazol-1-yl-oxy)heptanitride.


20

Preferred compounds of Formula (III) include:

Ethyl-7-(1,4,5-triphenyl-imidazol-2-yl-oxy)heptane methylphosphinate;
and
Diethyl-7-(1,4,5-triphenyl-imidazol-2-yl-oxy)heptane phosphonate.

25

The compounds of structure (III) can be prepared using procedures analogous to those known in the art. The present invention therefore provides in a further aspect a process for the preparation of compounds of structure (III) in which X is other than 5-tetrazolyl which comprises reaction of a compound of structure (IIIa):



30

(IIIa)

in which

R₁, R₃, m, n, and p are as described for structure (III) and L is a leaving group, with a suitable source of the group X; and optionally thereafter forming a pharmaceutically acceptable salt thereof.

5

Compounds of structure (III) in which X is 5-tetrazolyl, can be prepared from compounds of structure (IIIa) by standard techniques, for example, when L is bromine, by reaction with sodium cyanide in a suitable solvent such as dimethylsulphoxide, to form the intermediate compound in which L is cyano; followed by reaction with tri-n-butyl tin azide in, for example, tetrahydrofuran to form the desired compound of structure (III).

10

Suitable leaving groups L will be apparent to those skilled in the art and include, for example, halogen, such as bromine.

15

Suitable sources of the group X will again be apparent to those skilled in the art and include, for example, where X is SO₃Na, sodium sulphite.

20


The reaction between the compounds of structure (IIIa) and the source of X is carried out in a solvent at elevated temperature. Preferably, for example where X is SO₃Na the reaction is carried out in aqueous ethanol at reflux temperature for a suitable period to allow the reaction to go to completion; and where X is a phosphorus containing group the reaction is carried out in an organic solvent such as toluene or xylene.

25

The compounds of structure (IIIa) can be prepared from compounds of structure (IIIb):

30

-36-




in which

R_1 , R_3 , Y , m , n , and p are as described for structure (III) by
 5 reaction with, for example, a compound of formula $L^1(CH_2)_nL$, in which
 L and L^1 are suitable leaving groups, in the presence of a base such as
 potassium carbonate and a suitable solvent such as butanone. Suitable
 groups L are as described for structure (IIIa). Suitable groups L^1 will be
 apparent to those skilled in the art, and include halogen, in particular
 10 bromine.

Compounds of structure (IIIb) are known or can be prepared by
 standard techniques.

15 Examples 50 to 55 found in the synthetic chemistry section serve to
 illustrate the preparation of compounds represented by structure (III).

The compounds of Formula (IV) are represented by the structure



20 wherein

X is nitrogen or CR^1 ;

R^1 is hydrogen, C_{1-4} alkyl, optionally substituted phenyl or

optionally substituted heteroaryl;

25 Y is nitrogen, $N(CH_2)_nA$ or $C(CH_2)_nA$

Z is nitrogen, oxygen or $N(CH_2)_nA'$, and the dotted line indicates

-37-

the optional presence of a double bond so as to form a fully unsaturated heterocyclic ring;

n is 4 to 12;

5 A is CO_2H or a group hydrolysable to CO_2H , OH , Br , Cyano, 5-tetrazolyl, SO_3H , $\text{P}(\text{O})(\text{OR})_2$, $\text{P}(\text{O})(\text{OH})_2$, or $\text{P}(\text{O})(\text{R})(\text{OR})$ in which R is hydrogen or C_{1-4} alkyl;

A' is CO_2H or a group hydrolysable to CO_2H , 5-tetrazolyl, SO_3H , $\text{P}(\text{O})(\text{OR})_2$, $\text{P}(\text{O})(\text{OH})_2$, or $\text{P}(\text{O})(\text{R})(\text{OR})$ in which R is hydrogen or C_{1-4} alkyl;

10 R^2 is independently C_{1-4} alkyl, halo substituted C_{1-4} alkyl, halogen, hydroxy or C_{1-4} alkoxy;

m is a number having a value of 1 to 3;

provided that

- a) X , Y and Z are not all at the same time, nitrogen;
- 15 b) when X is CR^1 , Y and Z are not both nitrogen;
- c) when Y is $\text{N}(\text{CH}_2)_n\text{A}$, Z is nitrogen; and
- d) when Z is oxygen, Y is $\text{C}(\text{CH}_2)_n\text{A}$;
- e) when Y is $\text{N}(\text{CH}_2)_n\text{A}$, X and Z are nitrogen, $(\text{R}_2)_m$ is the same and is hydrogen, and n is 6, 7, or 8 then X is not $-\text{CO}_2\text{-C}_{1-6}$
- 20 alkyl;
- f) when Z is oxygen, Y is $\text{C}(\text{CH}_2)_n\text{A}$, n is 8, and $(\text{R}_2)_m$ is the same and is hydrogen, then X is not cyano;
- g) when Z is $\text{N}(\text{CH}_2)_n\text{A}'$, X is nitrogen, Y is nitrogen, $(\text{R}_2)_m$ is the same and is hydrogen, and n is 7, then X is not CO_2H ;
- 25 h) when Y is $\text{N}(\text{CH}_2)_n\text{A}$, X and Z are nitrogen, $(\text{R}_2)_m$ is the same and is hydrogen, and n is 8 then X is not cyano; or a pharmaceutically acceptable salt thereof.

Suitably, X is nitrogen or CR^1 ; preferably X is nitrogen.

30

Suitably, Y is nitrogen, $\text{N}(\text{CH}_2)_n\text{A}$ or $\text{C}(\text{CH}_2)_n\text{A}$; preferably, Y is nitrogen or $\text{N}(\text{CH}_2)_n\text{A}$; most preferably Y is $\text{N}(\text{CH}_2)_n\text{A}$.

35 Suitably, Z is nitrogen, $\text{N}(\text{CH}_2)_n\text{A}$ or oxygen; preferably Z is nitrogen or $\text{N}(\text{CH}_2)_n\text{A}$; most preferably Z is nitrogen.

Suitably, n is 4 to 12, preferably 4 to 8 and most preferably 7 or 8.

Suitably, A is CO_2H or a group hydrolysable to CO_2H , OH, Br, cyano, 5-tetrazolyl, SO_3H , $\text{P}(\text{O})(\text{OR})_2$, $\text{P}(\text{O})(\text{OH})_2$, or $\text{P}(\text{O})(\text{R})(\text{OR})$ in which
5 R is hydrogen or C_{1-4} alkyl; preferably A is CO_2H or a group hydrolysable to CO_2H , for example $\text{CO}_2\text{C}_{1-4}$ alkyl such as CO_2CH_3 or $\text{CO}_2\text{C}_2\text{H}_5$.

Suitably, A' is CO_2H or a group hydrolysable to CO_2H , 5-tetrazolyl, SO_3H , $\text{P}(\text{O})(\text{OR})_2$, $\text{P}(\text{O})(\text{OH})_2$, or $\text{P}(\text{O})(\text{R})(\text{OR})$ in which R is hydrogen or
10 C_{1-4} alkyl; preferably A is CO_2H or a group hydrolysable to CO_2H , for example $\text{CO}_2\text{C}_{1-4}$ alkyl such as CO_2CH_3 or $\text{CO}_2\text{C}_2\text{H}_5$.

Suitably, R^1 is hydrogen, C_{1-4} alkyl, optionally substituted phenyl or optionally substituted heteroaryl. Preferably R^1 is hydrogen.
15

Suitable R^2 substituents or substituents for R^1 as an optionally substituted phenyl groups Ar and R^1 include, for example, 1 to 3 groups which may be the same or different and are selected from C_{1-4} alkyl, haloC_{1-4} alkyl, such as CF_3 , halogen, hydroxy and C_{1-4} alkoxy.
20

Suitable heteroaryl groups include, for example, saturated or unsaturated 5- or 6-membered rings comprising 1 to 3 heteroatoms selected from nitrogen, oxygen and sulphur. Preferably such rings include, for example, thienyl and furyl rings.
25

Particularly preferred compounds of structure (IV) include:
1-(8-Bromooctyl)-4,5-diphenyl-1,2,3-triazole;
2-(8-Bromooctyl)-4,5-diphenyl-1,2,3-triazole;
1-(8-cyanooctyl)-4,5-diphenyl-1,2,3-triazole;
30 2-(8-cyanooctyl)-4,5-diphenyl-1,2,3-triazole;
2-(8-carboxyoctyl)-4,5-diphenyl-1,2,3-triazole;
1-(8-carboxyoctyl)-4,5-diphenyl-1,2,3-triazole;
2-(8-ethoxycarbonyloctyl)-4,5-diphenyl-1,2,3-triazole;
2-(6-Ethoxycarbonylhexyl)-4,5-diphenyl-1,2,3-triazole;
35 2-(6-Carboxyheptyl)-2,4,5-triphenyl-1,2,3-triazole;
2-(7-Carboxyheptyl)-4,5-diphenyloxazole;

- 1-(7-bromoheptyl)-4,5-diphenyloxazole;
 2-(7-cyanoheptyl)-4,5-diphenyloxazole;
 8-(3,4-Diphenylpyrazol-1-yl)octanoic acid;
 8-(4,5-Diphenylpyrazol-1-yl)octanoic acid;
 5 1-(7-Methoxycarbonylheptyl)-4,5-diphenyl-1,2,3-triazole;
 2-(7-Methoxycarbonylheptyl)-4,5-diphenyl-1,2,3-triazole;
 1-(7-Carboxyheptyl)-4,5-diphenyl-1,2,3-triazole;
 8-(3,4-diphenylpyrazol-1-yl)octanoic acid;
 8-(4,5-diphenylpyrazol-1-yl)octanoic acid; and
 10 2-(9-Hydroxynonyl)-4,5-diphenyl-1,2,3-triazole.


Preferred compounds of structure (IV) include:

- 1-(8-Bromooctyl)-4,5-diphenyl-1,2,3-triazole;
 2-(8-cyanooctyl)-4,5-diphenyl-1,2,3-triazole;
 15 8-(3,4-diphenylpyrazol-1-yl)octanoic acid;
 2-(9-Hydroxynonyl)-4,5-diphenyl-1,2,3-triazole;
 2-(7-Methoxycarbonylheptyl)-4,5-diphenyltriazole;
 8-(3,4-Diphenylpyrazol-1-yl)octanoic acid;
 8-(4,5-Diphenylpyrazol-1-yl)octanoic acid;
 20 2-(6-Carboxyheptyl)-2,4,5-triphenyl-1,2,3-triazole; and
 2-(7-Carboxyheptyl)-4,5-diphenyloxazole.

Most preferred compounds of structure (IV) include:

- 2-(9-Hydroxynonyl)-4,5-diphenyl-1,2,3-triazole;
 25 2-(7-Methoxycarbonylheptyl)-4,5-diphenyltriazole; and
 1-(8-Bromooctyl)-4,5-diphenyl-1,2,3-triazole.

The compounds of structure (IV) can be prepared using
 procedures analogous to those known in the art. The present invention
 30 therefore provides in a further aspect a process for the preparation of
 compounds of structure (IV) which comprises:



in which


R^2 , X, m are as described for structure (IV) and Y_a is N or $C(CH_2)_nA$; with a compound of structure :



in which n and A are as described for structure (IV) and L is a leaving group, or

(b) reaction of a compound of structure (IVc):

10



in which R^2 , m and X are as described in structure (IV), Y_b is N, $N(CH_2)_nA_b$ or $C(CH_2)_nA_b$, Z_b is N, O or $N(CH_2)_nA_b$ provided that:

15

- X, Y_b and Z_b are not all nitrogen,
- when X is CR^1 , Y_b and Z_b are not both nitrogen,
- when Y_b is $N(CH_2)_nA_b$, Z_b is nitrogen, and
- when Z_b is O, Y_b is $-C(CH_2)_nA_b$;

20

A_b is a group convertible to a group A as described in structure (IV), with a reagent suitable to convert the group A_b into a group A and, optionally thereafter, converting one group A into another group A, and optionally forming a salt.

25

Suitable leaving groups L will be apparent to those skilled in the art and include, for example, halogen, such as bromine.

Suitable groups A_b convertible to a group A include, for example, where A is CO_2H , CN groups, which can be converted into CO_2H groups by reaction with, for example, sulphuric acid. Other groups and suitable reagents will be apparent to those skilled in the art.


30

The reaction between compounds of structures (IVa) and (IVb) can be carried out in a suitable solvent in the presence of a base at a temperature of between ambient and the reflux temperature of the solvent used. For example, compounds of structure (IV) in which X and Y are both nitrogen and Z is $N(CH_2)_n CO_2R$, can be prepared by reacting a compound of structure (IVa) in which X and Y_a are both nitrogen with a compound of structure (IVb) in which L is bromine and A is CO_2H , in aqueous solution in the presence of sodium hydroxide as base. Further reaction of said compound of structure (IV) with, for example, p-toluene sulphonic acid in methanol gives the corresponding compound in which A is CO_2CH_3 . The compounds of structures (IVa) and (IVb) are available commercially, or can be prepared by standard techniques.

The reaction between compounds of structure (IVc) and a reagent suitable to convert the group A_b to a group A will, of course, take place under conditions which will depend on the nature of the group A_b . As already described, for example when A_b is CN, reaction with sulphuric acid under aqueous conditions affords the desired compounds of structure (IV) in which A is CO_2H .

Other suitable groups and conditions will be apparent to those skilled in the art. Compounds of structure (IVc) are available commercially or can be prepared by standard procedures. For example, compounds of structure (IVc) in which X is nitrogen, Y_b is $C(CH_2)_n CN$ and Z_b is oxygen can be prepared via the following reaction sequence:


-42-



Examples 56 to 68 in the Synthetic Chemistry section serve to illustrate the preparation of compounds representative of structure (IV).

5

Compounds of Formula (V) are represented by the structure:



wherein

R_1 is hydrogen, C_{1-4} alkyl, or optionally substituted phenyl;

10 n is 2 or 4 to 12;

X is cyano, CO_2H or a group hydrolysable to CO_2H ;

R_3 is independently C_{1-4} alkyl, halo substituted C_{1-4} alkyl, halogen, hydroxy or C_{1-4} alkoxy;

q is an integer having a value of 1 to 3;

15 or a pharmaceutically acceptable salt thereof.

Suitably, p is 1 to 3, and R₃ is independently selected from hydrogen, C₁₋₄ alkyl, haloC₁₋₄ alkyl, such as CF₃, halogen, hydroxy or C₁₋₄ alkoxy. Preferably R₃ is hydrogen. Suitable when n is 2 then X is not cyano.

5 Suitably, R₁ is hydrogen, C₁₋₈ alkyl, C₁₋₈ alkoxy, SC₁₋₈ alkyl, optionally substituted phenyl, or phenyl C₁₋₄ alkyl in which the phenyl group is optionally substituted. Preferably R₁ is C₁₋₄ alkyl or optionally substituted phenyl. When R₁ is an optionally substituted phenyl the
10 substituent include, for example, 1 to 3 groups which may be the same or different and are selected from C₁₋₄ alkyl, haloC₁₋₄ alkyl, such as CF₃, halogen, hydroxy and C₁₋₄ alkoxy.

Suitably, n and m together are 4 to 12, preferably 4 to 8, and most preferably 6 or 7.


15 Suitable groups X, hydrolysable to CO₂H include for example, nitriles, amides and ester groups. Examples of ester groups are C₁₋₆ alkyl esters and optionally substituted benzyl esters. Particular ester groups include mono-C₁₋₄ alkoxy carbonyl groups such as ethoxycarbonyl
20 and methoxycarbonyl, and tri-C₁₋₄ alkoxy carbonyl groups such as methoxyethoxyethoxy carbonyl groups (CH₃O(CH₂)₂O(CH₂)₂O-C(O)-).

Compounds of Formula (V) include:

Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate;
25 Ethyl 6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;
Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate;
9-[1-(3,4,5-Triphenyl-2-oxo-2,3-dihydroimidazolyl)]nonanoic acid;
7-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)heptanitrile;
Ethyl 6-(3-methyl-4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;
30 11-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)undecanoic acid; or
Ethyl-8-(4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octanoate.

Compounds of Formula (VI) are represented by the structure:

-44-



wherein

R₁ is hydrogen, C₁₋₄ alkyl, or optionally substituted phenyl;

n is 4 to 12;

5 Y is oxygen or sulfur;

X is CO₂H or a group hydrolysable to CO₂H;

R₃ is independently C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl, halogen, hydroxy or C₁₋₄ alkoxy;

q is an integer having a value of 1 to 3;

10 or a pharmaceutically acceptable salt thereof.

Suitably the variables R₁, R₃, p, n, and X as described in Formula (V) are the same for Formula (VI).

15 Compounds of Formula (VI) include:

Ethyl 5-(1,4,5-triphenylimidazol-1-yl-oxy)valerate;

8-(1,4,5-Triphenylimidazol-2-yl-oxy)octanamide;

8-[1,4,5-Triphenylimidazol-2-yl-oxy]octanoic acid; or

8-[1,4,5-triphenylimidazol-2-yl-oxy]octanoic acid ammonium salt.

20

Additional compounds which are not encompassed by Formula(s) (I) to (VI) but are useful in this invention are listed below:

7-(3,4,5-Triphenylimidazol-1-yl-oxy)heptanitrile;

8-(2,3-Diphenylmaleimido)octanoic acid;

25 11-(2,3-Diphenylmaleimido)undecanoic acid;

1-(7-Ethoxycarbonyl)-4-phenylimidazole;

Methyl-7-(3,4,5-triphenyl)-2-oxo-1,2-dihydroimidazol-1-yl)-5-heptynoate;

2-[4-(3-Carboxypropoxy)phenyl]-4,5-diphenylimidazole;

30 1-(7-Carboxyheptyl)-2-phenylimidazole;

1-(7-Ethoxycarbonyl)-4-phenylimidazole;

-45-

1-(7-Carboxyheptyl)-2-octylthio-4,5,-diphenylimidazole;
8-(1,4,5-Triphenylimidazol-2-yl-oxy)octanamide; and the
pharmaceutically acceptable salts thereof.

5 Preferred compounds of the Formula (V), (VI) and the additional
compounds noted above are:

- 1-(7-Carboxyheptyl)-2-octylthio-4,5,-diphenylimidazole;
8-[1,4,5-Triphenylimidazol-2-yl-oxy]octanoic acid;
Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate;
10 Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate;
Ethyl 6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;
7-(3,4,5-Triphenylimidazol-2-oxo-2,3-dihydroimidazol-1-yl)-
heptanonitrile;
Ethyl 6-(3-methyl-4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;
15 1-(7-Ethoxycarbonyl)-4-phenylimidazole; and
Methyl-7-(3,4,5-triphenyl)-2-oxo-1,2-dihydroimidazol-1-yl)-5-heptynoate.

More preferred compounds for use herein are:

- 1-(7-Carboxyheptyl)-2-octylthio-4,5,-diphenylimidazole;
20 8-[1,4,5-Triphenylimidazol-2-yl-oxy]octanoic acid;
Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate;
Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate; and
7-(3,4,5,-Triphenylimidazol-2-oxo-2,3-dihydroimidazol-1-yl)-
heptanonitrile.

25

Examples 69 to 83 in the Synthetic Chemistry section serve to
illustrate the preparation of compounds representative of structure (V),
(VI) and the additional compounds noted above.

30 Methods of Treatment

Inhibition of CoA-IT and the simultaneous reduction of PAF and
free arachidonic acid and eicosanoid release from inflammatory cells
according to this invention is of therapeutic benefit in a broad range of
diseases or disorders. The invention is useful to treat disease states both
35 in humans and in other mammals.

This invention reveals that inhibition of CoA-IT is an effective

means for simultaneously reducing PAF, free arachidonic acid and eicosanoids produced in inflammatory cells. Since PAF, free arachidonic acid and eicosanoids mediate a broad range of diseases and disorders in human and other mammals, blockage of CoA-IT will be a useful way to

5 treat these disease states. The therapeutic utility of blocking lipid mediator generation has been recognized for many years. For example, inhibitors of cyclooxygenase, such as aspirin, indomethacin, acetaminophen and ibuprofen, have demonstrated broad therapeutic utilities. CoA-IT inhibitors inhibit cyclooxygenase products. Another

10 class of inhibitors which are used in a broad range of inflammatory disorders are the corticosteroids. Corticosteroids induce inflammatory cells to produce proteins which inhibit free arachidonic acid release. CoA-IT inhibitors block the release of free arachidonic acid. Inhibitors of 5-lipoxygenase block the production of leukotrienes and leukotriene

15 antagonists prevent the bioactions of leukotrienes. Recent studies indicate that both will have broad therapeutic utilities, and CoA-IT inhibitors block the production of leukotrienes. Inhibitors of phospholipase A₂ block the release of free arachidonic acid and the formation of lyso PAF (the immediate precursor of PAF). PLA₂ inhibitors are proposed to have broad

20 therapeutic utilities. CoA-IT inhibitors block the release of free arachidonic acid and PAF generation. Taken together with the *in vivo* data presented in figure 5, inhibition of CoA-IT will have broad therapeutic utility by virtue of its capacity to block lipid mediator generation. Compounds that inhibit CoA-IT activity will thus be useful in

25 many disease states. However, it does not follow that these disease states are in fact caused by altered CoA-IT activity. Thus, the disease may not be directly mediated by CoA-IT activity. It only follows that CoA-IT activity is required for the continued expression of symptoms of the disease state and that CoA-IT inhibitors will be beneficial against the symptoms of these

30 disease states.

This invention reveals that inhibition of CoA-IT, an enzyme that affects arachidonate movement, blocks PAF production. This is an expected result because PAF metabolism and arachidonic acid

35 metabolism are closely linked, in that 1-alkyl-2-arachidononyl-GPC is a major precursor for PAF [Chilton et al., *J. Biol. Chem.* 259:12014-12019, (1984)] and arachidonate in the sn-2 position of this molecule appears to

play a role in its recognition by PLA2 enzymes specific for arachidonic acid [Bonelli et al., J. Biol. Chem., 264:14723-14728 (1989); Channon et al., J. Biol. Chem., 265:5409-5413 (1990); Diez et al., J. Biol. Chem., 265:14654-14661 (1990)]. Arachidonate depletion in cells has further been coupled to a loss of PAF production and refeeding of arachidonate to those cells restored PAF production. These data suggest that maintenance of arachidonate containing alkyl- and alkenyl-linked phospholipid pools, a process mediated by CoA-IT, may in effect prime inflammatory cells for the coordinated production of prostaglandins, leukotrienes and PAF.

Interruption of CoA-IT activity would therefore inhibit arachidonate reincorporation into the alkyl and alkenyl-linked phospholipid pools (Figure 1, pool 2). Further inhibition of CoA-IT could also lead to depletion of arachidonate in the alkyl and alkenyl phospholipid pools and consequently decrease both free arachidonic acid release and PAF production. Finally, CoA-IT may also be important in the initial mobilization of precursors to PAF (lysoPAF) and arachidonic acid metabolites (free arachidonic acid). Inhibitors of CoA-IT have now been shown to block the formation of these intermediates.

This invention reveals that inhibition of CoA-IT reduces PAF production and this finding has a number of therapeutic implications. PAF itself has been implicated as being involved in a number of medical conditions. Thus in circulatory shock, which is characterised by systemic hypotension, pulmonary hypertension and increased lung vascular permeability, the symptoms can be mimicked by infusion of PAF. This coupled with evidence showing that circulating PAF levels are increased by endotoxin infusion indicate that PAF is a prime mediator in certain forms of shock.

Intravenous infusion of PAF at doses of 20-200 pmol kg⁻¹ min⁻¹ into rats has been reported to result in the formation of extensive haemorrhagic erosions in the gastric mucosa. Thus PAF is the most potent gastric ulcerogen yet described whose endogenous release may underlie or contribute to certain forms of gastric ulceration. Psoriasis is an inflammatory and proliferative disease characterised by skin lesions.

PAF is pro-inflammatory and has been isolated from lesioned scale of psoriatic patients indicating PAF has a role in the disease of psoriasis. And finally, increasing evidence supports a potential patho-physiological role for PAF in cardiovascular disease. Thus recent studies in angina patients show PAF is released during atrial pacing. Intracoronary injection of PAF in pigs induces a prolonged decrease in coronary flow and, in guinea pig hearts, it induces regional shunting and ischaemia. In addition PAF has been shown to initiate thrombus formation in a mesenteric artery preparation, both when administered exogenously and when released endogenously. More recently PAF has been shown to play a role in brain ischaemia induced in animal models of stroke.

Thus the compounds of the invention, by virtue of their ability to antagonise CoA-IT and thus block the production of PAF, free arachidonic acid and its metabolites, are likely to be of value in the treatment of any of the above conditions.

For therapeutic use the compounds of the present invention will generally be administered in a standard pharmaceutical composition obtained by admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, they may be administered orally in the form of tablets containing such excipients as starch or lactose, or in capsule, ovules or lozenges either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. They may be injected parenterally, for example, intravenously, intramuscularly or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The choice of form for administration as well as effective dosages will vary depending, inter alia, on the condition being treated. The choice of mode of administration and dosage is within the skill of the art.

The compounds of structures (I) to (VI) and any others noted herein or their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups,

suspensions or emulsions, tablets, capsules and lozenges.

5 A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.

10 A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.

15 A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or
20 suspension then filled into a soft gelatin capsule.

Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol,
25 polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.

30 A typical suppository formulation comprises a compound of structure (I) or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent such as polymeric glycols, gelatins or cocoa butter or other low melting vegetable or synthetic waxes or fats.

35 Preferably the composition is in unit dose form such as a tablet or capsule.

Each dosage unit for oral administration contains preferably from 1 to 250 mg (and for parenteral administration contains preferably from 0.1 to 25 mg) of a compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base.

5

The pharmaceutically acceptable compounds of the invention will normally be administered to a subject in a daily dosage regimen. For an adult patient this may be, for example, an oral dose of between 1 mg and 500 mg, preferably between 1 mg and 250 mg, or an intravenous, 10 subcutaneous, or intramuscular dose of between 0.1 mg and 100 mg, preferably between 0.1 mg and 25 mg, of the compound of the structure (I) or a pharmaceutically acceptable salt thereof calculated as the free base, the compound being administered 1 to 4 times per day.

15 Disease states which could benefit from the inhibition of CoA-IT include, but are not limited to, adult respiratory distress syndrome, asthma, arthritis, reperfusion injury, endotoxic shock, inflammatory bowel disease, allergic rhinitis and various inflammatory skin disorders. Each of these disorders is mediated in some part by lipid mediators of 20 inflammation. Compounds which inhibit CoA-IT, by virtue of their ability to block the generation of lipid mediators of inflammation, are of value in the treatment of any of these conditions.

SYNTHETIC CHEMISTRY

25 Without further elaboration, it is believed that one skilled in the art can, using the preceding descriptions, utilize the present invention to its fullest extent. The following examples further illustrate the synthesis of compounds of this invention. The following examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the 30 present invention in any way.

Temperatures are recorded in degrees centigrade unless otherwise noted.

EXAMPLE 1

35 Sodium 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-heptane-sulphonate

A mixture of 1,4,5-triphenylimidazol-2-one (15.3g),

dibromoheptane (50.6g) and potassium carbonate (13.8g) was heated at reflux temperature in dry butanone (750ml) for 20 hours. The mixture was cooled, filtered and the filtrate evaporated to an oil which was chromatographed on silica gel (hexane/ethyl acetate) to give 1,4,5-triphenyl-3-(7-bromoheptyl)imidazole-2-one (11.1g, 46%) as an oil.

NMR δ (CDCl_3) 1.2-1.9 (10H, m, $5 \times \text{CH}_2$), 3.4 (2H, t, $-\text{CH}_2\text{Br}$), 3.7 (2H, t, $-\text{CH}_2\text{N}$), 6.8-7.4 (15H, m, $3 \times \text{Ph}$) ppm.

A solution of 1,4,5-triphenyl-3-(7-bromoheptyl)imidazol-2-one (2.0g) in ethanol (10ml) was refluxed with a solution of sodium sulphite (0.55g) in water (5ml) for 20 hours. More sodium sulphite (0.2g) was added and refluxing continued for a further 20 hours. The mixture was evaporated to dryness, boiled in ethanol, filtered hot and evaporated to an oil. This was taken up in a small volume of ethanol, excess diethyl ether added and the precipitated solid filtered off and chromatographed on silica gel (dichloro-methane/methanol 5:1). The resulting oil in methanol/water 1:1 was passed down an Amberlyst 15 ion exchange resin (Na form) and evaporated to a solid. This was taken up in ethanol and precipitated with diethyl ether giving sodium 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane-sulphonate (0.49g), 23%) as a white solid, m.p. 160°C .

Found: C, 63.47; H, 5.69; N, 5.04; S, 5.63%; $\text{C}_{28}\text{H}_{29}\text{N}_2\text{NaO}_4\text{S} + 3.5\%$ water; Requires: C, 63.31; H, 5.89; N, 5.28; S, 6.04%

25

EXAMPLE 2

7-(3,4,5-Triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-heptanephosphonic acid

Diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptanephosphonate (0.58g) was dissolved in dry chloroform, cooled to -40°C and to it was added trimethylsilyl iodide (1.05g) over 2 mins under an atmosphere of nitrogen. The cooling bath was removed and the reaction mixture was stirred for 2.5 hours at room temperature then evaporated to an oil and re-evaporated from methanol, treated with excess aqueous sodium bicarbonate, evaporated to an oil and re-evaporated from methanol, water and ethanol respectively. The oil was taken up in ethanol, treated with excess aqueous sodium bicarbonate, evaporated to

-52-

dryness then taken up in ethanol, filtered and the filtrate evaporated to an oil which solidified under ether. The solid was dissolved in water and passed down a Dowex 1 x 2-200 ion exchange resin in the formate form.

- 5 Elution with aqueous formic acid gave on evaporation of the solvent 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane-phosphonic acid (0.078g, 15%) as a light brown foam.

Found: C, 66.50; H, 6.08; N, 5.39%; $C_{28}H_{31}N_2O_4P$ + 3% water

Requires: C, 66.50; H, 6.52; N, 5.54%

10

EXAMPLE 3

Diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydro-imidazol-1-yl)heptane-phosphonate

- 15 A solution of 1,4,5-triphenyl-3-(7-bromoheptyl)imidazol-2-one (1.0g) and triethylphosphite (1.66g) in xylene (5ml) was heated at reflux temperature for 40 hours. The solution was evaporated to an oil and chromatographed on silica gel (ethyl acetate/ethanol).

- 20 The resulting oil was taken up in diethyl ether, filtered and evaporated to give diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptanephosphonate as a clear oil (0.84g, 75%).

Found: C, 70.11; H, 7.37; N, 4.94%; $C_{32}H_{39}N_2O_4P$; Requires: C, 70.31; H, 7.19; N, 5.12%

EXAMPLE 4

- 25 Ethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)methyl-phosphinate

- A solution of 1,4,5-triphenyl-3-(7-bromoheptyl)-imidazol-2-one (2.0g) and diethyl methylphosphonite (2.17g) in toluene (15ml) was heated at reflux temperature for 48 hours with the addition of more diethyl methyl-phosphonite (0.5g) after 24 hours. Water (5ml) was added and the solution was evaporated to an oil which was chromatographed on silica gel (ethyl acetate/ethanol). The resulting oil was taken up in diethyl ether, filtered and evaporated to give ethyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)methyl-phosphinate (1.34g), 65%) as a clear oil.

- 35 Found: C, 70.70; H, 7.53; N, 5.35%; $C_{31}H_{37}N_2O_3P$ + 0.9% Et_2O + 2% H_2O ; Requires: C, 70.56; H, 7.36; N, 5.26%.

EXAMPLE 5

Diisopropyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane
phosphonate

- 5 A solution of 1,4,5-triphenyl-3-(7-bromoheptyl)-imidazol-2-one
(1.47g) and triisopropyl phosphite (3.12 g) in xylene (15ml) was heated at
reflux temperature for 48 hours. The solution was evaporated to an oil
and chromatographed on silica gel (ethyl acetate/ethanol). The resulting
oil was taken up in diethyl ether, filtered and evaporated to the titled
10 compound as a clear oil (0.33g; 19%) Found: C, 70.02; H, 7.53; N, 5.19%;
 $C_{34}H_{43}N_2O_4P + 1.5\% H_2O$; Requires: C, 69.99; H, 7.60; N, 4.80%.

EXAMPLE 6

Dimethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane
phosphonate

- 15 A solution of 1,4,5-triphenyl-3-(7-bromoheptyl)-imidazol-2-one
(1.47g) and trimethyl phosphite (1.89g) in xylene (10ml) was heated at
reflux temperature for 6 days. The solution was evaporated to an oil and
chromatographed on silica gel (ethyl acetate/ethanol). The resulting oil
was taken up in diethyl ether, filtered and evaporated to the titled
20 compound as a clear oil (0.30g; 19%)
NMR δ ($CDCl_3$) 1.2-1.9 (10H, m, 5 x CH_2), 3.6-3.8 (8H, m, $-CH_2N + 2$
x $-OCH_3$), 6.8-7.4 (15H, m, 3 x Ph) ppm.

EXAMPLE 7

- 25 Diethyl-6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexane
phosphonate

- A solution of 1,4,5-triphenyl-3-(6-bromoheptyl)-imidazol-2-one
(1.43g) and triethyl phosphite (2.49g) in xylene (8ml) was heated at reflux
temperature for 65 hours. The solution was evaporated to an oil and
30 chromatographed on silica gel (ethyl acetate/ethanol). The resulting oil
was taken up in diethyl ether, filtered and evaporated to the titled
compound as a clear oil (1.15g; 72%) Found: C, 69.67; H, 7.13; N, 5.43%;
 $C_{31}H_{37}N_2O_4P$; Requires: C, 69.91; H, 7.00; N, 5.26%.

35

EXAMPLE 8

Diethyl-8-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octane

phosphonate

A solution of 1,4,5-triphenyl-3-(8-bromoheptyl)-imidazol-2-one (1.52g) and triethyl phosphite (2.49g) in xylene (10ml) was heated at reflux temperature for 65 hours. The solution was evaporated to an oil and chromatographed on silica gel (ethyl acetate/ethanol). The resulting oil was taken up in diethyl ether, filtered and evaporated to the titled compound as a clear oil (1.28g; 76%) Found: C, 70.15; H, 7.41; N, 5.06%; $C_{33}H_{41}N_2O_4P + 1\% H_2O$; Requires: C, 69.99; H, 7.41; N, 4.85%.

10

Example 9

1-(7-ethoxycarbonylheptyl)-2,4,5-triphenylimidazole

A mixture of 2,4,5-triphenylimidazole (11g), ethyl 8-bromooctanoate (18.64g), anhydrous potassium carbonate (51.3g) and dry butanone (350ml) was heated at reflux for 26h. The cooled reaction mixture was filtered to remove inorganics and the filtrate was evaporated to dryness in vacuo. The residue was stirred in hexane and unreacted 2,4,5-triphenylimidazole was collected by filtration (3.1g). The filtrate was cooled and a white precipitate was collected. Recrystallisation from hexane gave 1-(7-ethoxy-carbonyl-heptyl)-2,4,5-triphenylimidazole (8.37g, 48.4%) as a white solid, m.p. 65-7°.

20

Found C, 79.97; H, 7.32; N, 6.39%;

$C_{31}H_{34}N_2O_2$ requires: C, 79.79; H, 7.34; N, 6.00%.

Example 10

25 1-(7-carboxyheptyl)-2,4,5-triphenylimidazole

A mixture of 1-(7-ethoxycarbonylheptyl)-2,4,5-triphenyl-imidazole (13.6g), 2N aqueous sodium hydroxide (300ml) and ethanol (200ml) was heated at reflux for 2.5h. The ethanol was removed in vacuo and the reaction mixture was acidified with 2N aqueous hydrochloric acid. The aqueous solution was extracted with ethyl acetate (4 x 200ml) and the organic extracts were combined, dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Recrystallisation from ethanol gave 1-(7-carboxyheptyl)-2,4,5-triphenylimidazole (9.77g, 76.4%) as a white solid, m.p. 162°; Found C, 79.43; H, 6.93; N, 6.36%; $C_{29}H_{30}N_2O_2$ requires: C, 79.42; H, 6.90; N, 6.39%.

30

35

Example 11

1-(7-methoxycarbonylheptyl)-2,4,5-triphenylimidazole

A mixture of 1-(7-carboxyheptyl)-2,4,5-triphenyl-imidazole (0.5g), concentrated sulphuric acid (2ml) and methanol (100ml) was heated at reflux for 24h. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate (50ml), washed with water (50ml), saturated NaHCO₃ solution (50ml), water (50ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with a dichloromethane:methanol gradient gave 1-(7-methoxycarbonylheptyl)-2,4,5-triphenylimidazole (0.28g, 54%) as an oil.

Found: C, 79.74; H, 7.55; N, 5.99%;
C₃₀H₄₂N₂O₂ requires: C, 79.61; H, 7.13; N, 6.19%.

Example 12

1-(6-ethoxy-carbonylhexyl)-2,4,5-triphenylimidazole

2,4,5-Triphenylimidazole (1.3g) was added to a suspension of sodium hydride (0.23g) (50% dispersion in oil, washed with hexane) in dry dimethylformamide (40ml) under nitrogen. The reaction was stirred at 45°C for 1.5h, cooled and ethyl 7-bromoheptanoate (1.1g) in dry dimethylformamide (10ml) was added. The reaction was stirred at 50°C for 5h, cooled and water was carefully added. The solvent was removed in vacuo and the residue was dissolved in ethyl acetate (100ml). The organic solution was washed with saturated sodium chloride solution (150ml), water (100ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. The residue was chromatographed on silica gel eluted with a dichloro-methane:ethanol gradient to give 1-(6-ethoxy-carbonylhexyl)-2,4,5-triphenylimidazole (0.81g, 41%) as an oil. Found: C, 79.74; H, 7.32; N, 6.12%; C₃₀H₃₂N₂O₂ requires: C, 79.61; H, 7.13; N, 6.19%.

Example 13

1-(6-carboxyhexyl)-2,4,5-triphenylimidazole

Reaction of 1-(6-ethoxycarbonylhexyl)-2,4,5-triphenylimidazole (0.4g) with sodium hydroxide in a method similar to Example 10 gave, after recrystallisations from ethanol and isopropanol, 1-(6-carboxyhexyl)-2,4,5-triphenylimidazole (0.19g, 51%) as a white solid, m.p. 149-150°; Found: C, 79.34; H, 6.65; N, 6.48%; C₂₈H₂₈N₂O₂ requires: C, 79.22; H,

6.65; N, 6.60%.

Example 14

1-[6-(5-tetrazolyhexyl)-2,4,5-triphenylimidazole

- 5 a) A mixture of 2,4,5-triphenylimidazole (52.5g),
dibromohexane (174g) and potassium carbonate (48.4 g) in dry butanone
(400 ml) were heated at reflux temperature for 20 hours. The mixture
was filtered and the filtrate evaporated to an oil. Approximately half of
10 the excess dibromohexane was removed by distillation and the
remaining oil was chromatographed on silica gel (hexane/ethyl acetate)
giving, after recrystallisation from ethyl acetate, 1-(6-bromohexyl)-2,4,5-
triphenyl-imidazole (35.0g, 43%) as a colourless solid, m.p. 106-7°; NMR d
(CDCl₃) 0.9-1.7 (8H, m, 4 x CH₂), 3.2 (2H, t, CH₂Br), 3.9 (2H, t, CH₂N), 7.1-
7.7 (15H, m, 3 x Ph) ppm.

- 15 b) 1-(6-Bromohexyl)-2,4,5-triphenylimidazole (27.6g) in dry
dimethylsulphoxide (70ml) was added over 10 minutes to a mixture of
sodium cyanide (3.68g) in dimethyl-sulphoxide (50ml) and the reaction
was stirred at room temperature for 20h. The reaction mixture was
20 poured into water (300ml) and extracted with dichloromethane (3 x
150ml). The extracts were combined, washed with water, dried over
anhydrous magnesium sulphate and evaporated to dryness in vacuo.
Recrystallisation from diethyl ether and hexane gave 1-(6-cyanoethyl)-
2,4,5-triphenylimidazole (24.19g, 99%) as a white solid, m.p. 104-6°.
25 NMR d (CDCl₃) 0.8-1.1 (4H, m, 2 x CH₂), 1.1-1.4 (4H, m, 2 x CH₂),
2.1 (2H, t, CH₂CN), 3.90 (2H, t, NCH₂), 7.0-7.8 (15H, m, 3 x Ph) ppm

- c) A mixture of 1-(6-cyanoethyl)-2,4,5-triphenyl-imidazole
(2g), tri-n-butyl tin azide (5g) (Kricheldorf, H, Leppert, E, Synthesis,
30 (1976) 329) and dry tetrahydrofuran (10ml), under nitrogen, was heated at
reflux for 20h. Tri-n-butyl tin azide (5g) in dry tetrahydrofuran (10ml)
was added and the reaction was heated at reflux for 24h. The cooled
reaction mixture was poured into 2N aqueous hydrochloric acid (100ml)
and water (100ml) was added. The aqueous mixture was extracted with
35 dichloromethane (2 x 50ml). The organic extracts were combined,
washed with saturated sodium chloride solution (50 ml) dried over
anhydrous magnesium sulphate and evaporated to dryness in vacuo.

Chromatography on silica gel eluted with a dichloro-methane:methanol gradient and recrystallisation from ethanol/water gave 1-[6-(5-tetrazolyhexyl)-2,4,5-triphenylimidazole (0.25g, 11.4%) as a white solid, m.p. 196-7°; Found: C, 75.07; H, 6.40; N, 18.61%;
5 $C_{28}H_{28}N_6$ requires: C, 74.97; H, 6.29; N, 18.74%.

Example 15

1-(8-carboxyoctyl)-2,4,5-triphenylimidazole

a) 2,4,5-Triphenylimidazole (5g) was added to a suspension of
10 sodium hydride (1.0g) (50% dispersion in oil, washed with hexane) in dry dimethylformamide (80ml) under nitrogen. The reaction was stirred at 45°C for 1h, cooled and added, over 1h to a solution of 1,8-dibromo-octane (30g) in dry dimethylformamide (100ml) under nitrogen. The reaction
15 was stirred at room temperature for 24h, water was carefully added and the solvent was removed in vacuo. The residue was dissolved in ethyl acetate (500ml), washed with water (250ml), 2N aqueous hydrochloric acid (250ml), saturated sodium chloride solution (250ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Distillation to remove 1,8-dibromooctane and chromatography on silica
20 gel eluted with dichloromethane gave 1-(8-bromooctyl)-2,4,5-triphenylimidazole (4.1g, 50%) as an oil; NMR d ($CDCl_3$) 0.9-1.7 (12H, m, 6 x CH_2), 3.3 (2H, t, $BrCH_2$), 3.9 (2H, t, $N-CH_2$), 7.1-7.7 (15H, m, 3 x Ph) ppm.

25 b) 1-(8-Bromooctyl)-2,4,5-triphenylimidazole (4g) in dimethylsulphoxide (30ml) was added dropwise to a mixture of sodium cyanide (0.5g) in dry dimethylsulphoxide (30ml). The reaction mixture was stirred at 50°C for 2h, cooled and poured into water (400ml). The
30 aqueous was extracted with diethyl ether (4 x 100ml), the extracts were combined, washed with water (100ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Chromatography on silica gel eluted with a dichloromethane:methanol gradient and recrystallisation from ether gave 1-(8-cyanoctyl)-2,4,5-triphenylimidazole (1.1g, 31%) as a white solid, m.p. 72-73°. Found: C, 83.10; H, 7.21; N,
35 9.69%; $C_{30}H_{31}N_3$ requires: C, 82.90; H, 7.19; N, 9.57%.

c) A mixture of 1-(8-cyanoctyl)-2,4,5-triphenyl-imidazole

(0.8g), concentrated sulphuric acid (10ml) and water (10ml) was stirred at reflux for 4h. Water (50ml) was added to the cooled mixture and the mixture was extracted with ethyl acetate (2 x 25ml). The organic extracts were combined, washed with water (25ml), dried over
5 anhydrous magnesium sulphate and evaporated to dryness in vacuo. Recrystallisation from ethanol/water gave 1-(8-carboxyoctyl)-2,4,5-triphenylimidazole (0.22 g, 26%) as a cream solid, m.p. 149-150° C; Found C: 79.32; H, 7.17; N, 5.95%; $C_{30}H_{32}N_2$ requires: C, 79.61; H, 7.13; N, 6.19%.

10

Example 16

1-(10-carboxydecyl)-2,4,5-triphenylimidazole

(a) 2,4,5-Triphenylimidazole (2.5g) and ethyl 11-bromoundecanoate (4.94g) were reacted in a method similar to Example
15 9. Work-up and column chromatography on silica gel eluted with 30:1 dichloromethane:ethanol gave 1-(10-ethoxy-carbonyldecyl)-2,4,5-triphenylimidazole (1.95g, 45%) as an oil.

(b) 1-(10-Ethoxycarbonyldecyl)-2,4,5-triphenylimidazole (1.3g)
20 was reacted with 2N sodium hydroxide in a method similar to Example 10 to give, after column chromatography on silica gel eluted with a dichloro-methane:methanol gradient and recrystallisation from ethyl acetate/hexane, 1-(10-carboxydecyl)-2,4,5-triphenylimidazole (0.25g, 19.2%) as a cream solid, m.p. 76-78°; Found: C, 79.68%; H, 7.56%; N, 5.78%; $C_{32}H_{36}N_2O_2$ requires: C, 79.96%; H, 7.55; N, 5.83%.

25

Example 17

1-(7-carboxyheptyl)-2-methyl-4,5-diphenylimidazole

a) 2-Methyl-4,5-diphenylimidazole (2.5g) (*J. Org. Chem.*, 1937,
30 2, 328) was reacted with sodium hydride (0.62g) and ethyl 8-bromooctanoate (3.36g) in a method similar to Example 12. Chromatography on silica gel eluted with a dichloromethane:ethanol gradient gave 1-(7-ethoxycarbonyl-heptyl)-2-methyl-4,5-diphenylimidazole (3.1g, 72.1%) as an oil.

35 NMR d ($CDCl_3$) 1.15 (6H, m, 3 x CH_2), 1.25 (3H, t, CH_2CH_3), 1.50 (4H, m, NCH_2CH_2 , $O=CCH_2CH_2$), 2.23 (2H, t, CH_2CO_2), 2.50 (3H, s, CH_3), 3.69 (2H, t, NCH_2), 4.10 (2H, q, $O=C-OCH_2$), 7.10-7.50 (10H, m,

2 x Ph) ppm

1-(7-Ethoxycarbonylheptyl)-2-methyl-4,5-diphenyl-imidazole

- b) 1-(7-Ethoxycarbonylheptyl)-2-methyl-4,5-diphenyl-imidazole
5 (3.0g) was reacted with 2N sodium hydroxide in a method similar to Example 10 to give, after recrystallisation from acetonitrile, 1-(7-carboxyheptyl)-2-methyl-4,5-diphenylimidazole (1.19g, 42.5%) as white needles, m.p. 135-6°; Found: C, 75.37; H, 7.39; N, 7.27%; $C_{24}H_{28}N_2O_2$ 1.9% H_2O requires: C, 75.14; H, 7.57; N, 7.30%.

10

Example 18

1-(7-ethoxycarbonylheptyl)-2-methyl-4,5-diphenyl-imidazole

- A mixture of 1-(7-carboxyheptyl)-2-methyl-4,5-diphenyl-imidazole
15 (0.5g), concentrated sulphuric acid (0.5ml) and absolute alcohol (50ml) was heated at reflux for 3h. The solvent was removed in vacuo, the residue dissolved in ethyl acetate (50ml), washed with water (25ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with a dichloro-
20 methane:ethanol gradient gave 1-(7-ethoxycarbonylheptyl)-2-methyl-4,5-diphenyl-imidazole (0.22g, 41%) as an oil.

Found: C, 75.70; H, 7.88; N, 7.01%;
 $C_{26}H_{32}N_2O_2$ 1.7 H_2O requires: C, 75.90; H, 8.03; N, 6.89%.

25

Example 19

1-(7-(5-tetrazolylheptyl)-2,4,5-triphenylimidazole

- a) A mixture of 2,4,5-triphenylimidazole (11.5g), 1,7-dibromo-
heptane (50g) and potassium carbonate (27g) in dry butanone (250ml) was
heated at reflux for 20 hours. The mixture was filtered and the filtrate
30 evaporated to an oil. Chromatography on silica gel (hexane/ethyl acetate) and recrystallisation from hexane gave 1-(7-bromoheptyl)-2,4,5-triphenylimidazole (11.3g, 61.4%) as a colourless solid, m.p. 69-71°.

Found: C, 71.18; H, 6.22; N, 5.99; Br, 16.95%;
 $C_{28}H_{29}BrN_2$ requires: C, 71.03; H, 6.17; N, 5.92; Br, 16.88%;

35

- b) 1-(7-Bromoheptyl)-2,4,5-triphenylimidazole (7g) in dry

dimethylsulphoxide (15ml) was added over 20 minutes to a mixture of sodium cyanide (0.87g) in dimethyl-sulphoxide (25ml). The reaction was stirred at 40°C for 1 hour. The cooled reaction mixture was poured into water (800ml) and extracted with diethyl ether (4 x 100 ml). The extracts
 5 were combined, washed with water, dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Recrystallisation from dichloro-methane/hexane gave 1-(7-cyanoheptyl)-2,4,5-triphenylimidazole (3.7g, 60%) as a white solid, m.p. 93-94°; Found: C, 82.35; H, 6.90; N, 9.96%;
 10 $C_{29}H_{29}N_3$ 1% CH_2Cl_2 requires C, 82.43; H, 6.91; N, 9.91%.

c) A mixture of 1-(7-cyanoheptyl)-2,4,5-triphenyl-imidazole (2g), tri-n-butyl tin azide (5g) and dry tetrahydrofuran (30ml), under nitrogen, was heated at reflux for 8 hours. Tri-n-butyl tin azide (4.9g) in
 15 dry tetrahydrofuran (5ml) was added and the reaction was heated at reflux for 48 hours. The cooled reaction mixture was poured into 2N hydrochloric acid (100ml) and water (100ml) was added. The aqueous mixture was extracted with dichloromethane (2 x 50 ml). The organic extracts were combined, washed with saturated sodium chloride solution
 20 (50ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Chromatography on silica gel (dichloromethane/methanol) gave 1-(7-(5-tetrazolylheptyl)-2,4,5-triphenylimidazole (0.2g, 9%) as a foam.
 Found: C, 74.08; H, 6.63; N, 17.30%; $C_{29}H_{30}N_6$ 0.5% W/N C_2H_5OH
 25 requires C, 74.14; H, 6.87; N, 17.26%.

Example 20

2-(2-methoxyethoxy)ethyl 8-(2,4,5-triphenylimidazol-1-yl)octanoate
 a) 8-Bromooctanoic acid (22.3g), 2-(2-methoxyethoxy)-ethanol
 30 (14.08g) and p-toluenesulphonic acid (0.1g) were added to toluene (250ml) and the resulting solution heated at reflux temperature for 16 hours. Ethyl acetate (500ml) was then added and the solution washed with aqueous K_2CO_3 solution and water, dried and evaporated. The residual
 oil was distilled to give 2-(2-methoxyethoxy)-ethyl 8-bromooctanoate
 35 (25.5g, 77%) as a colourless oil, b.p. 126-128°C/0.08 mm Hg.

b) The above alkyl bromide (7.5g) and 2,4,5-triphenyl-imidazole

-61-

(4.44g) were treated with K_2CO_3 (3.1g) in refluxing 2-butanone (60ml) for 18 hours. The solvent was evaporated and the resulting solid chromatographed on silica gel to give 2-(2-methoxyethoxy)-ethyl 8-(2,4,5-triphenylimidazol-1-yl)octanoate (1.5g, 42%) as a colourless oil. Found: C, 75.13; H, 7.47; N, 5.18%; $C_{34}H_{40}N_2O_4$ requires: C, 75.53; H, 7.46; N, 5.18%

Example 21

Ethyl 8-(4,5-diphenylimidazol-1-yl)octanoate
4,5-Triphenylimidazole (5.5g) was treated with ethyl 8-bromooctanoate (12.55g) by the method described in example 5 to give, after work-up and chromatography, ethyl 8-(4,5-diphenylimidazol-1-yl)octanoate (7.8g, 80%) as a pale yellow oil. Found: C, 76.67; H, 7.85; N, 7.07%;
 $C_{25}H_{30}N_2O_2$ requires: C, 76.89; H, 7.74; N, 7.17%

Example 22

8-(4,5-diphenyl-imidazol-1-yl)octanoic acid
Ethyl 8-(4,5-diphenylimidazole-1-yl)octanoate (3.25g) was treated with sodium hydroxide as described in example 10 to give 8-(4,5-diphenyl-imidazol-1-yl)octanoic acid (0.6g, 20%) as colourless needles, m.p. 129.5-130°C.

Found: C, 75.75; H, 7.20; N, 7.53%
 $C_{23}H_{26}N_2O_2 \cdot 0.1 HCl$ requires: C, 75.45; H, 7.18; N, 7.65%

Example 23

2-(2-methoxyethoxy)ethyl 8-(4,5-diphenylimidazole-1-yl)- octanoate
4,5-Diphenylimidazole (2.85g) was treated with 2-(2-methoxyethoxy)ethyl 8-bromooctanoate (8.63g) as described in Example 20 to give 2-(2-methoxyethoxy)ethyl 8-(4,5-diphenylimidazole-1-yl)octanoate as a colourless oil (1.5g, 25%). Found: C, 72.28; H, 7.91; N, 6.35%
 $C_{28}H_{36}N_2O_4$ requires: C, 72.38; H, 7.81; N, 6.03%

Example 24

1-(7-carboxyheptyl)-2-(4-methoxyphenyl)-4,5-diphenyl-imidazole
a) 2-(4-Methoxyphenyl)-4,5-diphenylimidazole (10g) (J. Org. Chem., 1964, 29, 1926-30) was reacted with sodium hydride (1.7g) and

ethyl 8-bromooctanoate (9.6g) in a method similar to Example 12. Chromatography on silica gel eluted with chloroform gave 1-(7-ethoxycarbonylheptyl)-2-(4-methoxyphenyl)-4,5-diphenylimidazole (12.9g, 85%) as an oil.

5

- b) 1-(7-Ethoxycarbonylheptyl)-2-(4-methoxyphenyl)-4,5-diphenyl-imidazole (5g) was treated as in Example 10. Work-up and recrystallisation from ethanol gave 1-(7-carboxyheptyl)-2-(4-methoxyphenyl)-4,5-diphenyl-imidazole (3.51g, 75%) as a white solid, m.p 173-4°. Found: C, 76.23; H, 6.89; N, 5.71%; $C_{30}H_{32}N_2O_3$ + 1% w/w C_2H_5OH requires: C, 76.64; H, 6.94; N, 5.92%;

10

Example 25

- 1-(7-ethoxy-carbonylheptyl)-2-(4-methoxyphenyl)-4,5-diphenylimidazole (0.4g) was reacted with ethanol and concentrated sulphuric acid in a method similar to Example 18 to give, after work-up and column chromatography on silica gel eluted with a dichloromethane:ethanol gradient, 1-(7-ethoxy-carbonylheptyl)-2-(4-methoxyphenyl)-4,5-diphenylimidazole (0.21g, 50%) as an oil. Found: C, 77.39; H, 7.55; N, 5.96%; $C_{32}H_{36}N_2O_3$ requires: C, 77.39; H, 7.31; N, 5.64%.

15

20

Example 26

- 1-(7-carboxy-heptyl)-2-(4-hydroxyphenyl)-4,5-diphenyl-imidazole (2.5g) was added, in portions over 40 minutes, to a solution of boron tribromide (2.17ml) in anhydrous dichloromethane (40ml). The reaction was stirred at room temperature for 5h, cooled and water (50ml) was carefully added. The organic layer was removed and the aqueous layer was washed with dichloromethane (3 x 75ml). The organic extracts were combined, dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with a dichloro-methane:methanol gradient and recrystallisation from ethanol/water and acetonitrile gave 1-(7-carboxy-heptyl)-2-(4-hydroxyphenyl)-4,5-diphenyl-imidazole (0.49g, 20%) as a white solid, m.p. 171-172°. Further material was obtained from the mother liquors (0.79g, 33%) m.p. 167°. Found C: 76.85; H, 6.65; N, 6.20%; $C_{29}H_{30}N_2O_3$ requires:

25

30

35

C, 76.63; H, 6.65; N, 6.16%;

Example 27

5 1-(7-carboxy-heptyl)-2-(4-hydroxy-3,5-diiodophenyl)-4,5-diphenyl-imidazole

A solution of iodine (0.25g) and potassium iodide (0.48g) in water (1ml) was added to a mixture of 1-(7-carboxyheptyl)-2-(4-hydroxyphenyl)-4,5-diphenyl-imidazole (0.2g) in 25% aqueous methylamine (1.5ml), cooled in an ice-bath. The reaction mixture was stirred at room
10 temperature for 2h, aqueous sodium metabisulphite solution was added and stirring was continued for 0.5h. The reaction mixture was acidified to pH 3 with glacial acetic acid. The resulting orange solid was collected and washed with aqueous sodium metabisulphite solution. Recrystallisation from ethanol/water gave 1-(7-carboxy-heptyl)-2-(4-
15 hydroxy-3,5-diiodophenyl)-4,5-diphenyl-imidazole (0.14g, 45%) as an off-white solid, m.p. 186°. Found: C, 49.49; H, 3.99; N, 4.36; I, 35.64%; $C_{29}H_{28}I_2N_2O_3$ requires: C, 49.31; H, 4.00; N, 3.97; I, 35.93%.

Example 28

20 2-benzyl-1-(7-ethoxycarbonylheptyl)-4,5-diphenylimidazole

2-Benzyl-4,5-diphenylimidazole (3.3g) (Weiss, M, J. Am. Chem. Soc., 1952, 74, 5193-5) was reacted with ethyl 8-bromooctanoate as in Example 9. Column chromatography on silica gel eluted with a dichloro-
methane:ethanol gradient followed by distillation at 200°C/0.1 torr to
25 remove volatile impurities gave a yellow oil. Recrystallisation from hexane gave 2-benzyl-1-(7-ethoxycarbonylheptyl)-4,5-diphenylimidazole (2.69g, 52.6%) as a white solid, m.p. 82-3°. Found: C, 80.35; H, 7.58; N, 6.08%; $C_{32}H_{36}N_2O_2$ requires: C, 79.96; H, 7.55; N, 5.83%.

Example 29

30 2-benzyl-1-(7-carboxyheptyl)-4,5-diphenylimidazole

2-Benzyl-1-(7-ethoxycarbonylheptyl)-4,5-diphenyl-midazole (1.5g) was treated in a method similar to Example 10. Ethanol was removed in vacuo and the aqueous solution was acidified with 2N aqueous
35 hydrochloric acid and extracted with dichloromethane (2 x 75ml). The extracts were combined, dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Recrystallisation from ethanol gave 2-

benzyl-1-(7-carboxy-heptyl)-4,5-diphenylimidazole (1.14 g, 81%) as a white solid, m.p. 148-9°. Found: C, 79.56; H, 7.13; N, 6.04%; $C_{30}H_{32}N_2O_2$ requires: C, 79.61; H, 7.13; N, 6.19%.

5

Example 30

1-(7-carboxyheptyl)-2-[4-octyloxy-phenyl]-4,5-diphenylimidazole

- a) 2-(4-Hydroxyphenyl)-4,5-diphenylimidazole (5g) (J. Org. Chem., 1964, 29, 1926) was reacted with 8-bromooctane (6.2g) in a method similar to Example 9. Work-up and recrystallisation from ethanol and water gave 2-(4-octyloxyphenyl)-4,5-diphenylimidazole (4.29g, 63%) as a white solid, m.p. 178°. Found: C, 82.31; H, 7.66; N, 6.73%; $C_{29}H_{32}N_2O$ requires C, 82.04; H, 7.60; N, 6.60%.

- b) 2-(4-Octyloxyphenyl)-4,5-diphenylimidazole (2.5g) was reacted with ethyl 8-bromooctanoate (2.96g) in a method similar to Example 9. Column chromatography on silica gel eluted with a hexane:ethyl acetate gradient gave 1-(7-ethoxycarbonylheptyl)-2-[4-octyloxyphenyl]-4,5-diphenylimidazole (3.48g, 94%) as an oil. NMR d ($CDCl_3$); 0.8-1.5 (23 H, m, 10 x CH_2 , CH_3), 1.8 (2 H, q, OCH_2CH_2), 2.2 (2H, t, $CH_2(C=O)$), 3.85 (2H, t, NCH_2), 4.05 (4H, m, $CH_2OC=O$, $COCH_2$), 6.95-7.6 (14H, m, ArH) ppm.

- c) 1-(7-Ethoxycarbonylheptyl)-2-[4-octyloxyphenyl]-4,5-diphenylimidazole (3.2g) was reacted with 2N sodium hydroxide in a method similar to Example 9. Column chromatography on silica gel eluted with a dichloro-methane:methanol gradient and recrystallisation from acetonitrile gave 1-(7-carboxyheptyl)-2-[4-octyloxy-phenyl]-4,5-diphenylimidazole (1.7g, 58.6%) as a white solid, m.p. 114-115°. Found: C, 78.61; H, 8.23; N, 4.96%; $C_{37}H_{46}N_2O_3$ requires: C, 78.41; H, 8.18; N, 4.94%.

Example 31

1-(7-carboxyheptyl)-2 octylthio-4,5-diphenyl-imidazole

- a) A mixture of 4,5-diphenyl-2-imidazolethiol (2.5g), 8-bromooctane (3.8g), anhydrous potassium carbonate (13.7g) and dry butanone (60ml) was stirred at reflux for 2h. The cooled reaction mixture was filtered to remove solid and the filtrate was evaporated to dryness.

The residue was mixed with hexane and the resulting precipitate was collected by filtration. Recrystallisation from ethanol and water gave 2-octylthio-4,5-diphenylimidazole (1.9g, 53%) as a white solid, m.p. 133-4°.

5 Found: C, 76.15; H, 7.82; N, 7.74, S, 9.23%;
 $C_{23}H_{28}N_2S$ requires: C, 75.78; H, 7.74; N, 7.68; S, 8.80%.

b) 2-Octylthio-4,5-diphenylimidazole (1.7g) was reacted with ethyl 8-bromooctanoate in a method similar to Example 9 to give, after chromatography on silica gel eluted with a hexane:dichloromethane
10 gradient, 1-(7-ethoxycarbonyl-heptyl)-2-octylthio-4, 5-diphenylimidazole (2.19g, 87.6%) as an oil. NMR d ($CDCl_3$) 0.89 (3H, t, CH_2CH_3), 1.0-1.8 (20H, m, $10 \times (CH_2)$), 2.2 (2H, t, $CH_2=O$), 3.2 (2H, t, SCH₂), 3.78 (2H, t, NCH₂), 4.1 (2H, q, $CH_2OC=O$), 7.0-7.5 (10H, m, 2 x Ph) ppm.

15 c) 1-(7-Ethoxycarbonylheptyl)-2-octylthio-4,5-diphenylimidazole (1g) was reacted with 2N sodium hydroxide in a method similar to Example 10 to give, after chromatography on silica gel eluted with a dichloro-methane:methanol gradient, 1-(7-carboxyheptyl)-2
20 octylthio-4,5-diphenyl-imidazole (0.47g, 49%) as an oil. Found: C, 73.56; H, 8.59; N, 5.60; S, 6.47%;
 $C_{31}H_{42}N_2O_2S$ requires: C, 73.47; H, 8.35; N, 5.53; S, 6.33%.

Example 32

1-(7-ethoxycarbonyl-heptyl)-4,5-bis(4-methoxyphenyl)imidazole
25 4,5-Bis(4-methoxyphenyl)imidazole (1.8g) (J. Med. Chem., 1974, 17, 1182-8) and ethyl 8-bromooctanoate (3.2g) were reacted in a method similar to Example 9. Column chromatography on silica gel eluted with a dichloro-methane:ethanol gradient gave 1-(7-ethoxycarbonyl-heptyl)-
30 4,5-bis(4-methoxyphenyl)imidazole (2.42g, 83%) as an oil. Found: C, 72.30; H, 7.72; N, 6.21%; $C_{27}H_{34}N_2O_4$ requires: C, 71.97; H, 7.61; N, 6.22%.

Example 33

1-(7-carboxyheptyl)-4,5-bis(4-methoxyphenyl)imidazole
35 1-(7-Ethoxycarbonylheptyl)-4,5-bis(4-methoxyphenyl)-imidazole (0.58g) was reacted with 2N sodium hydroxide in a method similar to Example 10. Recrystallisations from ethanol and water gave 1-(7-carboxyheptyl)-4,5-bis(4-methoxyphenyl)-imidazole (0.25g, 46%) as a

white solid, m.p. 142-143°.

Found: C, 71.17; H, 7.20; N, 6.67%;

$C_{25}H_{30}N_2O_4$ requires: C, 71.07; H, 7.16; N, 6.63%.

5

Example 34

1-(7-carboxyheptyl)-4,5-bis(4-hydroxyphenyl)imidazole

- a) Boron tribromide (1.3ml) was added to a solution of 1-(7-ethoxycarbonylheptyl)-4,5-bis(4-methoxyphenyl)-imidazole (1.25g) in dry dichloromethane (30ml). The reaction was stirred at room temperature for 4h, cooled and water (20ml) was carefully added. The resulting purple precipitate was collected and column chromatography on silica gel eluted with a dichloromethane:methanol gradient, followed by recrystallisation from ethanol and water gave 1-(7-ethoxycarbonylheptyl)-4,5-bis(4-hydroxyphenyl)-imidazole as a white solid (0.58g, 50%), m.p. 186-187°.

- b) The above ester (0.5g) was reacted with 2N sodium hydroxide in a method similar to Example 10. Recrystallisations from ethanol and water gave 1-(7-carboxyheptyl)-4,5-bis(4-hydroxyphenyl)-imidazole (0.16g, 34%) as a white solid, m.p. 203-204°. Found: C, 69.71; H, 6.70; N, 6.99%; $C_{23}H_{26}N_2O_4$ requires: C, 70.03; H, 6.64; N, 7.10%.

Example 35

1-(7-carboxyheptyl)-4,5-bis-(2-chlorophenyl)imidazole

- a) 4,5-Bis(2-chlorophenyl)imidazole (1.2g) (Chem. Ber., 1959, 92, 338-343) and ethyl 8-bromooctanoate (2.1g) were reacted in a method similar to Example 9. Column chromatography on silica gel eluted with a dichloro-methane:ethanol gradient gave 4,5-bis(2-chlorophenyl)-1-(7-ethoxycarbonyl-heptyl)imidazole (0.45g, 23.7%) as an oil. NMR d ($CDCl_3$) 1.0-1.8 (11H, m, 4 x CH_2 , CH_3), 2.2 (2H, t, $CH_2C=O$), 3.8 (2H, m, N- CH_2), 4.1 (2H, q, $CH_2OC=O$), 7.1-7.45 (8H, m, ArH), 7.69 (1H, s, N=CH) ppm

- b) 4,5-Bis(2-chlorophenyl)-1-(7-ethoxycarbonylheptyl)-imidazole (0.4g) was reacted with 2N sodium hydroxide in a method similar to Example 10. Work-up and chromatography on silica gel eluted with a dichloromethane:methanol gradient followed by recrystallisation from dichloro-methane and hexane gave 1-(7-carboxyheptyl)-4,5-bis-(2-

-67-

chlorophenyl)imidazole (0.25g, 67%) as a white solid, m.p. 145-6°.

Found: C, 64.20; H, 5.61; N, 6.64; Cl, 16.62%; $C_{23}H_{24}Cl_2N_2O_2$

Requires: C, 64.04; H, 5.61; N, 6.49; Cl, 16.44%.

5

Example 36

1-(7-carboxyheptyl)-4,5-bis(2-chloro-phenyl)-2-phenylimidazole

a) 4,5-Bis(2-chlorophenyl)-2-phenylimidazole (1.7g) (J. Org. Chem., 1971, 36, 2262) was reacted with ethyl 8-bromooctanoate in a method similar to Example 9. Column chromatography on silica gel
10 eluted with a dichloro-methane:ethanol gradient gave 4,5-bis(2-chloro-phenyl)-1-(7-ethoxycarbonylheptyl)-2-phenylimidazole (1.94g, 77.6%) as an oil.

NMR d ($CDCl_3$) 0.8-1.5 (10H, m, 5 x CH_2), 2.18(2H, t, $CH_2C=O$), 3.85 (2H, m, NCH_2), 4.1 (2H, q, $CH_2OC=O$), 7.1-7.5 (13H, m, ArH) ppm.

15

b) 4,5-Bis(2-chlorophenyl)-1-(7-ethoxycarbonylheptyl)-2-phenylimidazole (1.9g) was reacted with 2N sodium hydroxide in a method similar to Example 10. The aqueous reaction mixture was evaporated to remove ethanol and acidified to pH 5 with 2N aqueous
20 hydrochloric acid. The resulting white solid was collected and recrystallisation from ethanol gave 1-(7-carboxyheptyl)-4,5-bis(2-chloro-phenyl)-2-phenylimidazole (1.31g, 73%) as a white solid, m.p. 198°. Found: C, 68.53; H, 5.60; N, 5.37; Cl, 14.79%; $C_{29}H_{28}Cl_2N_2O_2$ 0.2% w/w C_2H_5OH requires: C, 68.31; H, 5.70; N, 5.40, Cl, 13.69%.

25

Example 37

1-(7-carboxyheptyl)-4,5-bis(4-methoxy-phenyl)-2-phenylimidazole

a) 4,5-Bis(4-methoxyphenyl)-2-phenylimidazole (7g) (J. Med. Chem., 1974, 17, 1182-8) and ethyl 8-bromo-octanoate (9.9g) were reacted
30 in a method similar to Example 9. Column chromatography on silica gel eluted with a hexane:ethyl acetate gradient gave 1-(7-ethoxy-carbonylheptyl)-4,5-bis(4-methoxyphenyl)-2-phenyl-imidazole (10.3g, 100%) as an oil.

NMR d ($CDCl_3$) 0.8-1.5 (13H, m, 5x CH_2 , CH_3), 2.18 (2H, t, $CH_2=O$),
35 3.75 (3H, s, OCH_3), 3.88 (5H, m, NCH_2 , OCH_3), 4.1 (2H, q, $CH_2OC=O$), 6.7-7.7 (13H, m, ArH) ppm.

b) 1-(7-Ethoxycarbonylheptyl)-4,5-bis(4-methoxyphenyl)-2-phenylimidazole (10g) was reacted with 2N sodium hydroxide in a method similar to Example 10. The aqueous reaction mixture was evaporated to dryness in vacuo and the residue was mixed with ethanol (150ml) and insoluble material was filtered off. The filtrate was evaporated to dryness and the residue was purified by column chromatography on silica gel eluted with a dichloromethane:methanol gradient. Further purification on Amberlite resin IRA-400 eluted with a methanol:water to methanol:2N HCl gradient and recrystallisation from ethanol gave 1-(7-carboxyheptyl)-4,5-bis(4-methoxyphenyl)-2-phenylimidazole (2.01g, 21%) as a white solid, m.p. 149-150°. Found: C, 74.50; H, 6.75; N, 5.69%; $C_{31}H_{34}N_2O_4$ 0.5% w/w C_2H_5OH requires: C, 74.56; H, 6.90; N, 5.59%.

15

Example 38

1-(7-carboxyheptyl)-4,5-bis-(4-hydroxyphenyl)-2-phenylimidazole
Boron tribromide (0.7ml) was added to a suspension of 1-(7-carboxyheptyl)-4,5-bis(4-methoxyphenyl)-2-phenylimidazole (0.7g) in anhydrous dichloromethane (20ml) and the reaction was stirred at room temperature for 1h. Boron tribromide (0.3ml) was added and the reaction was stirred at reflux for 2h and at room temperature for 20h. Water was carefully added to the cooled reaction mixture and the resulting yellow precipitate was collected. Column chromatography on silica gel eluted with a dichloromethane:methanol gradient and recrystallisation from ethanol and water gave 1-(7-carboxyheptyl)-4,5-bis-(4-hydroxyphenyl)-2-phenylimidazole (0.44g, 67%) as a cream solid, m.p 135-7°; Found C, 73.97; H, 6.38; N, 5.98%; $C_{29}H_{30}N_2O_4$ requires: C, 74.02; H, 6.42; N, 5.95%.

30

Example 39

8-(4,5-di-(4-bromophenyl)imidazol-1-yl)- octanoate

4,5-Di-(4-bromophenyl)imidazole (2.13g) was treated with ethyl 8-bromooctanoate (2g) and K_2CO_3 (0.5g) in 2-butanone as described in Example 9 to give ethyl 8-(4,5-di-(4-bromophenyl)imidazol-1-yl)- octanoate (2.2g, 52%) as a pale yellow oil.; Found: C, 55.13; H, 5.19; N, 5.18; Br, 28.76%; $C_{28}H_{28}Br_2N_2O_2$ requires: C, 54.76; H, 5.15; N, 5.11; Br, 29.15%

35

Example 40

1-(7-carboxyheptyl)-2-heptyl-4,5-diphenylimidazole

- a) 2-Heptyl-4,5-diphenylimidazole (1g) was reacted with ethyl 8-bromooctanoate (1.6g) in a method similar to Example 9 with a reaction time of 48 hours. Chromatography on silica gel (hexane/ethyl acetate) gave 1-(7-ethoxycarbonyl-heptyl)-2-heptyl-4,5-diphenylimidazole (1.3g, 87%) as an oil. Found: C, 78.98; H, 9.22; N, 5.76%; $C_{32}H_{44}N_2O_2$ requires: C, 78.64; H, 9.08; N, 5.73%;
- b) 1-(7-Ethoxycarbonylheptyl)-2-heptyl-4,5-diphenylimidazole (1g) was reacted with sodium hydroxide in a method similar to Example 10 to give, after column chromatography on silica gel (dichloromethane/methanol) and recrystallisation from hexane, 1-(7-carboxyheptyl)-2-heptyl-4,5-diphenylimidazole (0.26g, 28%) as a white solid, m.p. 75-6°. Found: C, 78.04; H, 8.85; N, 6.10%; $C_{30}H_{40}N_2O_2$ requires: C, 78.22; H, 8.75; N, 6.08%;

Example 41

6-(2,4,5-triphenylimidazol-1-yl)hexylthio-acetic acid

- To a solution of sodium (0.17g) in dry methanol (10ml) was added mercaptoacetic acid (0.3g followed by 1-(6-bromohexyl)-2,4,5-triphenylimidazole (1.38g). The suspension was stirred at room temperature for 2 hours then at reflux temperature for 4 hours. The solvent was evaporated and the residue was dissolved in water and acidified to pH 4 with dilute hydrochloric acid. The precipitated oil was taken up in dichloromethane, washed with water, dried over magnesium sulphate and evaporated to an oil which was chromatographed on silica gel (dichloromethane/methanol) giving, after recrystallisation from ethanol, 6-(2,4,5-triphenylimidazol-1-yl)hexylthio-acetic acid (0.86 g, 61%) as a colourless crystalline solid, m.p. 158-9°C. Found: C, 74.14; H, 6.43; N, 5.77; S, 6.91%; $C_{29}H_{30}N_2O_2S$ requires: C, 74.01; H, 6.43; N, 5.95; S, 6.81%

Example 42

5-(2,4,5-triphenylimidazol-1-yl)pentyl-thioacetic acid

- a) A mixture of 2,4,5-triphenylimidazole (20g), dibromopentane (62g) and potassium carbonate (18g) in dry butanone (200ml) was heated at

-70-

reflux temperature for 24 hours. The mixture was filtered and the filtrate evaporated to an oil. This was washed with hexane then chromatographed on silica gel (hexane/ethyl acetate) to give 1-(5-bromopentyl)-2,4,5-triphenyl-imidazole (7.9g, 27%) as a pale yellow oil.

5 NMR d (CDCl_3) 1.0-1.6 (3H, m, $3 \times \text{CH}_2$), 3.1 (2H, t, CH_2Br), 3.9 (2H, t, CH_2N), 7.1-7.7 (15H, m, $3 \times \text{Ph}$) ppm.

b) Mercaptoacetic acid (0.3g) and 1-(5-bromopentyl)-2,4,5-triphenylimidazole (1.34g) were reacted in a method similar to example 10 42 (a) above giving, after recrystallisation from isopropanol, 5-(2,4,5-triphenylimidazol-1-yl)pentyl-thioacetic acid (0.52g, 38%) as a colourless crystalline solid, m.p. 166-9°C; Found: C, 72.98; H, 6.07; N, 5.87; S, 6.90%; $\text{C}_{28}\text{H}_{28}\text{N}_2\text{O}_2\text{S} + 1\%$ isopropanol + 0.5% water requires: C, 73.15; H, 6.28; N, 6.04; S, 6.92%

15

Example 43

7-(1,2,4-triphenylimidazolyl)-hept-5-ynoic acid

A solution of 2,4,5-triphenylimidazole (1.07g) in dimethylformamide (20ml) was treated with sodium hydride 50% in oil (0.17g) and methyl 7-bromohept-5-ynoate (0.95g). The solution was stirred for 18 20 hours when the solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluted with chloroform-hexane to give a clear oil which was dissolved in methanol (20ml) and treated with 10% potassium hydroxide solution (10ml) for 2 hours. The 25 methanol was removed under reduced pressure and the remaining aqueous was acidified (pH 3) and filtered. The filtrate was extracted with chloroform (3 x 50ml). The chloroform extracts were dried over magnesium sulphate, filtered and the solvent removed to give a solid which was recrystallised from acetonitrile to give 7-(1,2,4-triphenyl- 30 imidazolyl)-hept-5-ynoic acid as white prisms, m.p. 144-145°C; Found: C, 79.99; H, 5.81; N, 6.40% ($\text{C}_{28}\text{H}_{24}\text{N}_2\text{O}_2$); Requires: C, 79.97; H, 5.75; N, 6.66%

Example 44

35 9-(1,2,4-triphenylimidazolyl)-2,2-dimethylnonanoic acid

A mixture of 2,4,5-triphenylimidazole (4.13g), ethyl 9-bromo-2,2-dimethylnonanoate (10.95g), potassium carbonate (10g) and 2-butanone

-71-

was stirred at reflux for 48 hours. The mixture was filtered, solvent removed under reduced pressure and the residue was chromatographed on silica gel eluted with chloroform to give a clear oil which was dissolved in dimethyl sulphoxide (30ml) and treated with potassium hydroxide (3g). The mixture was stirred at 40°C for 24 hours when the solvent was removed under reduced pressure. Water (50ml) was added, the pH of the solution was adjusted to 4 and the aqueous was extracted with chloroform (3 x 50ml). The chloroform extracts were dried over magnesium sulphate, filtered and the solvent removed to give a solid which was recrystallised from acetonitrile to give 9-(1,2,4-triphenylimidazolyl)-2,2-dimethylnonanoic acid as a white crystalline solid, m.p. 119-120°C; Found: C, 79.85; H, 7.64; N, 6.23% ($C_{32}H_{36}N_2O_2$); Requires: C, 79.96; H, 5.54; N, 5.82%

15 Example 45

4-[4-(2,4,5-triphenylimidazolyl)butyloxy]benzoic acid

a) A mixture of 1,4 dibromobutane (50ml), methyl 4-hydroxybenzoate (15.2g, 0.1 mole), potassium carbonate (40g) in 2-butanone (500ml) was refluxed for 24 hours. The mixture was filtered, solvent removed and the residue was chromatographed on silica gel eluted with chloroform/petrol and recrystallised from pentane to give methyl 4-(4-bromobutyloxy)benzoate (19.26g).

b) A mixture of 2,4,5-triphenylimidazole (5.93g), methyl 4-(4-bromobutyloxy)benzoate (3.81g), potassium carbonate (25g) and 2-butanone (250ml) was stirred at reflux for 36 hours. The mixture was filtered, solvent removed under reduced pressure and the residue was chromatographed on silica gel eluted with chloroform and recrystallised from methanol to give 4-[4-(2,4,5-triphenylimidazolyl)butyloxy]benzoate as a white crystalline solid (5.38g), m.p. 145-146°C; Found: C, 79.16; H, 6.15; N, 6.03% ($C_{33}H_{30}N_2O_3$); Requires: C, 78.86; H, 6.01; N, 5.57%

c) Methyl 4-[4-(2,4,5 triphenylimidazolyl)butyloxy]-benzoate (1.5g) was dissolved in methanol (50ml) and treated with 10% potassium hydroxide solution (15ml) for 0.5 hours. The methanol was removed under reduced pressure and the remaining aqueous was acidified (pH4) and the pre-cipitate was collected by filtration and

recrystallised from methanol to give 4-[4-(2,4,5-triphenylimidazolyl)-butyloxy]-benzoic acid (1.3g) as white prisms m.p. 202-203°C; Found: C, 78.79; H, 5.75; N, 5.81% ($C_{32}H_{28}N_2O_3$); Requires: C, 78.66; H, 5.78; N, 5.73%

5

Example 46

7-(2,4,5-triphenylimidazol-1-yl)heptane-sulphonate

2,4,5-Triphenyl-1-(7-bromoheptyl)imidazole (0.95g) was dissolved in hot ethanol (10ml) and a solution of sodium sulphite (0.38g) in hot water (5ml) was added. The white suspension was heated at reflux temperature for 20 hours then evaporated to dryness. The mixture was taken up in dichloromethane, filtered and the filtrate evaporated to an oil which was chromatographed on silica gel (dichloromethane/methanol). The resulting oil was dissolved in methanol and excess ether added giving an oil which slowly solidified to give sodium 7-(2,4,5-triphenylimidazol-1-yl)heptane-sulphonate (0.32g; 32%) as a white solid, m.p. 310°C.

15

Found: C, 65.98; H, 6.11; N, 5.71; S, 6.22% ; $C_{28}H_{29}N_2NaO_3S + 2.5\% H_2O$ requires: C, 66.03; H, 6.02; N, 5.50; S, 6.30%

20

Example 47

7-(2,4,5-triphenylimidazol-1-yl)heptanephosphonic acid

A mixture of 2,4,5-triphenyl-1-(7-bromoheptyl)-imidazole (0.95g) and triethyl phosphite (1.66g) in xylene (5ml) was heated at reflux temperature for 20 hours. The mixture was evaporated to an oil and chromatographed on silica gel (ethyl acetate/ ethanol) to give diethyl 7-(2,4,5-triphenylimidazol-1-yl)heptane-phosphonate (0.37g, 35%) as a light brown oil.

25

NMR δ ($CDCl_3$) 0.9-1.7 (18H, m, $6 \times CH_2 + 2 \times CH_3$), 3.9 (2H, t, CH_2N), 4.1 (4H, m, $2 \times CH_2O$), 7.1-7.7 (15H, m, $3 \times Ph$) ppm.

30

Diethyl 7-(2,4,5-triphenylimidazol-1-yl)heptane-phosphonate (0.35g) was dissolved in dry chloroform, cooled to -40°C and to it was added trimethylsilyl iodide (0.66g) over 2 minutes under an atmosphere of nitrogen. The cooling bath was removed and the reaction mixture was stirred for 3 hours at room temperature then evaporated to an oil and re-evaporated from methanol and water respectively. The oil was taken up

35

in methanol, treated with excess aqueous sodium bicarbonate, evaporated to dryness then taken up in ethanol, filtered and the filtrate evaporated to an oil. This was taken up in water, filtered and dilute hydrochloric acid added to pH4. The precipitated oil was washed with water, taken up in methanol and precipitated with ether to give 7-(2,4,5-triphenylimidazol-1-yl)heptane-phosphonic acid (0.16g, 51%) as a light brown oil. Found: C, 68.12; H, 6.39, N, 5.60% $C_{28}H_{31}N_2O_3P + 4\% H_2O$ requires: C, 68.03; H 6.76; N, 5.66%.

10

Example 48

Ethyl 8-(phenanthrimidazol-1-yl)octanoate

Phenanthrimidazole (2.18g) (J. Am. Chem. Soc., 1943, 65, 452-6) was treated with ethyl 8-bromooctanoate (5.02g) and K_2CO_3 (2.76g) in 2-butanone (100ml) as described in Example 9 to give, after work up and chromatography, ethyl 8-(phenanthrimidazol-1-yl)octanoate (0.8g, 20%) as off white crystals, m.p. 99-101°C; Found: C, 77.34; H, 7.19; N, 7.04%; $C_{25}H_{28}N_2O_2$ requires: C, 77.29; H, 7.26; N, 7.21%

15

Example 49

20 1-(7-carboxyheptyl)-2-(5-formylpentyl)-4,5-diphenylimidazole

a) A mixture of 4,5-diphenyl-2-imidazolethiol (2.66g), 2-(5-iodopentyl)-1,3-dioxalane (3g), anhydrous potassium carbonate (7.26g) and dry 2-butanone (70ml) was heated at reflux for 4 hours. The cooled reaction mixture was filtered and the filtrate was evaporated to dryness in vacuo. The residue was stirred under hexane and the resulting white precipitate was collected by filtration. Recrystallisations from ethanol/water and dichloro-methane/hexane gave 2-(5-[1,3-dioxalan-2-yl]heptyl-thio)-4,5-diphenylimidazole (3.1g, 75%) as a white solid, m.p. 116-118°C; NMR d ($CDCl_3$) 1.5-1.7 (8H, m, 4 x CH_2), 3.09 (2H, t, SCH_2), 3.8-4.0 (4H, m, $O(CH_2)_2O$), 4.8 (1H, t, CH), 7.1-7.7 (10H, m, 2 x Ph) ppm.

30

b) 2-(5-[1,3-dioxalan-2-yl]pentylthio)-4,5-diphenyl-imidazole (3g) and ethyl 8-bromooctanoate (3.82g) were reacted in a method similar to Example 9. Distillation to remove volatile impurities and column chromatography on silica gel (dichloro-methane/ethanol) gave 2-(5-[1,3-dioxalan-2-yl]heptylthio)-1-(7-ethoxycarbonylpentyl)-4,5-diphenyl-imidazole (3.02g, 70%) as a colourless oil. Found: C, 70.23; H, 8.09; N,

35

5.04; S, 5.85%; $C_{33}H_{44}N_2O_4S$ requires: C, 70.18; H, 7.85; N, 4.96; S, 5.65%

- c) 2-(5-[1,3-Dioxalan-2-yl]pentylthio)-1-(7-ethoxy-carbonylheptyl)-4,5-diphenylimidazole (7g) was reacted with 2N sodium hydroxide in a method similar to Example 10. Work-up and column chromatography on silica gel (dichloromethane/methanol) gave 1-(7-carboxyheptyl)-2-[5-(1,3-dioxalan-2-yl]pentylthio)-4,5-diphenylimidazole (6.44g, 89%) as a colourless oil. NMR δ ($CDCl_3$) 1.0-1.9 (18H, m, 9 x CH_2), 2.3 (2H, t, CH_2), 3.2 (2H, t, SCH_2), 3.7-4.0 (6H, m, $O(CH_2)_2O$, NCH_2), 4.8 (1H, m, CH), 7.0-7.5 (10H, m, 2 x Ph) ppm.

- d) A mixture of 1-(7-carboxyheptyl)-2-(5-[1,3-dioxalan-2-yl]pentylthio)-4,5-diphenylimidazole (2g), tetrahydro-furan (100ml), water (100ml) and concentrated hydrochloric acid (10ml) was stirred at 90°C for 1 hour. The reaction mixture was evaporated to remove tetrahydrofuran and the aqueous was extracted with diethyl ether (3 x 75ml). The extracts were combined and washed with water (3 x 75ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel (dichloro-methane/methanol) gave 1-(7-carboxyheptyl)-2-(5-formylpentyl)-4,5-diphenylimidazole (0.93g, 50%) as a colourless oil. Found: C, 70.62; H, 7.88; N, 5.32; S, 6.34%; $C_{29}H_{36}N_2SO_3$ requires: C, 70.70; H, 7.37; N, 5.39; S, 6.51%

EXAMPLE 50

Sodium 6-(1,4,5-triphenylimidazol-2-yloxy)hexanesulphonate

- 25 A mixture of 1,4,5-triphenylimidazol-2-one (6.25g), dibromohexane (24.4g) and potassium carbonate (5.53g) in dry butanone (300ml) was heated at reflux temperature for 24 hours. The mixture was cooled and the filtrate evaporated to an oil which was chromatographed on silica gel (hexane/ethyl acetate) to give 1,4,5-triphenyl-2-(6-bromohexyloxy)-imidazole (2.8g, 29%) as a white solid, m.p. 87-9°C.
- 30 NMR δ ($CDCl_3$) 1.3-1.9 (8H, m, 5 x CH_2), 3.4 (2H, t, $-CH_2Br$), 4.5 (2H, t, $-CH_2O$), 7.0-7.6 (15H, m, 3 x Ph) ppm.

- 1,4,5-Triphenyl-2-(6-bromohexyloxy)imidazole (0.95g) was dissolved in hot ethanol (5ml) and a solution of sodium sulphite (0.25g) in hot water (3ml) was added. The white suspension was heated at reflux for 24 hours then evaporated to dryness. The residue was recrystallised from ethanol

-75-

then methanol/ethanol to give sodium 6-(1,4,5-triphenylimidazol-2-yloxy)hexane-sulphonate (0.15g, 15%) as a colourless solid, m.p. 265°C. Found: C, 64.22; H, 5.51; N, 5.32; S, 6.24% $C_{27}H_{27}N_2NaO_4S + 1.2\% H_2O + 0.5\% EtOH$; Requires: C, 64.20; H, 5.57; N, 5.52; S, 6.32%.

5

EXAMPLE 51

Sodium 7-(1,4,5-triphenylimidazol-2-yloxy)heptanesulphonate

A mixture of 1,4,5-triphenylimidazol-2-one (15.3g), dibromoheptane (50.6g) and potassium carbonate (13.8g) was heated at reflux temperature in dry butanone (750ml) for 20 hours. The mixture was cooled, filtered and the filtrate evaporated to an oil which was chromatographed on silica gel (hexane/ethyl acetate) to give 1,4,5-triphenyl-2-(7-bromoheptyloxy)imidazole (5.0g, 21%) as a white solid, m.p. 97-9°C.

15 NMR d ($CDCl_3$) 1.3-1.9 (10H, m, 5 x CH_2), 3.4 (2H, t, $-CH_2Br$), 4.5 (2H, t, $-CH_2O$), 7.0-7.6 (15H, m, 3 x Ph) ppm.

A solution of 1,4,5-triphenyl-2-(7-bromoheptyloxy)-imidazole (2.0g) in ethanol (10ml) was refluxed with a solution of sodium sulphite (0.55g) in water (5ml) for 20 hours. More sodium sulphite (0.2g) in water (1ml) was added and refluxed a further 20 hours. The mixture was evaporated to dryness, boiling ethanol added and filtered hot. Chromatography of the filtrate on silica gel (dichloromethane/methanol 5:1) followed by crystallisation from ethanol/isopropanol gave sodium 7-(1,4,5-triphenylimidazol-2-yloxy)heptanesulphonate (0.3g, 15%) as a colourless solid, m.p. 246-8°C. Found: C, 64.47; H, 5.85; N, 5.09; S, 5.50%; $C_{28}H_{29}N_2NaO_4S + 2\% isopropanol + 2\% water$; Requires: C, 64.19; H, 5.96; N, 5.25; S, 6.01%.

30

EXAMPLE 52

Ethyl 7-(1,4,5-triphenylimidazol-2-yloxy)heptanemethyl-phosphinate

A solution of 1,4,5-triphenyl-2-(7-bromoheptyloxy)-imidazole (1.75g) and diethyl methylphosphonite (2.45g) in toluene (10 ml) was heated at reflux temperature for 48 hours. Methanol and water were added and the mixture evaporated to an oil. This was chromatographed on silica gel (ethyl acetate/ethanol). The resulting oil slowly crystallised and was triturated with ether/petroleum ether,

35

filtered then recrystallised from ethanol/ether to give ethyl 7-(1,4,5-triphenyl-imidazol-2-yloxy)heptane-methylphosphinate (1.06g, 57%) as a white solid, m.p. 101-2°C. Found: C, 72.05; H, 7.26; N, 5.52%; $C_{31}H_{37}N_2O_3P$; Requires: C, 72.07; H, 7.22; N, 5.42%.

5

EXAMPLE 53

Diethyl 7-(1,4,5-triphenylimidazol-2-yloxy)heptanephosphonate

A mixture of 1,4,5-triphenyl-3-(7-bromoheptyl)-imidazol-2-one (1.0g) and triethyl phosphite (1.66g) was heated at reflux temperature in xylene (5 ml) for 40 hours. The solution was evaporated to an oil and re-evaporated from ethanol. The oil was partitioned between ether and water, the ether solution was separated, dried over magnesium sulphate and evaporated to an oil which was chromatographed on silica gel (ethyl acetate) to give diethyl 7-(1,4,5-triphenylimidazol-2-yl-oxy)heptanephosphonate as an oil which solidified on standing to a white solid (0.83g; 75%), m.p. 76-7°C. Found: C, 70.49; H, 7.40; N, 4.94%; $C_{32}H_{39}N_2O_4P$; Requires: C, 70.31; H, 7.19; N, 5.12%.

20

EXAMPLES 54 and 55

7-(3,4,5-Triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptanonitrile; and 7-(1,4,5-Triphenylimidazol-2-yloxy)heptanonitrile

1,4,5-Triphenylimidazol-2-one was treated with 7-bromoheptanonitrile and potassium carbonate in butanone to give after chromatographic work-up 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptanonitrile, m.p. 100-101°C, Found: C, 79.7; H, 6.6; N, 9.8%; $C_{28}H_{27}N_3O$ requires: C, 79.9; H, 6.4; N, 10.0%; and

7-(1,4,5-triphenylimidazol-2-yloxy)heptanonitrile, m.p. 93-94°C, Found: C, 79.5; H, 6.6; N, 9.7%; $C_{28}H_{27}N_3O$ requires: C, 79.9; H, 6.4; N, 10.0%.

30

EXAMPLES 56 AND 57

1-(7-Methoxycarbonylheptyl)-4,5-diphenyltriazole; and 2-(7-Methoxycarbonylheptyl)-4,5-diphenyltriazole

A solution of 8-bromooctanoic acid (8.32g) and sodium hydroxide (1.49g) in water (50ml) was added to solution of 4,5-diphenyltriazole (7.5g) (Chem. Ber., 1970, 103, 1908-17) and sodium hydroxide (1.36g) in water (75ml) and the mixture was stirred at 80°C for 21 hours.

35

-77-

2N Aqueous hydrochloric acid (50ml) was carefully added to the cooled reaction and then extracted with diethyl ether (3x100ml). The ether extracts were combined, washed with water (100ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo to give a mixture of 1(2)-(7-carboxyheptyl)-4,5-diphenyltriazole (12.2g) as an oil.

The above mixture (12.2g), p-toluene sulphonic acid, monohydrate (1.2g) and methanol (250ml) were heated at reflux through a soxhlet extractor containing 4A molecular sieves for 3.5 hours. The methanol was removed in vacuo and the residue was dissolved in dichloromethane (250ml), washed with saturated sodium hydrogen carbonate solution (200ml), water (200ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with dichloromethane gave 1-(7-methoxycarbonylheptyl)-4,5-diphenyltriazole (Example 56) (2.4g, 19.4%) and 2-(7-methoxycarbonylheptyl)-4,5-diphenyltriazole. (Example 57) (3.2g, 25.2%) as oils.

Example 56 found: C, 72.85; H, 7.23; N, 10.93%

Example 57 found: C, 73.08, H, 7.20; N, 11.00%

$C_{23}H_{27}N_3O_2$ requires: C, 73.18; H, 7.21; N, 11.13%

Example 58

1-(7-Carboxyheptyl)-4,5-diphenyltriazole

1-(7-Methoxycarbonylheptyl)-4,5-diphenyltriazole (1g) was treated with 2N sodium hydroxide in aqueous ethanol at reflux temperature for 2.5 hours. The ethanol was removed in vacuo and the residual mixture acidified with 2N aq HCl. The aqueous solution was extracted with ethyl acetate and the organic extracts combined, dried over magnesium sulphate and evaporated to dryness in vacuo. Recrystallisation from ethanol and water gave 1-(7-carboxyheptyl)-4,5-diphenyltriazole (0.61g, 64%) as a white solid, m.p. 103-104°C. Found: C, 72.66; H, 6.92; N, 11.44%
 $C_{22}H_{25}N_3O_2$ requires: C, 72.70; H, 6.93; N, 11.56%

Example 59

2-(7-Carboxyheptyl)-4,5-diphenyltriazole

2-(7-Methoxycarbonylheptyl)-4,5-diphenyltriazole (1g) was reacted with 2N sodium hydroxide in a method similar to Example 58. Recrystallisation from ethanol and water gave 2-(7-carboxyheptyl)-4,5-

-78-

diphenyltriazole (0.76g, 79%) as a white solid, m.p. 86-88°C.

Found: C, 72.70; H, 6.94; N, 11.47%

$C_{22}H_{25}N_3O_2$ requires: C, 72.70; H, 6.93; N, 11.56%

5

Example 60

2-(8-Carboxyoctyl)-4,5-diphenyltriazole

- a) A mixture of 4,5-diphenyltriazole (11g), 1,8-dibromooctane (67.6g), and potassium carbonate (10.31g) in dry butanone (300 ml) was heated at reflux temperature for 24 hours. The mixture was filtered and the solvent evaporated to give an oily residue. Distillation to remove 1,8-dibromooctane and column chromatography on silica gel eluted with a hexane:ethyl acetate gradient gave 2-(8-bromooctyl)-4,5-diphenyl-triazole (11.13g, 54%) as an oil. NMR d ($CDCl_3$) 1.2-1.5 (8H, m, $4 \times CH_2$), 1.84 (2H, m, CH_2), 2.05 (2H, m, CH_2), 3.37 (2H, t, Br- CH_2), 4.47 (2H, t, N- CH_2), 7.3-7.6 (10H, m, $2 \times Ph$) ppm

- b) 1-(8-Bromooctyl)-4,5-diphenyl-1,2,3-triazole
4,5-Diphenyl-1,2,3-triazole was treated with 1,8-dibromooctane and potassium carbonate in butanone to give after chromatographic work up the title compound, m.p. 90-91°C, Found: C, 64.0; H, 6.5; N, 10.1; Br, 19.8%; $C_{22}H_{26}BrN_3$ requires: C, 64.1; H, 6.4; N, 10.2; Br, 19.4%.

- And 1-(8-bromooctyl)-4,5-diphenyltriazole (2.12g, 10.3%) as a white solid, m.p. 90-91°C after recrystallisation from hexane.

- Found: C, 64.01; H, 6.47; N, 10.09; Br, 19.84%;
 $C_{22}H_{26}BrN_3$ requires C, 64.08; H, 6.36; N, 10.19; Br, 19.38%
NMR d ($CDCl_3$) 1.1-1.5 (8H, m, $4 \times CH_2$), 1.65-1.9 (4H, m, $2 \times CH_2$), 3.37 (2H, t, Br- CH_2), 4.20 (2H, t, N- CH_2), 7.2-7.55 (10H, m, $2 \times Ph$) ppm

- c) 2-(8-Bromooctyl)-4,5-diphenyltriazole (7g) in dimethylsulphoxide (220ml) was added to a suspension of sodium cyanide (1g) in dimethylsulphoxide (60ml) over 15 minutes. The reaction mixture was stirred at 24°C for 1 hour and at 50°C for 2 hours. The cooled reaction mixture was poured into water (600ml), extracted with diethyl ether ($4 \times 200ml$). The extracts were combined, washed with water (100ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with a

hexane:ethyl acetate gradient gave 2-(8-cyanoctyl)-4,5-diphenyl-triazole (5.6g, 92%) as an oil.

Found: C, 75.13; H, 7.16; N, 15.24%;

$C_{23}H_{26}N_4 \cdot 0.5H_2O$ requires: C, 75.18; H, 7.41; N, 15.25.

5

d) 2-(8-Cyanoctyl)-4,5-diphenyltriazole (3.0g) was treated with sulphuric acid (50ml) and water (50ml) and the mixture heated at reflux temperature for 4 hours. Water (200ml) was added and the cooled mixture was extracted with ethyl acetate (3 x 75ml), and the organic
10 extracts combined and evaporated to give a solid. Recrystallisation from ethanol and water gave 2-(8-carboxyoctyl)-4,5-diphenyltriazole (2.37g, 75%) as a white solid m.p. 84-85°C. Found: C, 72.92; H, 7.20; N, 11.07%;
 $C_{23}H_{27}N_3O_2$ requires: C, 73.18; H, 7.21; N, 11.13%.

15

Example 61

1-(8-Carboxyoctyl)-4,5-diphenyltriazole

a) 1-(8-Bromooctyl)-4,5-diphenyltriazole (ex. example 60a) (1.8g) was reacted with sodium cyanide in a method similar to Example 60b). Work-up and recrystallisation from dichloromethane and hexane
20 gave 1-(8-cyanoctyl)-4,5-diphenyltriazole (1.16g, 74.4%) as a white solid, m.p. 77-8°C. Found: C, 77.03; H, 7.25; N, 15.35%; $C_{23}H_{26}N_4$ requires: C, 77.06; H, 7.31; N, 15.63%.

b) 1-(8-Cyanoctyl)-4,5-diphenyltriazole (0.9g) was treated with
25 sulphuric acid in a method similar to Example 60a. Work-up and recrystallisation from ethanol and water gave 1-(8-carboxyoctyl)-4,5-diphenyltriazole (0.58g, 64%) as a cream solid, m.p. 86-87°C. Found: C, 73.10; H, 7.23; N, 10.82%; $C_{23}H_{27}N_3O_2$ requires: C, 73.18, H, 7.21, N, 11.13%.

30

Example 62

2-(8-Ethoxycarbonyloctyl)-4,5-diphenyltriazole

A mixture of 2-(8-carboxyoctyl)-4,5-diphenyltriazole (1g), absolute alcohol (100ml) and concentrated sulphuric acid (1ml) was heated at
35 reflux temperature for 3 hours. The solvent was removed in vacuo, the residue dissolved in diethyl ether (100ml), washed with water (50ml), dried and evaporated. The residue was chromatographed on silica gel

eluted with a hexane:ethyl acetate to give 2-(8-ethoxy-carbonyloctyl)-4,5-diphenyltriazole (0.81g, 76%) as an oil. Found: C, 73.84; H, 7.78; N, 10.22%; $C_{25}N_3O_2$ requires: C, 74.04; H, 7.71; N, 10.36%.

5

Example 63

2-(6-Ethoxycarbonylhexyl)-4,5-diphenyltriazole

4,5-Diphenyltriazole (2.0g) and ethyl 7-bromo-heptanoate (1.5g) were reacted in a method similar to Example 60. Column chromatography on silica gel eluted with a hexane:ethyl acetate gradient gave 2-(6-ethoxy-carbonylhexyl)-4,5-diphenyltriazole (1.1g, 46%) as an oil.

Found: C, 73.10; H, 7.45; N, 11.11%
 $C_{23}H_{27}N_3O_2$ requires C, 73.18; H, 7.21; N, 11.13%;

10

Example 64

15 2-(6-Carboxyhexyl)-4,5-triphenyltriazole

2-(6-Ethoxycarbonylhexyl)-4,5-diphenyltriazole (0.7g) was reacted with sodium hydroxide in a method similar to Example 58.

Recrystallisation from ethanol and water gave 2-(6-carboxyhexyl)-4,5-triphenyltriazole (0.41g, 63%) as white needles, m.p. 88-89°C.

20

Found: C, 71.30; H, 6.54; N, 11.73%;
 $C_{21}H_{23}N_3O_3 \cdot 0.2H_2O$ requires: C, 71.44; H, 6.68; N, 11.90%.

Example 65

2-(7-Carboxyheptyl)-4,5-diphenyloxazole

25 a) A mixture of benzoin (26.15g), 8-bromooctanoic acid (25.0g), 4-dimethylaminopyridine (1.35g), 1,3-dicyclo-hexylcarbodiimide (25.4g) and dry tetrahydrofuran (350ml) was stirred under nitrogen at room temperature for 20 hours. The reaction mixture was filtered and the filtrate was evaporated to dryness in vacuo. The residue was dissolved in
 30 dichloromethane (350ml), washed with 5% aqueous hydrochloric acid (3 x 175ml), saturated sodium hydrogen carbonate solution (2 x 200ml), saturated sodium chloride solution (220ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with a hexane: dichloromethane
 35 gradient gave a yellow oil. This oil was stirred in hexane to give 2-oxo-1,2-diphenyl-ethyl 8-bromooctanoate (27.1g, 52.7%) as a pale yellow solid m.p. 60-61°C.

NMR d (CDCl_3) 1.2-1.9 (10H, m, $5 \times \text{CH}_2$), 2.46 (2H, m, $\text{CH}_2\text{C}=\text{O}$), 3.4 (2H, t, BrCH_2), 6.86 (1H, s, PhCH), 7.35-7.95 (10H, m, $2 \times \text{Ph}$) ppm.

- b) A mixture of the above ester (26.8g), ammonium acetate (19.4g) and glacial acetic acid (500ml) was stirred at 80°C , under nitrogen, for 2 hours. The glacial acetic acid was removed in vacuo and water (1000ml) was added. The aqueous was extracted with dichloromethane ($3 \times 250\text{ml}$). The organic extracts were combined, washed with water (200ml), saturated sodium chloride solution (200ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with dichloromethane gave 1-(7-bromoheptyl)-4,5-diphenyloxazole (14.09g, 55%) as an oil.

NMR d (CDCl_3) 1.4 (6H, m, $3 \times \text{CH}_2$), 1.87 (4H, m, $2 \times \text{CH}_2$), 2.85 (2H, t, $\text{N}=\text{CCH}_2$), 3.41 (2H, t, BrCH_2), 7.3-7.7 (10H, m, $2 \times \text{Ph}$) ppm.

- c) 2-(7-Bromoheptyl)-4,5-diphenyloxazole (13.8g) in dimethylsulphoxide (80ml) was added over 45 minutes to a mixture of sodium cyanide (1.87g) in dimethylsulphoxide (80ml). The reaction was stirred at 50°C for 2h, cooled and poured into water (500ml). The aqueous was extracted with diethyl ether ($4 \times 250\text{ml}$). The ether extracts were combined, washed with water (250ml), dried over anhydrous magnesium sulphate and evaporated to dryness in vacuo. Column chromatography on silica gel eluted with a hexane: dichloromethane gradient gave 2-(7-cyanoheptyl)-4,5-diphenyloxazole (4.89g, 41%) as an oil. Found: C, 80.20; H, 7.02; N, 8.13%; $\text{C}_{23}\text{H}_{24}\text{N}_2\text{O}$ requires: C, 80.31; H, 7.18; n, 8.16%;

- d) 2-(7-Cyanoheptyl)-4,5-diphenyloxazole (2.5g) was reacted with sulphuric acid in a method similar to Example 60c. Recrystallisation from ethanol and water gave 2-(7-carboxyheptyl)-4,5-diphenyloxazole (1.1g, 41.7%) as a cream solid, m.p. $82-83^\circ\text{C}$. Found: C, 76.07; H, 6.99; N, 3.79%; $\text{C}_{23}\text{H}_{25}\text{NO}_3$ requires: C, 76.00; H, 6.93; N, 3.85%.

35

Examples 66 & 67

8-(3,4-Diphenylpyrazol-1-yl)octanoic acid, and

8-(4,5-Diphenylpyrazol-1-yl)octanoic acid

a) Formyldeoxybenzoin (10g) was suspended in ethanol (50ml) and hydrazine hydrate (5ml) added giving an orange solution which warmed to 40°C. This solution was stirred at room temperature for 3 hours and the solvent evaporated. The resulting oil was taken up in dichloromethane and washed with dilute hydrochloric acid (pH 2) and water, dried over potassium carbonate and evaporated to an orange solid. This was boiled in ether, cooled and filtered giving 3,4-diphenylpyrazole (5.64g, 57%) as pale yellow crystals, m.p. 155-6°C.

10 NMR d (CDCl₃) 7.2-7.5 (10 H, m, 2 x Ph), 7.6 (1H, s, pyraz 5-H) ppm

b) A mixture of 3,4-diphenylpyrazole (2.2g), ethyl 8-bromooctanoate (5.5g) and potassium carbonate (3.7g) in dry butanone (50ml) was heated at reflux temperature for 44 hours. The mixture was filtered and the filtrate evaporated to an oil which was chromatographed on silica gel (hexane/ethyl acetate). The oil obtained was heated at reflux temperature in a mixture of ethanol and 2N sodium hydroxide (1:1) for 1 hour. The ethanol was evaporated and the aqueous residue was acidified with dilute hydrochloric acid to pH 3, extracted with dichloromethane, dried over magnesium sulphate and evaporated to a solid. This was recrystallised from dichloromethane/ether to give 8-(3,4-diphenylpyrazol-1-yl)octanoic acid (0.48g, 13%) as colourless crystals, m.p. 114-5°C. Found: C, 76.02; H, 7.25; N, 7.63%; C₂₃H₂₆N₂O₂ requires: C, 76.21; H, 7.23; N, 7.73%

15
20
25

c) The mother liquor from above was evaporated to an oil which was chromatographed on silica gel (dichloromethane/methanol) giving a solid which was recrystallised from ether/petroleum ether to give 8-(4,5-diphenylpyrazol-1-yl)octanoic acid (0.15g, 5%) as colourless crystals, m.p. 94-5°C. Found: C, 76.53; H, 7.26; N, 7.82% C₂₃H₂₆N₂O₂ requires: C, 76.21; H, 7.23; N, 7.73%

30

Example 68

2-(9-Hydroxynonyl)-4,5-diphenyl-1,2,3-triazole

35 4,5-Diphenyl-1,2,3-triazole was treated with 9-bromononan-1-ol and potassium carbonate in butanone to give after chromatography the title compound as a light brown oil. Found: C, 76.0; H, 8.2; N, 11.2%

$C_{23}H_{29}N_3O$ requires: C, 76.0; H, 8.0; N, 11.6%.

EXAMPLE 69

5 Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate
1,4,5-Triphenylimidazole-2-one was treated with ethyl 3-bromo-
propionate and potassium carbonate in butanone to give after work-up
the title compound. m.p. 111-112 °C. Found: C, 76.0; H, 5.9; N,
6.7%; $C_{26}H_{24}N_2O_3$ requires: C, 75.7; H, 5.9; N, 6.8%

10 EXAMPLES 70 & 71

Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate; and
Ethyl 5-(1,4,5-triphenylimidazol-2-yloxy)valerate

1,4,5-Triphenylimidazol-2-one was treated with ethyl 5-
bromovalerate and potassium carbonate in butanone to give after
15 chromatographic work-up ethyl 5-(3,4,5-triphenyl-2-oxo 2,3-
dihydroimidazol-1-yl)valerate, m.p. 78-80°C, Found: C, 76.7; H, 6.6; N, 6.4%;
 $C_{28}H_{28}N_2O_3$ requires: C, 76.3; H, 6.4; N, 6.4%

and ethyl 5-(1,4,5-triphenylimidazol-2-yloxy)valerate, m.p. 95-96°C,
Found: C, 76.5; H, 6.5; N, 6.3%; $C_{28}H_{28}N_2O_3$

20 requires: C, 76.3; H, 6.4; N, 6.4%

EXAMPLE 72

Ethyl 6-(3-methyl-4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-5-
hexanoate

25 1-Methyl-4,5-diphenylimidazol-2-one was treated with ethyl 6-bromo-
hexanoate and potassium carbonate in butanone to give after work-up the
title compound, m.p. 93-94°C. Found: C, 73.7; H, 7.1; N, 6.9%;
 $C_{24}H_{28}N_2O_3$ requires: C, 73.4; H, 7.2; N, 7.1%

30 EXAMPLE 73

Ethyl 8-(4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octanoate

4,5-Diphenylimidazol-2-one was treated with ethyl 8-
bromooctanoate and potassium carbonate in butanone to give after work-
up the title compound, m.p. 78-79°C, Found: C, 73.7; H, 7.4; N,
35 6.7%; $C_{25}H_{30}N_2O_3$ requires: C, 73.9; H, 7.4; N, 6.9%

EXAMPLE 74

9-(3,4,5-Triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)nonanoic acid

1,4,5-Triphenylimidazol-2-one was treated with ethyl 9-bromononanoate and potassium carbonate in butanone, followed by sodium hydroxide in ethanol and water, to give after work-up the title compound, m.p. 123-124°C, Found: C, 76.9; H, 6.9; N, 5.7%; $C_{30}H_{32}N_2O_3$ requires: C, 76.9; H, 6.9; N, 6.0%

EXAMPLE 75**Methyl 7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)-5-heptynoate**

1,4,5-Triphenylimidazol-2-one was treated with methyl 7-bromo-5-heptynoate and potassium carbonate in butanone to give after work-up the title compound, m.p. 133-134°C, Found: C, 76.9; H, 5.8; N, 6.0%; $C_{29}H_{26}N_2O_3$ requires: C 77.3; H, 5.8; N, 6.2%

EXAMPLE 76**Ethyl 8-(4-phenylimidazol-1-yl)octanoate**

4-Phenylimidazole was treated with ethyl 8-bromooctanoate and potassium carbonate in butanone to give after work-up the title compound, m.p. 56-57°C, Found: C, 72.8; H, 8.4; N, 9.0%; $C_{19}H_{26}N_2O_2$ Requires: C, 72.6; H, 8.3; N, 8.9%

EXAMPLE 77**8-(4-5-Diphenylimidazol-2-ylthio)octanoic acid**

4,5-Diphenyl-2-imidazoletiol was treated with ethyl 8-bromooctanoate and potassium carbonate in butanone, followed by sodium hydroxide in ethanol and water, to give after work-up the title compound, m.p. 154-156°C, Found: C, 70.0; H, 6.4; N, 7.2; S, 7.9%; $C_{23}H_{26}N_2O_2S$ Requires: C, 70.0; H, 6.6; N, 7.1; S, 8.1%

EXAMPLE 78 & 79**11-(2,3-Diphenylmaleimido)undecanoic acid; and****8-(2,3-Diphenylmaleimido)undecanoic acid**

2,3-Diphenylmaleic anhydride was treated with 11-aminoundecanoic acid and triethylamine in toluene at reflux temperature to give after work-up the title compound, m.p. 124-125°C, Found: C, 74.5; H, 7.1; N, 3.2% $C_{27}H_{31}NO_4$; requires: C, 74.8; H, 7.2; N,

3.2%.

and in a similar manner with 8-aminoundecanoic acid yields m.p. 107-108°C, Found C, 73.7; H, 6.6; N, 3.5; C₂₄H₂₅NO₄ requires: C, 73.6; H, 6.5, N 3.6%.

5

EXAMPLE 80

8-(1,4,5-Triphenylimidazol-2-yloxy)octanoic acid

1,4,5-Triphenyl-2-chloroimidzole was treated with 8-hydroxyoctanoic acid and sodium hydride in dimethylformamide to give the title compound, m.p. 158-159°C, Found: C, 75.3; H, 6.6; N, 6.0%; C₂₉H₃₀N₂O₃•0.43H₂O Requires: C, 75.3; H, 6.7; N, 6.0%

10

EXAMPLE 81

Ethyl 6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate

A mixture of 1,4,5 triphenylimidazole (6.24g), ethyl 6-bromohexanoate (13.38g), potassium carbonate (13.2g) and 2-butanone was stirred at reflux for 6 hours. The mixture was filtered, and the filtrate was evaporated. The residue was chromatographed on silica gel eluted with ethanol-hexane to give the title compound (5.61g) m.p. 104-106°C. Found: C, 76.35; H, 6.58; N, 6.07%; (C₂₉H₃₀N₂O₂O₃) Requires: C, 76.63; H, 6.65; N, 6.16%

15

20

EXAMPLE 82

8-(1,4,5-Triphenylimidazol-2-yloxy)octanamide

8-(1,4,5-Triphenylimidazol-2-yloxy)octanoic acid was treated with thionyl chloride followed by ammonia to give the title compound, m.p. 152.5-153.5°C, Found: C, 76.6; H, 7.0; N, 9.1%; C₂₉H₃₁N₃O₂ requires: C, 76.8; H, 6.9; N, 9.3%

25

30

EXAMPLE 83

11-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)undecanoic acid

1,4,5-Triphenylimidazol-2-one was treated with ethyl 9-bromo-undecanoate and potassium carbonate in butanone, followed by sodium hydroxide in ethanol and water, to give after work-up the title compound, m.p. 83-84°C. Found: C, 77.5; H, 7.3; N, 5.4%; C₃₂H₃₆N₂O₃ requires: C, 77.4; H, 7.3; N, 5.6%

35

The remaining compounds disclosed herein can be produced in an analogous manner to Examples 1 to 83 as described above or are readily ascertainable to one skilled in the art.

5

Key (for FIGURE 1)


AA-CoA SynTase; Arachidonic acid CoA synthetase
AA-CoA Tase; Arachidonic acid CoA transferase
10 CoA-IT; CoA-independent transacylase
PLA2; phospholipase A2
Acetyl-CoA Tase; Acetyl CoA : lyso PAF transferase
AA; arachidonic acid
CO; cyclooxygenase
15 5-LO; 5-lipoxygenase
PGs; prostaglandins
TXs; thromboxanes
LT; leukotrienes

20

The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one
25 skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore, the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.

What is claimed is:

1. A method for treating disease or disorders mediated by the lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprises administering to a mammal in need thereof an effective amount of a compound which inhibits the production, activation or action of Coenzyme A-independent transacylase (CoA-IT).
2. The method according to Claim 1 wherein the disease or disorder is allergic rhinitis, asthma, myocardial infarction, stroke, circulatory shock, hypotension, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome, anaphylaxis, shock, endotoxic shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any other disease, disorder or syndrome mediated in some part by the lipid inflammatory mediators.
3. A method for treating disease or disorders mediated by the lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of the formula



- wherein
- R₁ is hydrogen, C₁₋₄ alkyl, optionally substituted phenyl or optionally substituted heteroaryl;
- n is 4 to 12;
- X is 5-tetrazolyl, SO₃H, P(O)(OR₂)₂, P(O)(OH)₂, or P(O)(R₂)(OR₂);
- R₂ is hydrogen or C₁₋₄ alkyl;
- R₃ is independently hydrogen, C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl,

halogen, hydroxy or C1-4 alkoxy;
m is a number having a value of 1 to 3;
q is a number having a value of 1 to 3;
or a pharmaceutically acceptable salt thereof.

5

4. The method according to Claim 3 wherein the compound is
Diethyl-7-(3,4,5-triphenylimidazol-2-oxo-2,3-dihydroimidazol-1-yl)heptane
phosphonate;

Ethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)methyl-
10 phosphinate; or
7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptanephosphonate.

5. A compound selected from
Diisopropyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane
15 phosphonate;

Dimethyl-7-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)heptane
phosphonate;

Diethyl-6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexane
phosphonate; or

20 Diethyl-8-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-
yl)octanephosphonate; or a pharmaceutically acceptable salt thereof.


6. A pharmaceutical composition comprising a compound
according to Claim 5 and a pharmaceutically acceptable diluent or carrier.
25

7. The method according to claim 3 or 4 wherein the disease or
disorder is allergic rhinitis, asthma, myocardial infarction, stroke,
circulatory shock, hypotension, ischemia, reperfusion injury, arthritis,
inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma,
30 adult respiratory distress syndrome, anaphylaxis, shock, endotoxic
shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any
other disease, disorder or syndrome mediated in some part by the lipid
inflammatory mediators.

35 8. A method for treating disease or disorders mediated by the lipid
inflammatory mediators, arachidonic acid, its metabolites and/or platelet

-89-

activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of the formula



wherein

R is hydrogen, C₁₋₈alkyl, C₁₋₈alkoxy, SC₁₋₈alkyl, optionally substituted phenyl, phenyl C₁₋₄alkyl in which the phenyl group is optionally substituted, C₁₋₆alkylCHO or C₁₋₆alkylCH(OR¹)(OR²) in which each group R¹ and R² is C₁₋₄alkyl, or together form an ethane 1,2-diyl or propane 1,3-diyl group;

n is an integer having a value of 2 to 6;

m is an integer having a value of 0 to 6;

p is an integer having a value of 1 to 3;

R³, R⁴, R⁵ and R⁶ are independently hydrogen or C₁₋₄alkyl;

AB is a bond, -CH=CH-, -S-, S-phenyl or O-phenyl;

X is CO₂H or a group hydrolysable to CO₂H, 5-tetrazolyl, SO₃H, P(O)(OR)₂, P(O)(OH)₂, or P(O)(R)(OR) in which R is hydrogen or C₁₋₄alkyl;

R⁷ is hydrogen, C₁₋₄alkyl, haloC₁₋₄alkyl, halogen, hydroxy, or C₁₋₄alkoxy;

or a pharmaceutically acceptable salt thereof;

provided that:

a) when X is 5-tetrazolyl, R⁷ is hydrogen, R is phenyl, and AB is a bond, then n + m are equal to a number greater than 6;

b) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is hydrogen, then R is not hydrogen;

c) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is hydrogen, then R is not alkyl or hydrogen;

d) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 4-hydroxy, then R is not phenyl ; ;

-90-

- e) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 4-Methoxy or is 4-hydroxy, then R is not hydrogen;
- f) when X is CO₂H, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 2-chloro, then R is not hydrogen ; ;
- 5 g) when (R⁷)_p is the same and is hydrogen, R is phenyl, n is 4, m is 0, and AB is O-phenyl then X is not CO₂-C₁₋₆alkyl;
- h) when R is hydrogen, (R⁷)_p is the same and is hydrogen, AB is a bond, n + m is equal to 7, than X is not CH₃O-(CH₂)₂-O-(CH₂)₂-O-C(O)-;
- 10 i) when X is CO₂-C₁₋₆ alkyl, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is hydrogen, then R is not phenyl or 4-methoxyphenyl;
- j) when X is CO₂-C₁₋₆ alkyl, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is 4-bromo or 4-methoxy, then R is not hydrogen;
- 15 k) when X is CO₂-C₁₋₆ alkyl, AB is a bond, n + m is equal to 7, and (R⁷)_p is the same and is hydrogen, then R is not 2-(4-methoxybenzyl);
- l) when (R⁷)_p is the same and is hydrogen, R is phenyl, AB is a bond n + m is equal to 10, then X is not CO₂-C₁₋₆ alkyl;
- m) when (R⁷)_p is the same and is hydrogen, R is phenyl, n is 4, m is 0 and AB is O-phenyl, then X is not CO₂-C₁₋₆ alkyl;
- 20 n) when AB is - S-, n is 5 or 6, then m is 1 and X is CO₂H; or a pharmaceutically acceptable salt thereof.


9. The method according to Claim 8 wherein the compound is
- 1-(7-Carboxyheptyl)-2-heptyl-4,5-diphenylimidazole;
- 25 1-(7-(5-Tetrazolylheptyl)-2,4,5-triphenylimidazole;
- 1-(10-Carboxydecyl)-2,4,5-triphenylimidazole;
- 4-[4-(2,4,5-triphenylimidazolyl)butyloxy]benzoic acid;
- 9-(1,2,4-tri-phenylimidazolyl)-2,2-dimethylnonanoic acid;
- 1-(8-Carboxyoctyl)-2,4,5-triphenylimidazole;
- 30 1-(7-Carboxy-heptyl)-2-(4-hydroxy-3,5-diiodophenyl)-4,5-diphenyl-imidazole;
- Ethyl 8-(4,5-diphenylimidazol-1-yl)octanoate;
- 1-(7-Ethoxycarbonylheptyl)-2-methyl-4,5-diphenylimidazole; or
- 1-(7-Carboxyheptyl)-2-(4-hydroxyphenyl)-4,5-diphenyl-imidazole.
- 35

10. The method according to claim 8 or 9 wherein the disease or

-91-

disorder is allergic rhinitis, asthma, myocardial infarction, stroke, circulatory shock, hypotension, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome, anaphylaxis, shock, endotoxic
 5 shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any other disease, disorder or syndrome mediated in some part by the lipid inflammatory mediators.

11. A method for treating disease or disorders mediated by the lipid
 10 inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of the formula



wherein

R₁ is hydrogen, C₁₋₄ alkyl, optionally substituted phenyl or optionally substituted heteroaryl;

n is an integer having a value of 4 to 12;

20 Y is oxygen or sulfur;
 X is 5-tetrazolyl, SO₃H, P(O)(OR₂)₂, P(O)(OH)₂, or P(O)(R₂)(OR₂);

R₂ is hydrogen or C₁₋₄ alkyl;

R₃ is independently C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl, halogen, hydroxy or C₁₋₄ alkoxy;

25 m is an integer having a value of 1 to 3;

q is an integer having a value of 1 to 3;


or a pharmaceutically acceptable salt thereof.

12. The method according to Claim 11 wherein the compound is
 30 Ethyl-7-(1,4,5-triphenyl-imidazol-2-yl-oxy)heptane methylphosphinate; or Diethyl-7-(1,4,5-triphenyl-imidazol-2-yl-oxy)heptanephosphonate.

13. The method according to claim 11 or 12 wherein the disease or disorder is allergic rhinitis, asthma, myocardial infarction, stroke, circulatory shock, hypotension, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome, anaphylaxis, shock, endotoxic shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any other disease, disorder or syndrome mediated in some part by the lipid inflammatory mediators.

10

14. A method for treating disease or disorders mediated by the lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of the formula



wherein

X is nitrogen or CR¹;

R¹ is hydrogen, C₁₋₄ alkyl, optionally substituted phenyl or optionally substituted heteroaryl;

Y is nitrogen, N(CH₂)_n A or C(CH₂)_n A

Z is nitrogen, oxygen or N(CH₂)_n A', and the dotted line indicates the optional presence of a double bond so as to form a fully unsaturated heterocyclic ring;

n is an integer having a value of 4 to 12;

A' is CO₂H or a group hydrolysable to CO₂H, 5-tetrazolyl, SO₃H, P(O)(OR)₂, P(O)(OH)₂, or P(O)(R)(OR) in which R is hydrogen or C₁₋₄ alkyl;

A is CO₂H or a group hydrolysable to CO₂H, OH, Br, Cyano, 5-tetrazolyl, SO₃H, P(O)(OR)₂, P(O)(OH)₂, or P(O)(R)(OR) in which R is hydrogen or C₁₋₄ alkyl;

R² is independently C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl, halogen, hydroxy or C₁₋₄ alkoxy;

-93-

m is an integer having a value of 1 to 3;
provided that

- a) X, Y and Z are not all at the same time, nitrogen;
- b) when X is CR^1 , Y and Z are not both nitrogen;
- 5 c) when Y is $\text{N}(\text{CH}_2)_n\text{A}$, Z is nitrogen; and
- d) when Z is oxygen, Y is $\text{C}(\text{CH}_2)_n\text{A}$;
- e) when Y is $\text{N}(\text{CH}_2)_n\text{A}$, X and Z are nitrogen, $(\text{R}_2)_m$ is the same and is hydrogen, and n is 6, 7, or 8 then X is not $-\text{CO}_2\text{-C}_{1-6}$ alkyl;
- f) when Z is oxygen, Y is $\text{C}(\text{CH}_2)_n\text{A}$, n is 8, and $(\text{R}_2)_m$ is the same and is hydrogen, then X is not cyano;
- 10 g) when Z is $\text{N}(\text{CH}_2)_n\text{A}'$, X is nitrogen, Y is nitrogen, $(\text{R}_2)_m$ is the same and is hydrogen, and n is 7, then X is not CO_2H ;
- h) when Y is $\text{N}(\text{CH}_2)_n\text{A}$, X and Z are nitrogen, $(\text{R}_2)_m$ is the same and is hydrogen, and n is 8 then X is not cyano;
- 15 or a pharmaceutically acceptable salt thereof.


15. The method according to Claim 14 wherein the compound is
 - 1-(8-Bromooctyl)-4,5-diphenyltriazole;
 - 2-(8-Cyanooctyl)-4,5-diphenyl-triazole;
 - 20 8-(3,4-Diphenylpyrazol-1-yl)octanoic acid ;
 - 2-(9-Hydroxynonyl)-4,5-diphenyl-1,2,3-triazole
 - 2-(7-Methoxycarbonylheptyl)-4,5-diphenyltriazole
 - 8-(3,4-Diphenylpyrazol-1-yl)octanoic acid;
 - 8-(4,5-Diphenylpyrazol-1-yl)octanoic acid;
 - 25 2-(6-Carboxyhexyl)-4,5-triphenyltriazole; or
 - 2-(7-Carboxyheptyl)-4,5-diphenyloxazole.

16. The method according to claim 14 or 15 wherein the disease or disorder is allergic rhinitis, asthma, myocardial infarction, stroke,
 - 30 circulatory shock, hypotension, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome, anaphylaxis, shock, endotoxic shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any other disease, disorder or syndrome mediated in some part by the lipid
 - 35 inflammatory mediators.

17. A method for treating disease or disorders mediated by the lipid

inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of the Formula

5



wherein

R₁ is hydrogen, C₁₋₄ alkyl, or optionally substituted phenyl;

n is 2 or 4 to 12;

10 X is cyano, CO₂H or a group hydrolysable to CO₂H;

R₃ is independently C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl, halogen, hydroxy or C₁₋₄ alkoxy;

q is an integer having a value of 1 to 3;

or a pharmaceutically acceptable salt thereof.

15

18. The method according to Claim 17 wherein the compound is:

Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate;

Ethyl 6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;

Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate;

20 9-[1-(3,4,5-Triphenyl-2-oxo-2,3-dihydroimidazolyl)]nonanoic acid;

7-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)heptanitrile;

Ethyl 6-(3-methyl-4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;

11-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)undecanoic acid; or

Ethyl-8-(4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octanoate.


25

19. The method according to claims 17 or 18 wherein the disease or disorder is allergic rhinitis, asthma, myocardial infarction, stroke, circulatory shock, hypotension, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma, adult respiratory distress syndrome, anaphylaxis, shock, endotoxic shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any

30

other disease, disorder or syndrome mediated in some part by the lipid inflammatory mediators.

20. A method for treating disease or disorders mediated by the lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound of the Formula:



- 10 wherein
 R₁ is hydrogen, C₁₋₄ alkyl, or optionally substituted phenyl;
 n is 4 to 12;
 Y is oxygen or sulfur;
 X is CO₂H or a group hydrolysable to CO₂H;
 15 R₃ is independently C₁₋₄ alkyl, halo substituted C₁₋₄ alkyl, halogen, hydroxy or C₁₋₄ alkoxy;
 q is an integer having a value of 1 to 3;
 or a pharmaceutically acceptable salt thereof.
- 20 21. The method according to Claim 20 wherein the compound is
 Ethyl 5-(1,4,5-triphenylimidazol-1-yl-oxy)valerate;
 8-(1,4,5-Triphenylimidazol-2-yl-oxy)octanamide;
 8-[1,4,5-Triphenylimidazol-2-yl-oxy]octanoic acid; or
 8-[1,4,5-triphenylimidazol-2-yl-oxy]octanoic acid ammonium salt.

- 25 22. The method according to claim 20 or 21 wherein the disease or disorder is allergic rhinitis, asthma, myocardial infarction, stroke, circulatory shock, hypotension, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma,
 30 adult respiratory distress syndrome, anaphylaxis, shock, endotoxic shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any

other disease, disorder or syndrome mediated in some part by the lipid inflammatory mediators.

23. A method for treating disease or disorders mediated by the lipid inflammatory mediators, arachidonic acid, its metabolites and/or platelet activating factor (PAF), which method comprising administering to a mammal in need thereof an effective Coenzyme A independent transacylase (CoA-IT) inhibiting amount of a compound selected from
- 5 7-(3,4,5-Triphenylimidazol-1-yl-oxy)heptanitrile;
 - 10 8-(2,3-Diphenylmaleimido)octanoic acid;
 - 11-(2,3-Diphenylmaleimido)undecanoic acid;
 - 1-(7-Ethoxycarbonyl)-4-phenylimidazole;
 - Methyl-7-(3,4,5-triphenyl)-2-oxo-1,2-dihydroimidazol-1-yl)-5-heptynoate;
 - 15 2-[4-(3-Carboxypropoxy)phenyl]-4,5-diphenylimidazole;
 - 1-(7-Carboxyheptyl)-2-phenylimidazole;
 - 1-(7-Ethoxycarbonyl)-4-phenylimidazole;
 - 1-(7-Carboxyheptyl)-2-octylthio-4,5,-diphenylimidazole;
 - 8-(1,4,5-Triphenylimidazol-2-yl-oxy)octanamide; and the
 - 20 pharmaceutically acceptable salts thereof.

24. The method according to Claim 23 wherein the compound is
- 1-(7-Carboxyheptyl)-2-octylthio-4,5,-diphenylimidazole;
 - 8-[1,4,5-Triphenylimidazol-2-yl-oxy]octanoic acid;
 - 25 Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate;
 - Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate;
 - Ethyl 6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;
 - 7-(3,4,5-Triphenylimidazol-2-oxo-2,3-dihydroimidazol-1-yl)-heptanonitrile;
 - 30 Ethyl 6-(3-methyl-4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;
 - 1-(7-Ethoxycarbonyl)-4-phenylimidazole; and
 - Methyl-7-(3,4,5-triphenyl)-2-oxo-1,2-dihydroimidazol-1-yl)-5-heptynoate.

25. The method according to claims 23 or 34 wherein the disease or
- 35 disorder is allergic rhinitis, asthma, myocardial infarction, stroke, circulatory shock, hypotension, ischemia, reperfusion injury, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, asthma,

-97-

adult respiratory distress syndrome, anaphylaxis, shock, endotoxic shock, actinic keratosis, psoriasis, contact dermatitis, pyresis, or any other disease, disorder or syndrome mediated in some part by the lipid inflammatory mediators.

5

26. The compound which is

1-(7-Carboxyheptyl)-2-octylthio-4,5-diphenylimidazole;

8-(2,3-Diphenylmaleimido)octanoic acid;

11-(2,3-Diphenylmaleimido)undecanoic acid;

10

1-(7-Ethoxycarbonyl)-4-phenylimidazole;

7-(3,4,5-Triphenylimidazol-2-oxo-2,3-dihydroimidazol-1-yl)-
heptanonitrile;

Ethyl 3-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)propionate;

Ethyl 6-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;

15

Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate;

9-[1-(3,4,5-Triphenyl-2-oxo-2,3-dihydroimidazolyl)]nonanoic acid;

Ethyl 6-(3-methyl-4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)hexanoate;

Ethyl-8-(4,5-diphenyl-2-oxo-2,3-dihydroimidazol-1-yl)octanoate;

7-(3,4,5-Triphenyl-2-oxo-1,2-dihydroimidazol-1-yl)heptanitrile; or

20

Methyl-7-(3,4,5-triphenyl)-2-oxo-1,2-dihydroimidazol-1-yl)-5-heptynoate.

27. The compound according to Claim 26 which is

1-(7-Carboxyheptyl)-2-octylthio-4,5-diphenylimidazole; or

Ethyl 5-(3,4,5-triphenyl-2-oxo-2,3-dihydroimidazol-1-yl)valerate.

25

28. A pharmaceutical composition comprising a compound according to Claim 26 and a pharmaceutically acceptable diluent or carrier.

29. A method of screening compounds for potential activity against lipid mediator formation which method comprises

30

1) preparing an inflammatory cell for testing;

2) treating the prepared cell preparation with the compound to be tested;


3) measuring CoA-IT activity, the amount of PAF formed and/or the amount of arachidonic acid released; and

35

4) selecting those compounds which exhibit CoA-IT inhibitory activity, and inhibit the formation of lipid mediators of inflammation.


FIGURE 1

Role of CoA-Independent transacylase in
Arachidonic acid and Platelet-Activating
Factor Metabolism



SUBSTITUTE SHEET

FIGURE 2



SUBSTITUTE SHEET

FIGURE 3




FIGURE 4






FIGURE 5

Effect of Compound 3 on Inflammatory Responses in the Mouse Ear



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/01247

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/01247

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C07F 9/06,9/28 ; A61K 31/675,31/41,31/415 A01N 57/00,43/50,43/52,43/56;43/64,43/82,43/80,43/80,43/50; C12Q 1/100; G01N 33/63

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

Group I Claims 1-2, in part, 3-7, 17-19 a method for treating disease comprising administering a components of Formula I and V and a phosphorate and phosphinate compound and composition of in classes Formula I 548/112 and 514/94.

Group 2: claims 1-2, in part 8-10, a method for treating disease comprising administering a compound of formula II. in class 514/399.

Group 3: Claims 1-2, in part 11-13, 23-26,28 a method for treating disease comprising administering a compound of formula III in 514/398 and in which there is no challenge attaches to the imidazole ring in class 514/398.

Group 4, class 1-2, in pars, 14-16 in part a method of treating disease comprising administering a compound of formula IV when there of the 5 membrane heterocyclic substitutes are carbon and two are nitrogen in class 514/403.

Group 5, claims 1-2, in parts, 14-16 in part a method as in Group 4, when three of the 5-membered heterocyclic ring substitutes are nitrogen and A is not tetragoly, class 514/359.

Group 6, claims 1-2, in part, 14-16, in part a method as in group 4, when two of the 5 membered heterocyclic ring substituents are nitrogen and one is oxygen, class 514/364.

Group 7, claims 1-2 in part, 14-16 in part, a method as in Group 4, when two of the 5-membered heterocyclic ring substituents are nitrogen and A is tetrazoleyl, class 514/381.

Group 8, claims 1-2 in part, 14-16 in part a method as in Group 4, when two of the 5-membered heterocyclic ring substituents are nitrogen and A is nittetragilyl, class 514/385.

Group 9 class 1-2, in part, class 20-28, formula VI a method as in group 4, in which a chalcogen is attached directly to the imidazole ring, class 514/392.

Group 10 Claim 29, a method of screening compounds for potential acting against liped medicator formation class 435/7.91.

Because Group 1-9 do not share a single special technical feature which defines over the prior art, restriction forexamination purposes is proper.

Group 10 is to an inventive Concept distinct from the inventive concept of Group I-XXVIII.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/01247**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : Please See Extra Sheet.

US CL : 548/112; 514/94, 399, 398, 403, 359, 364, 381, 385, 392; 435/7.91.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/112; 514/94, 399, 398, 403, 359, 364, 381, 385, 392; 435/7.91

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN-CAS Structure, NLM&STN-CA bibliographic winkler chilton, hickey, acyltransferases, PAF, COA-IT Madline

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	CA 116(25): 255613 19 March 1992 Hickey et al. see entire document.	1-2,3-7
Y	CA 82(25): 170937W 1975 Jorgensen see entire document.	1-2,8-10
Y,P	CA 117 (3): 26565 19 March 1992 Hickey et al. see entire document.	1-2,11-13,23-26, 28
Y,P	CA 117(11) 111 616JA 19 March 1992 Hickey et al see entire document.	1-2,14-16
X	CA 115 (S): 49682 1991 Meanwell et al. see entire document.	1-2,14-16

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be part of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	
"P"	document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search

28 APRIL 1993

Date of mailing of the international search report

04 AUG 1993

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

REBECCA COOK

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/01247

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CA 112(6): 42581b 1989 Duerr see entire document.	1-2, 20-28
Y	CA 110(16): 141549h 1986 Schmitz et al. see entire document.	1-2,20-28
Y	CA 105(23): 20887p 1986 Lautenschlaeger et al. see entire document.	1-2,20-28
Y	Mealine 92170539 1991 Winkler see entire document.	1-2,29
Y	Medline 911521139 1991 Winkler see entire document.	1-2,29
Y	CA116 (13) 125547d 1991 Suguira et al see entire document.	1-2,29
Y	CA 115(17): 177545a 1991 Uemura et al. see entire document.	1-2,29

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*



PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07F 9/06, 9/28, A61K 31/675, 31/41, 31/415, A01N 57/00, 43/50, 43/52, 43/56, 3/64, 43/82, 43/80, 43/80, 43/50, C12Q 1/100, G01N 33/53		A1	(11) International Publication Number: WO 93/16674
			(43) International Publication Date: 2 September 1993 (02.09.93)
(21) International Application Number: PCT/US93/01247		(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/ US]; One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101 (US). SMITHKLINE BEECHAM PLC [GB/ GB]; New Horizon Court, Brentford, TW8 9BD (GB). THE JOHNS HOPKINS UNIVERSITY [US/US]; 720 Rutland Avenue, Baltimore, MD 21205 (US).	
(22) International Filing Date: 11 February 1993 (11.02.93)		(72) Inventors; and (75) Inventors/Applicants (for US only) : WINKLER, James, David [US/US]; 701 Hartranft Avenue, Fort Washing- ton, PA 19034 (US). CHILTON, Floyd, Harold, III [US/US]; 106 Needham Street, Pilot Mountain, NC 27041 (US). HICKEY, Deirdre, Mary, Bernadette [GB/ GB]; SmithKline Beecham, The Frythe, Welwyn, Hert- fordshire AL6 9AR (GB).	
(30) Priority data: 07/833,879 11 February 1992 (11.02.92) US 07/833,877 11 February 1992 (11.02.92) US 07/834,048 11 February 1992 (11.02.92) US 07/833,880 11 February 1992 (11.02.92) US 07/833,878 11 February 1992 (11.02.92) US 9202827.3 11 February 1992 (11.02.92) GB 07/833,850 11 February 1992 (11.02.92) US			
(60) Parent Applications or Grants GB 9202827.3 (Filed on 11 February 1992 (11.02.92)			
(63) Related by Continuation US 07/833,850 (CIP) Filed on 11 February 1992 (11.02.92) US 07/833,877 (CIP) Filed on 11 February 1992 (11.02.92) US 07/833,878 (CIP) Filed on 11 February 1992 (11.02.92) US 07/833,879 (CIP) Filed on 11 February 1992 (11.02.92) US 07/833,880 (CIP) Filed on 11 February 1992 (11.02.92) US 07/834,048 (CIP) Filed on 11 February 1992 (11.02.92)		(74) Agents: DINNER, Dara, L. et al.; SmithKline Beecham Corporation, Corporate Patents - U.S., UW2220, 709 Swedeland Road, P.O. Box 1539, King of Prussia, PA 19406-0939 (US).	
		(81) Designated States: AU, CA, GB, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: CoA-IT AND PAF INHIBITORS

Effect of Compound 3 on CoA-IT Activity



(57) Abstract

Coenzyme A-independent transacylase is required for the release of free arachidonic acid, and the production of arachidonic acid metabolites and platelet activation factor. Blocking of this enzyme inhibits the production of these inflammatory mediators and will be of therapeutic utility in a broad range of allergic and inflammatory diseases and disorders. Compounds are described herein which inhibit the action of CoA-IT and are therefore useful in the treatment of disease states caused thereby. The figure shows the effect of compound three on CoA-IT activity.

* (Referred to in PCT Gazette No. 07/1994, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TC	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				